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ABSTRACT 
There is a critical need for improved diagnostic tools to detect infectious diseases, especially 
in low-resource regions. A sample-to-answer point-of-care nucleic acid amplification test 
(NAAT) would be incredibly valuable for many different applications (e.g. COVID-19, 
Chlamydia/Gonorrhoeae, Influenza, Ebola, Zika/Chikungunya/Dengue, etc.). However, 
sample preparation (purification of pure nucleic acids) is a challenging bottleneck. In Chapter 
2, commercial NA extraction methods were studied and improved. In Chapter 3, commercial 
stocks of SARS-CoV-2 RNA used in FDA emergency-use authorizations were found to be 
inaccurate and were independently quantified using reverse transcription digital PCR. In 
Chapter 4, a 3D printed meter-mix device was developed for initial processing prior to the 
sample preparation device. In Chapter 5, a 3D printed sample-to-device interface was 
prototyped to facilitate loading multi-volume SlipChip devices with purified template mixed 
with LAMP reactants. In Chapters 6-7, advancements were made for image processing of 
commercial chips to study digital LAMP reactions. In Chapter 8, additional tools were 
developed towards sample-to-answer point-of-care NAAT including a sample preparation 
module, amplification module, cell-phone readout, and automated base station.  
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1 .  C h a p t e r  1  
OVERVIEW 
Background 
The global burden of communicable disease has been estimated at 3.2 billion DALYs 
(disability-adjusted life years) per year for 2017.1 Notable examples of communicable 
disease include ongoing pandemics COVID-192 and HIV/AIDS;3 recent outbreaks of 2014-
2016 Ebola,4 2015-2016 Zika virus,5 and 2009-2010 H1N1 Influenza;6 and ongoing 
challenges including respiratory diseases (Tuberculosis, Pertussis, Measles, etc.), diarrheal 
diseases (Rotavirus, E. coli, Norovirus, etc.), mosquito-borne pathogens (West Nile Virus, 
Dengue, Chikungunya, Malaria, etc.), and sexually transmitted infections (Chlamydia, 
Gonorrhoeaea, Syphilis, etc.).  
The appropriate treatment and containment of communicable diseases requires timely and 
effective diagnostics to identify the causative pathogen. A strong screening response enables 
pandemic tracking, quarantining of individuals, guidance of appropriate treatments, contact 
tracing, public policy advising, and proper resource allocation. Because pandemics do not 
discriminate by international borders, an effective containment approach necessitates testing 
on a global scale. However, current infrastructure and supplies are lacking for such wide-
scale testing capabilities, even in the most well-equipped countries.  
Diagnosing pathogens is not an effortless endeavor. Communicable diseases take many 
forms such as bacterial, viral, parasitic, and fungal infections. Furthermore, pathogens can 
be located in different sample matrices such as water, food, respiratory droplets, urine, blood, 
saliva, sputum, stool, and more. An ideal diagnostic platform would have the flexibility to 
detect different pathogens in different types of sample matrices. Furthermore, routes of 
transmission also vary by pathogen and include direct contact, indirect contact, respiratory 
droplets, food contamination, insect bites, and sexual transmission. Because an unknown 
sample could contain an unknown pathogen (different than the pathogen being tested for) 
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with an unknown route of transmission, all human-derived samples should be handled with 
care (e.g. minimum BSL-2). While some pathogens can be easily diagnosed by clinical 
presentation, many pathogens cannot be detected without diagnostics.7 This occurs when 
clinical presentations are shared among diseases, there is a high asymptomatic rate, or there 
exists a long incubation period. 
Accessibility is also a critical factor to consider when evaluating the effectiveness of a 
diagnostic tool. The 2013-2016 Ebola Virus outbreak demonstrated the vital role of 
diagnostics for confirming cases, monitoring disease progression, and resource allocation 
planning. Notably, long transport times (several days) and the lack of rapid diagnostics in 
both resource-rich and resource-limited settings contributed to the initial failure to contain 
the outbreak.8  
In considering the requirements for global-scale testing, the ideal test would be applicable at 
the point-of-care (POC, at the site of sample collection) and in limited-resource settings 
(LRS). Globally distributed testing imposes stringent requirements on diagnostics devices 
that can be summarized by the ASSURED criteria published by the World Health 
Organization.9 The ASSURED criteria stands for affordable, sensitive, specific, user-
friendly, rapid, robust, equipment-free, and deliverable. It is worth taking some time to 
elaborate on each requirement. 
Considering the global nature of pandemics, affordability is required to enable wide-scale 
testing, especially in the most vulnerable populations. The cost of a test must be weighed 
against the benefits, and is typically measured by disability-adjusted life years, or DALYs, 
avoided.10 The advantages of an on-site POC diagnosis include reduced required 
infrastructure, laboratory workload, and turn-around-time. Overall, the patient experiences 
improved quality of care. However, cost comparison of POC tests to centralized laboratory 
testing is a controversial issue. Perspectives vary among patients, insurance companies, 
laboratory employees, and hospital employees.11 While labor costs and the cost per test are 
quantifiable values, improvements in quality of care are more difficult to assess. Considering 
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the tricky cost landscape, it is prudent for diagnostic developers to weigh the cost of a new 
POC test against its clinical benefit.   
The combined properties of sensitivity and specificity refer to the accuracy of the test. It is 
clear that test accuracy is the benchmark feature of a diagnostic test; and yet, a number of 
diagnostic tests have been developed and sold with poor accuracy.12-14 While no test will be 
100% accurate, it is important to strive for high sensitivity and high specificity from the 
beginning of diagnostic assay design. Generally, a test with over 90% sensitivity and 90% 
specificity has good diagnostic performance, but the utility of a test also depends on the 
specific application, prevalence of the pathogen, and rate of testing. 
The ideal POC test would be user-friendly, equipment-free, and deliverable – an example of 
an ideal POC test (though not designed for disease detection) is the pregnancy test. The 
pregnancy test can be performed in the comfort of one’s home by an untrained user provided 
with a simple page of instruction. In contrast, many gold-standard diagnostic tests require a 
trained user working in a temperature-controlled laboratory with access to expensive 
equipment.15-17 However, much of the developing world does not have access to centralized 
lab testing. Even in developed countries, during times of high diagnostic demand such as a 
global pandemic, centralized lab facilities cannot meet testing demands. In the recent 
COVID-19 pandemic, we have observed long shipping times, lack of trained personnel to 
process samples, and a shortage of diagnostic testing supplies.18 This has resulted in both a 
shortage of testing and long time-to-results for patients that are tested. 
The ideal POC test should also be robust. This is especially important for globally distributed 
diagnostics because reagents must withstand longer shelf-times, various temperature 
conditions, and operation by untrained users. If the POC test is not sufficiently robust, the 
accuracy and utility of the test would suffer.  
Lastly, the ideal POC should be rapid. This is an important requirement for on-site testing. 
For example, it is highly preferably for a doctor’s office or mobile clinic to test patients 
within the timespan of their visit. If this were the case, the health provider could prescribe 
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the appropriate treatment and consult the patient during the visitation (rather than in a 
follow-up call). The shorter the test, the more likely it is that patients will wait, the less space 
is required for waiting rooms, and the more tests can be processed for any given amount of 
time.  
In addition to the ASSURED criteria, we have learned that it is important for tests to be 
highly parallelizable. In recent years, tests have been developed with turn-around time as fast 
as 45 min,19 but throughput (and associated costs) is still a concern since only one specimen 
can be tested at a time. 
For disease diagnostics, there are three commonly employed test strategies: (1) cell culture, 
(2) protein-based testing (lateral-flow immune assay or enzyme-linked immunosorbent 
assay, LFA or ELISA), and (3) nucleic acid amplification testing (NAAT).  
Cell culture is one of the earliest developed methods of testing, and involves growing the 
target pathogen and diagnosing the pathogen using some other method (visually, microscopy, 
ELISA, NAAT).  However, cell culture requires long incubation times of many hours (rapid 
systems are still 8 h) which is not suitable or testing at the POC.15 
There are two common implementations of protein-based testing: the enzyme-linked 
immunosorbent assay (ELISA) and the lateral-flow immunoassay (LFA). Both of these 
methods rely on antibodies which bind to the target antigen or protein of interest. Usually 
these antigens are peptides displayed on the surface of the pathogen or antibodies developed 
by the host (serology testing). A common concern for protein-based testing is non-specific 
protein adsorption or off-target binding, which leads to low specificity of the assay.20,21 For 
ELISA specifically, assay times are long, and there are many user steps making ELISA 
unsuitable for POC testing.22,23 Meanwhile, the LFA, which is commonly utilized in the off-
the-shelf pregnancy test is ideally suited for POC testing, but lacks the sensitivity required 
for many diagnostic applications.24-28 
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NAAT is perhaps the most powerful of these three approaches, with its relatively short time-
to-result, high sensitivity, and high specificity. For many pathogens, NAAT is the preferred 
gold-standard testing method. There are 3 components to a NAAT: (1) nucleic acid 
extraction, (2) nucleic acid amplification, and (3) readout. First, nucleic acids (NAs) are 
purified and concentrated from the patient sample to eliminate inhibitors present in the 
sample matrix. Secondly, the purified nucleic acids (NAs) are amplified, typically using 
polymerase chain reaction (PCR), to generate billions of DNA copies. This approach works 
by using conserved primer sequences that are specific to the pathogen of interest. Therefore, 
if the pathogen is present, many DNA copies will be generated. Lastly, the amplified NAs 
can be detected in a number of ways such as fluorescence or visual readout. 
While NAAT excels with its high sensitivity and specificity, NAAT does not meet any of 
the remaining POC requirements (requires highly trained users in centralized labs with 
expensive and bulky equipment). In recent years, research labs have made developments 
towards POC NAAT.29-33 The diagnostics industry has also been developing integrated POC 
NAAT assays, the two most POC-amenable being the Cepheid GeneXpert system and the 
Abbott ID Now.19 Nevertheless, more improvements can still be made to ensure fulfillment 
of all the ASSURED criteria.  
 
Outline 
In this doctoral thesis, I document my contributions towards improved POC NAAT.  
In Chapter 2, I identify extraction buffer carry-over in commercial NA extraction kits as a 
major culprit for inhibition in downstream NA amplification.34,35 I address this concern with 
the addition of a two-phase wash (TPW) which acts to reduce carry-over. By improving 
sample preparation purification, this enables the use of greater volumes of purified eluent, 
thereby improving sensitivity and limit-of-detection of downstream tests.  
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In Chapter 3, I identify a problem with the titer reported for commercial stocks when 
examining the analytical sensitivity of the CDC-recommend RT-qPCR protocol for 
diagnosing SARS-nCoV-2. I used an ultrasensitive and precise assay, reverse transcription 
digital PCR (RT-dPCR), to independently quantify the concentrations of commercial nucleic 
acid stocks. This work has broader implications because one of the commercial stocks was 
genomic RNA from BEI and measured 270% and 300% compared to the label concentration. 
This stock has been used in at least 11 approved FDA Emergency Use Authorizations as of 
April 27, 2020. The precise and accurate reporting of stock concentrations is necessary to 
improve the evaluation of different NAAT kits.   
In Chapters 4 and 5, I develop tools for solving the sample-to-answer interface problem. 
While much of the published literature has focused on individual components (NA 
extraction, NA amplification, or readout), relatively less work has been shown towards the 
integration of these components. I designed and developed a meter-mix device (Chapter 4) 
which addresses urine sample transfer to a NA extraction device while simultaneously lysing 
the sample (thereby simplifying the NA extraction).36,37 I also designed a 3D printed C-clamp 
(Chapter 5) which facilitated sample loading into glass microfluidic devices for nucleic acid 
amplification.38,39 
In Chapter 6 and 7, I developed MATLAB image processing scripts to automatically analyze 
images of a digital nucleic acid amplification tracked over time. Each experiment set 
contained 20,000 wells and 100s of images. The first script (Chapter 6) analyzed images with 
a single fluorescent channel,40 and the second script (Chapter 7) utilized dual-channel 
fluorescence to enable melt-curve analysis.41  
Lastly, in Chapter 8, I describe additional tools developed for integrated sample-to-answer 
NAAT diagnostics.42 In particular, I developed a parallel-filled amplification module for 
conducting lyophilized and multiplexed loop-mediated isothermal amplification reactions 
(LAMP). I designed and developed an automated base station featuring Arduino-controlled 
motor rotation and a heating element to automatically operate a nucleic acid extraction device 
and nucleic acid amplification device. Lastly, I showed a cell-phone modified for 
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fluorescence readout and automated MATLAB image analysis for readout of the parallel-
filled amplification module.  
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2 .  C h a p t e r  2  
TWO-PHASE WASH TO SOLVE THE UBIQUITOUS 
CONTAMINANT-CARRYOVER PROBLEM IN COMMERCIAL 
NUCLEIC-ACID EXTRACTION KITS 
 
E. Jue, D. Witters, and R.F. Ismagilov. 2020. Scientific Reports. 10(1940). 
doi:10.1038/s41598-020-58586-3 
 
Abstract 
The success of fundamental and applied nucleic acid (NA) research depends on NA purity, 
but obtaining pure NAs from raw, unprocessed samples is challenging. Purification using 
solid-phase NA extractions utilizes sequential additions of lysis and wash buffers followed 
by elution. The resulting eluent contains NAs and carryover of extraction buffers. Typically, 
these inhibitory buffers are heavily diluted by the reaction mix (e.g., 10x dilution is 1 µL 
eluent in 9 µL reaction mix), but in applications requiring high sensitivity (e.g., single-cell 
sequencing, pathogen diagnostics) it is desirable to use low dilutions (e.g., 2x) to maximize 
NA concentration. Here, we demonstrate pervasive carryover of inhibitory buffers into eluent 
when several commercial sample-preparation kits are used following manufacturer 
protocols. At low eluent dilution (2-2.5x) we observed significant reaction inhibition of 
polymerase chain reaction (PCR), loop-mediated isothermal amplification (LAMP), and 
reverse transcription (RT). We developed a two-phase wash (TPW) method by adding a wash 
buffer with low water solubility prior to the elution step. The TPW reduces carryover of 
extraction buffers, phase-separates from the eluent, and does not reduce NA yield (measured 
by digital PCR). We validated the TPW for silica columns and magnetic beads by 
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demonstrating significant improvements in performance and reproducibility of qPCR, 
LAMP, and RT reactions. 
 
Introduction 
Polymerase chain reaction (PCR) is a widely used tool in molecular biology for generating 
many nucleic acid (NA) copies from a starting DNA template. PCR may also be combined 
with reverse transcription (RT) to amplify many DNA copies from a starting RNA template. 
The amplified NAs then serve different purposes, such as detection, quantification, library 
preparation for sequencing, or generating constructs for cloning 1,2. NA amplification is 
crucial in highly sensitive applications (few DNA copies) such as single-cells analyses or the 
detection of SNPs, cell-free circulating DNA, or pathogens 3-5. Isothermal amplifications are 
an attractive alternative to PCR that eliminate the stringent temperature cycling requirements 
6. Specifically, loop-mediated isothermal amplification (LAMP) is faster than PCR and is 
especially promising for diagnostic devices in point-of-care settings 7,8. PCR, RT, and LAMP 
typically require purified NAs as a starting template; however, extracting purified NAs from 
raw, unprocessed samples is challenging 9. Though commonly overlooked, the efficient and 
effective extraction of pure NAs is of paramount importance 10. 
A primary function of NA extractions is to eliminate inhibitors. If inhibitors are transferred 
into the eluent, they can delay or completely inactivate downstream applications such as PCR 
and LAMP 11,12. Inhibitors have also been implicated in failed RT, molecular cloning, and 
sequencing experiments 13-15. We anticipate two potential sources of inhibitors: (1) those 
present in the raw, unprocessed sample and (2) those introduced during the NA extraction 16. 
There have been numerous studies demonstrating the adverse effects of inhibitors in 
challenging sample matrices, such as humic acids, food particles, cellular debris, urine, 
blood, and stool 11,12,17-25. To remove these inhibitors, solid-phase extractions are an effective 
choice because they have been found to yield higher purity compared with other extraction 
methods 19,20,26-29. The two most common solid-phase extraction methods use either spin 
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columns or magnetic beads 28,30. In both methods, the sample is first mixed with a 
lysis/binding buffer, the lysed sample contacts the solid phase allowing NAs to bind, the 
solid phase is cleansed with one or more wash buffers, and the NAs are eluted with water. 
Typically, the lysis/binding buffer contains a chaotropic salt (e.g., guanidinium 
isothiocyanate) whereas the wash buffer contains a high concentration of ethanol (or 
isopropanol). Any carryover of these extraction buffers (lysis buffer or wash buffer) into the 
eluent could be greatly inhibitory to downstream analyses. 
The purified eluent contains NAs and any carried-over extraction buffers at their highest 
concentration. To run a downstream reaction, a volume of eluent is mixed with a volume of 
reaction mix. For research applications, it is standard to dilute the eluent 10x (e.g., 1 µL 
eluent and 9 µL reaction mix) 31,32, 25x (e.g., 1 µL eluent and 24 µL reaction mix) 33, or more 
34,35. At these high eluent dilutions, concentrations of inhibitors present in the eluent are 
reduced and thus their potential negative effects on the reaction are mitigated. However, the 
dilution of inhibitors equally dilutes the NAs, which may be detrimental when the original 
sample has low NA concentrations 3 and/or when high sensitivity is desired. For example, 
single nucleotide polymorphisms 5, cell-free circulating DNA 4, and single-cell analyses all 
require maximizing the concentration of NA loaded into the amplification mix. Maximizing 
NA concentration is also important for infectious disease diagnostics and monitoring the 
water supply, food supply, and environment 32,36-38. For these applications, a higher NA 
concentration could be achieved with a lower dilution (e.g., a 2.5x dilution would be 4 µL 
eluent and 6 µL reaction mix). The theoretical maximum NA concentration could be attained 
by eliminating the dilution altogether, which is only possible by adding eluent directly to a 
dried reaction mix (e.g., 10 µL eluent and dry reaction mix to make ~10 µL reaction). This 
can be achieved with lyophilization, wherein reagents are freeze-dried to a powder, or other 
approaches for generating dry reaction mixes. The use of dry reagents has additional benefits: 
simple assay protocols, lenient reagent-storage conditions, and long reagent shelf-life, all of 
which are desirable characteristics for the development of point-of-care devices. However, 
in using low dilutions or no dilution, extraction buffers in the eluent are used at higher 
concentrations, which may have adverse effects on downstream reactions. 
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Few studies have directly investigated inhibition resulting from solid-phase extraction kit 
buffers 39,40. In this manuscript, we aimed to quantify and reduce inhibition arising from 
buffer carryover in commercial extraction kits from well-known suppliers. We first identified 
that kit buffer carryover is indeed a concern when using low eluent dilutions (≤2.5x) for both 
commercial silica-column and magnetic-bead extractions (following manufacturer 
protocols). To improve our understanding of inhibition, we performed a detailed study using 
a range of buffer dilutions from different extraction kits. To address the carryover of kit 
buffers, we developed modified extraction protocols utilizing an additional two-phase wash 
(TPW) that would integrate easily with the existing manufacturer protocols 41. The TPW is 
a compound with low water solubility, can be added in between the wash and elution steps, 
and phase-separates with water after the elution step. We identified an optimized set of TPW 
candidates among several potential compounds and then evaluated TPW performance by 
testing kit protocols from leading manufacturers (Zymo and Qiagen) at both low and high 
eluent dilutions. To unambiguously show that inhibition is due to kit buffer inhibitors, as 
opposed to sample inhibitors or losses of NAs, we performed extractions on pure water 
samples with or without the TPW, and added the resulting kit extract to spiked qPCR, LAMP, 
and RT assays. 
 
Materials and Methods 
NA Stocks and Primers 
Lambda (λ) phage DNA (linear double-stranded 500 µg/mL, N3011L, New England Biolabs 
(NEB)) was purchased from NEB and the stock was quantified at 1.1x1010 cp/µL using 
digital PCR (dPCR). Escherichia coli DNA was extracted from an NEB 5-alpha strain using 
Epicentre QuickExtract DNA Extraction Buffer (Lucigen Corporation,Middleton, WI, 
USA), and the stock was quantified at 1.4 x 107 cp/µL using dPCR. Neisseria gonorrhoeae 
live infectious stock (Z017, Zeptometrix, Buffalo, NY, USA) was resuspended to 5 x 107 
cfu/mL in pre-warmed (37 °C) Hardy Diagnostics FB Broth (K31, Hardy Diagnostics, Santa 
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Maria, CA, USA) and diluted an additional 10-fold in urine to 5 x 106 cfu/mL. Urine 
from healthy human donors (>18 years of age) was acquired and used in accordance with 
approved Caltech Institutional Review Board (IRB) protocol 15-0566. Informed consent was 
obtained from all participants. Urine sample donations were never tied to personal identifiers, 
and all research was performed in accordance with the approved IRB protocol and relevant 
institutional biosafety regulations. Urine samples were stored at room temperature and used 
within 1 h of collection. Spiked urine (125 µL) was mixed with DNA/RNA Shield (125 µL) 
and lysis buffer (500 µL) for a total lysed sample volume of 750 µL. Both DNA and RNA 
were extracted simultaneously with a ZR Viral DNA/RNA Kit, and N. gonorrhoeae 16S 
RNA was found to be in over 200-fold excess of 16S DNA as verified by dPCR with or 
without an RT step. All NA stocks were diluted at least 100-fold into all reactions, thereby 
eliminating the effects of any inhibitors that could be present in the NA stock. Lambda 
LAMP primers 42, Lambda PCR primers 43, E. coli 23S rRNA gene LAMP primers 44, E. coli 
23S rRNA gene PCR primers 45, and N. gonorrhoeae 16S rRNA gene PCR primers 46 have 
been previously published and were supplied by Integrated DNA Technologies using 
standard desalting purification. 
 
Kit Extractions 
We tested three different silica-column kits: Zymo ZR Viral DNA/RNA Kit (outdated 
protocol, D7021), Zymo Quick-DNA/RNA Kit (updated protocol, D7021), and the 
QIAquick PCR Purification Kit (28104, Qiagen). For all silica-column kits, fresh collection 
tubes were used after each spin, and centrifugation speeds were set to 16,000xg. 
Centrifugation was performed on either an Eppendorf 5415D centrifuge (Eppendorf, 
Hauppauge, NY, USA) or a Thermo Fisher Scientific AccuSpin Micro 17R centrifuge (13-
100-676). We note that the QIAquick protocol calls for 17,900xg, but we instead ran at 
16,000xg which was the max speed for the Eppendorf 5415D. For both Zymo kits, 750 µL 
lysed sample was prepared by mixing 125 µL sample with 125 µL Zymo 2x DNA/RNA 
Shield and 500 µL Viral DNA/RNA Buffer. For the Zymo ZR Viral DNA/RNA kit, 750 µL 
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lysed sample was centrifuged for 1 min, 500 µL Zymo Viral Wash Buffer was centrifuged 
for 2 min, and 50 µL nuclease-free water was centrifuged for 30 s into a clean 1.5 mL tube. 
Optionally, either a dry spin or 300 µL TPW was centrifuged for 2 min in between the Viral 
Wash Buffer and elution steps. For the Zymo Quick-Viral DNA/RNA kit, 750 µL lysed 
sample was centrifuged for 1 min, 500 µL Zymo Viral Wash Buffer was centrifuged for 30s, 
an additional 500 µL Zymo Viral Wash Buffer was centrifuged for 30s, 500 µL 200 proof 
ethanol was centrifuged for 1 min, and 50 µL nuclease-free water was centrifuged for 30 s 
into a clean 1.5 mL tube. Optionally, either a dry spin or 300 µL TPW was centrifuged for 1 
min in between the ethanol and elution steps. For the QIAquick PCR Purification Kit, 125 
µL sample was mixed with 625 µL Buffer PB without indicator. 750 µL lysed sample was 
centrifuged for 30s, followed by 750 µL Buffer PE for 30s, a dry spin for 1 min, and 50 µL 
nuclease-free water for 1 min. Optionally, the dry spin was skipped or the dry spin was 
replaced with a 300 µL TPW and centrifuged for 1 min. 
We tested the Zymo Quick-DNA/RNA Viral MagBead (R2140). For the Zymo MagBead 
kit, 200 µL sample was mixed with 200 µL Zymo 2x DNA/RNA Shield, 4 µL Proteinase K, 
and 800 µL Zymo Viral DNA/RNA Buffer. 1204 µL was added to each tube, mixed with 20 
µL MagBinding Beads, and placed on an UltraRocker Rocking Platform (1660709EDU, 
Bio-Rad, Hercules, CA, USA) for 10 min at max speed. Tubes were transferred to a 
DynaMag-2 magnetic rack (12321D, Thermo Fisher Scientific) and we followed 
manufacturer instructions for the remainder of the protocol. Optionally, the 10 min dry step 
was skipped or the dry step was instead replaced with the addition of 500 µL TPW. In the 
modified protocol for the Zymo MagBead kit, we waited at least one additional minute and 
performed a second aspiration after each aspiration step in the manufacturer’s protocol. 
 
qPCR Mix 
qPCR reactions contained 1X Bio-Rad SsoFast Supermix (1725201, Bio-Rad), PCR primers 
(IDT) at 0.5 µM each, and were supplemented with nuclease-free water up to 10 µL. Each 
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96-well plate (thin-wall clear well, HSP9641, Bio-Rad) was sealed (Microseal B, 
MSB1001, Bio-Rad) and briefly spun in a Mini Plate Spinner Centrifuge (14-100-141, Fisher 
Scientific). Heating and real-time imaging were performed on the Bio-Rad CFX-96 Touch 
Real-Time PCR Detection System by heating to 95 °C for 5 min, cycling 40 times between 
95 °C for 15 s, 60 °C for 15s, and 72 °C for 20s, and taking a melt-curve analysis. For the E. 
coli DNA dilution experiment, qPCR was run for 60 cycles. Fluorescence readings were 
taken at the end of each extension step. Quantification cycle (Cq) was determined when the 
software’s automated baseline corrected fluorescence reached 200 RFU. 
 
LAMP Mix 
LAMP reactions contained the following concentrations of reagents: 1X Isothermal 
Amplification Buffer (20 mM Tris-HCl pH 8.8, 10 mM (NH4)2SO4, 50 mM KCl, 5 mM 
MgSO4, 0.1% Tween-20, B0537S, NEB, Ipswich, MA, USA), an additional 2 mM MgSO4 
(B1003S, NEB), 1.4 mM deoxynucleotide mix (N0447L or N0446S, NEB), 2 µM Invitrogen 
Syto-9 (S34854, Thermo Fisher Scientific), 2 µM Invitrogen bovine serum albumin 
(15561020, Thermo Fisher Scientific), 320 U/mL WarmStart Bst 2.0 (M0538L, NEB), and 
were supplemented with nuclease-free water (not DEPC-Treated, 4387936, Thermo Fisher 
Scientific) up to 10 µL. LAMP primers (Integrated DNA Technologies (IDT), Coralville, 
IA, USA) were designed, ordered, and added at NEB’s recommended concentrations of 1.6 
µM FIP/BIP, 0.2µM F3/B3, and 0.4 µM LoopF/B. Each 96-well plate was sealed and briefly 
spun. Heating and real-time imaging were performed on the Bio-Rad CFX-96 Touch Real-
Time PCR Detection System (1855195, Bio-Rad). Each 96-well plate was cooled to 12 °C 
for 2 min, held at 68 °C for 47 min with 35-second fluorescence read intervals, and we 
performed a melt-curve analysis. For the E. coli DNA dilution experiment, the 68 °C step 
was held for 105 min. Time-to-positive (TTP) was determined when the software’s 
automated baseline corrected fluorescence reached 1000 RFU. 
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Buffer Inhibition 
For studying kit buffer inhibitors, LAMP and qPCR reactions were spiked to 5 x 104 cp/rxn 
λ phage DNA (NEB) and supplemented with half-log dilutions of either Koptec 200-proof 
ethanol (V1001, Decon Labs, King of Prussia, PA, USA), Viral RNA Wash Buffer 1X 
(R1034-2-48, Zymo Research, Tustin, CA, USA), Buffer PE (19065, Qiagen, Germantown, 
MD, USA), Zymo DNA/RNA Shield 1X (R1200-125), Zymo Viral DNA/RNA Buffer 
(D7020-1-100), or Qiagen Buffer PB (19066) to the appropriate final concentration. For 
selecting the optimal TPW, LAMP and qPCR reactions were spiked with 1 µL of 5 x 104 
cp/µL λ phage DNA, diluted to 10 µL, and an additional 1 µL was added of either nuclease-
free water, 200 proof ethanol, isopropanol (BP2618-500, Thermo Fisher Scientific, 
Waltham, MA, USA), 1-butanol (3000-04, Mallinckrodt Chemicals), isopentanol (2992-04, 
Mallinckrodt Chemicals), 1-hexanol (H13303-100mL, MilliporeSigma, St. Louis, MO, 
USA), 1-heptanol (H2805-250mL, MilliporeSigma), 1-octanol (SHBH2844V, 
MilliporeSigma), 1-nonanol (131210-100mL, MilliporeSigma), 1-decanol (2397563-50g, 
MilliporeSigma), 1-undecanol (MKCG3271, MilliporeSigma), 2-dodecanol (D221503-5G, 
MilliporeSigma), 5 cSt silicone oil (317667-250mL, MilliporeSigma), or Fluorinert FC-40 
(ZF-0002-1308-0, 3M, St. Paul, MN, USA). 
 
dPCR Mix 
Droplet digital PCR (dPCR) experiments were performed on a Bio-Rad QX200 Droplet 
Digital PCR System (1864001, Bio-Rad). dPCR mixes were made with 1X QX200 dPCR 
EvaGreen Supermix (1864034, Bio-Rad), 200 nM forward primer, and 200 nM reverse 
primer. Eluent was diluted 10x in separate tubes and an additional 10x into the reaction mix. 
All samples were made to 50 µL and duplicates were run by adding 22 µL to two sample 
wells in the DG8 Cartridge for droplet generator (1864008, Bio-Rad). Droplet generation, 
droplet transfer, and foil sealing followed the manufacturer’s instructions. Thermocycling 
took place on a C1000 Touch Thermal Cycler (Bio-Rad) with a pre-melt at 95 °C for 3 min, 
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40 cycles of 95 °C for 30s, 60 °C for 30s, and 68 °C for 30s, and a stabilization at 4 °C for 
5 min, 90 °C for 5 min, and a hold at 12 °C until droplet analysis. A temperature ramp rate 
of 2C/s was used for temperature transitions. Droplets were read according to the 
manufacturer’s instructions. Analysis thresholds were manually set at the valley between 
negative and positive droplets. Final concentrations were determined using the merge setting 
on the QuantaSoft analysis software. No template controls (NTC) were always run and 
showed negligible normalized counts (<0.1%). 
 
RT Mix 
The RT reaction contained 1X Isothermal Amplification Buffer, 0.5 mM dNTP Mix, 0.2 µM 
primers, 1U/µL Riboguard RNase Inhibitor (RG90910K, Lucigen, Middleton, WI, USA), 
and 0.15 U/µL WarmStart Rtx (M0380L, NEB). The extracted N. Gonorrhoeae RNA was 
diluted 10x in a separate tube and an additional 10x by adding 2.5 µL into the 25 µL reaction 
mix (100x dilution total). Kit extracts were spiked in the reaction mix by adding either 2.5 
µL (10x) or 12.5 µL (2x). We added water to a total reaction volume of 25 µL. Temperature 
was set to anneal for 5 min at 25 °C, incubate for 10 min at 55 °C, and inactivate for 10 min 
at 80 °C in a C1000 Touch Thermal Cycler (1851196, Bio-Rad). 
 
Results and Discussion 
Establishing the presence and prevalence of inhibitors in buffers 
We first carefully designed an experiment to evaluate the presence, prevalence, and effects 
of buffer carryover when using standard commercial NA extraction kits. To eliminate the 
confounding effects of NAs or inhibitors originating from the sample, we performed NA 
extractions on pure water samples (Figure 2.9). When extracting from pure water samples, 
we refer to the eluent as the “kit extract,” which only contains water and inhibitors originating 
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from buffers in the extraction kits. Here, we tested a centrifugation-based NA extraction 
using a Zymo ZR Viral DNA/RNA Kit and followed the manufacturer's protocol. Next, we 
mixed the kit extract into a qPCR reaction spiked with λ phage DNA at either a 10x dilution 
(1 µL kit extract, 0.5 µL template DNA, 5.5 µL reaction mix) or 2.5x dilution (4 µL kit 
extract, 0.5 µL template, 5.5 µL reaction mix). We used heavily diluted purified λ phage 
DNA to ensure no inhibition originated from the template. The 10x and 2.5x dilution 
reactions contained different volumes of kit extract, but each had a final volume of 10 µL 
and contained the same concentration of λ phage template, λ phage primers, and qPCR 
components. We ran qPCR on a thermocycler for 40 cycles while taking readings at the end 
of each cycle. If the kit extracts have no inhibitory effect, we would expect the same 
quantification cycle (Cq) for both reactions. Given the amount of input DNA (5 x 10
4 copies), 
we expect amplification to occur at ~20 cycles. 
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Figure 2.1: Schematic depicting the carryover of buffers during sample 
preparation when nucleic acids (NA) are extracted using either (a) spin column 
centrifugation or (b) magnetic beads.  
Dashed red boxes highlight carryover of buffer into the eluent. Carryover buffer from 
the previous wash either mixes with the eluent (top dashed box in each panel) or 
phase separates (bottom dashed box in each panel) when the two-phase wash (TPW) 
is used. (c) Inset graph shows a qPCR run spiked with 5 x 104 copies λ phage DNA 
and λ phage primers into which we added Zymo ZR “kit extract.” (When extracting 
from pure water samples, we refer to the eluent as the “kit extract,” which only 
contains water and inhibitors originating from buffers in the extraction kits.) The 
graph compares the reaction inhibition in a 10x extract dilution and a 2.5x extract 
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dilution and shows the effect of adding a TPW (+TPW) during the nucleic-acid 
extraction step. Inhibition is similarly observed for magnetic bead extraction kits. 
N.D. stands for not detected. We ran 6 extractions (3 silica columns x 2 conditions) 
and used the same kit extract to make the high- and low-dilution conditions. 
 
Using the centrifugation sample-preparation protocol (Figure 2.1a) and a 2.5x dilution of kit 
extract, amplification in qPCR was completely inhibited (Figure 2.1c). In contrast, using the 
10x dilution, all three kit extracts (three separate columns) amplified at ~20 cycles as 
expected. The only variable that differed between the two conditions was that the 2.5x 
dilution (4 µL kit extract) contained four times the concentration of buffer compared with 
the 10x dilution (1 µL kit extract). This result led us to conclude that carryover of inhibitory 
buffers is inhibiting the qPCR reaction. 
We suspect that carryover results from residual buffer trapped in the column that is picked 
up during elution. Although centrifugation moves most of the extraction buffers to the waste 
tube for removal, some lysis/binding buffer and/or wash buffers may remain stuck in the 
column after each centrifugation step (Figure 2.1a). This could occur due to physical 
entrapment, surface tension, or physicochemical interactions with either the silica column or 
the walls of the tube. Furthermore, it is possible for some of the inhibitory components 
contained in the buffer to become unevenly trapped on the column. During the elution step, 
water could mix with these trapped buffers/inhibitors and carry them into the final eluent. 
We emphasize that for a standard elution volume of 50 µL water, even low volumes of 
carryover may correspond to a sufficiently inhibitory percentage of buffer in the eluent. For 
example, 500 nL buffer carryover corresponds to 1% buffer in the eluent and 2.5 µL 
corresponds to 5% buffer in the eluent. 
Buffer carryover also occurred when using magnetic-bead extraction. In these protocols, 
magnetic beads that bind to NAs in the appropriate buffer conditions are added to the sample. 
Extraction buffers are then added (lysis and multiple washes) by sequential rounds of buffer 
addition, magnetization to pull the magnetic beads to the side of the tube, and aspiration of 
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each buffer. (Figure 2.1b). For the elution step, water is added which releases the NAs 
from the magnetic beads, the magnetic beads are drawn to the sides of the tube, and the eluent 
is transferred to a clean tube. During this process, however, some buffer components may 
stick to the magnetic beads or adhere to the walls of the tube. Thus, although most of the 
buffers are removed during aspiration, a low concentration of extraction buffers transfer into 
the eluent when using the standard manufacturer protocols. Below (section “TPW validation 
for magnetic-bead extractions”), we explicitly examine the extent of buffer carryover for 
magnetic-bead extractions using low and high dilutions of eluent. 
We hypothesized that we could address the issue of extraction buffer carryover in 
commercial NA extraction kits by the addition of a TPW. The TPW is composed of an 
immiscible compound that phase separates with water, and we added it in between the wash 
step and the final elution (Figure 2.1a bottom, Figure 2.1b bottom). Our aim was to 
develop a TPW that would be simple, inexpensive, and that would integrate easily with 
existing protocols. If successful, the TPW would greatly reduce buffer carryover and improve 
downstream assay performance. In our study (Figure 2.1c), incorporating the TPW 
recovered qPCR (2.5x dilution of kit extract) and provided the expected Cq of ~20 cycles. 
This was a drastic performance improvement compared with the complete reaction inhibition 
we observed when the same dilution was run using the manufacturer protocol. 
 
Exploring the effects of buffer inhibition on amplification 
Having established that buffer carryover is a problem, we next aimed to better understand 
the effects of inhibition on amplification in qPCR and LAMP. We selected extraction buffers 
from a Zymo viral DNA/RNA kit and a Qiagen PCR purification kit. We chose these two 
commercial kits in particular because they both utilize minimal protocols (lysis, wash, elute) 
with no added steps (e.g. bacterial pellet spins, proteinase K, lysozyme, DNase/RNase, 
filtration, etc.). Specifically, we wanted to identify the concentration at which each buffer 
inhibits qPCR and LAMP. First, we added buffers at half-log dilutions (from 10% down to 
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0.032%) into λ phage spiked qPCR or LAMP reactions (1 µL diluted buffer, 1 µL template, 
8 µL reaction mix). We were also curious to see whether qPCR and LAMP were affected 
differently by inhibitors. We expected differences between the two amplification methods 
because qPCR amplification is temperature-gated, whereas LAMP amplifies continuously. 
Previous literature on this topic shows “mixed results;” many studies have shown that LAMP 
is more robust than PCR in the presence of inhibitors, 47-50 whereas others have shown that 
inhibition of PCR and LAMP depends on which inhibitor was used 40. 
We found that all extraction buffers were inhibitory to both types of reactions, but at different 
concentrations (Figure 2.2). As a control, for each kit, we ran the protocol with 0% buffer 
and found amplification with qPCR to yield a Cq of ~20.0 ± 0.3 cycles and amplification 
with LAMP to have a TTP of 7.1 ± 0.6 min. As a general trend, we found that wash buffers 
(ethanol, Zymo Viral Wash Buffer, and Qiagen Buffer PE; Figure 2.2a-c,g-l) were less 
inhibitory than lysis buffers (Zymo DNA/RNA Shield, Zymo DNA/RNA Viral Buffer, and 
Qiagen Buffer PB; Figure 2.2d-f,j-l). For qPCR, we observed a statistically significant (P < 
0.05) Cq delay of at least 0.5 cycles for wash buffer concentrations starting at 10% (Figure 
2.2a-c, Table 2-1) and for lysis buffers starting between 0.32 – 1% (Figure 2.2d-f, Table 
2-2). For LAMP, we observed a statistically significant (P < 0.05) TTP delay of at least 0.5 
min for wash buffer concentrations starting at 1–3.2% (Figure 2.2g-i, Table 2-3) and for 
lysis buffers starting at 0.32–3.2% (Figure 2.2j-l, Table 2-4). These results imply that the 
extent of inhibition on qPCR and LAMP reactions is inhibitor-dependent, which may help 
explain the “mixed results” in the literature. 
Next, we observed the presence of inhibitors at very low concentrations using melting 
temperature (Tm), as compared with Cq, TTP, or endpoint fluorescence (Figure 2.10-13). 
Interestingly, we observed that the presence of extraction buffers raised or lowered the Tm 
of the DNA product even at very low concentrations (1% - 3.2% for ethanol buffers, 0.32% 
- 1% for lysis buffers). Detecting a change in the Tm of an NA product could be a useful tool 
for diagnosing the presence or absence of extraction buffers in a reaction. 
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Figure 2.2: (a-f) qPCR and (g-l) LAMP experiments demonstrate reaction 
inhibition from NA extraction kit buffers. 
Quantification cycles (Cq) for qPCR or time to positive (TTP) for LAMP spiked with 
5 x 104 copies λ phage DNA and primers with increasing concentrations of extraction 
kit buffers. For ethanol dilutions (a,g), three separate amplification mixes were each 
combined with an independent ethanol dilution series. All remaining buffer dilutions 
(b-f, h-l) shared the same set of three amplification mixes (same 0% condition), and 
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each amplification mix was combined with an independent dilution series of each 
buffer. Each bar is the average of qPCR or LAMP technical triplicates (black circles). 
Where shown, numbers above a bar indicate the number of samples that amplified 
out of technical triplicates. Gray shading indicates when inhibition (>0.5 cycles or 
>0.5 min) was observed according to changes in Cq or TTP. Samples marked N.D. 
were not detected within either 40 cycles or 40 min. 
 
Inhibition in samples with low NA concentrations 
We next wished to test the effects of buffer-related inhibition in samples containing low NA 
concentrations. For applications requiring high sensitivity (e.g., single-cell sequencing, cell-
free circulating DNA, SNP genotyping, and diagnostics), amplification reactions are often 
run at or near the limit-of-detection (LOD). Samples starting with low NA concentrations 
thus require the polymerase to replicate more DNA than in samples that start with a high NA 
concentration. Therefore, we hypothesized that the inhibition effect resulting from buffer 
carryover would be stronger for these low NA samples (and detected as delayed Cq or TTP). 
Additionally, it has been recorded that PCR reactions with different primers and targets can 
respond differentially to inhibitors 11. To ensure the inhibitory effects we saw with λ phage 
DNA were not specific to just the set of DNA and primers we used, we ran this experiment 
using Escherichia coli DNA and E. coli primers. 
With qPCR, we found that the cycle delay as a result of buffer inhibitors was higher at lower 
NA concentrations (Figure 2.3a,b). We started with a medium concentration of target (5 x 
104 E. coli 23S copies) and tested 4-fold dilutions down to 0.05 copies with either control 
(no inhibition) or in the presence of 1% Zymo Viral DNA/RNA Buffer. We chose 1% lysis 
buffer because we had found 1% lysis buffer to be weakly inhibitory, and we suspected 
inhibition may worsen with decreasing DNA concentration.  
Our control reactions matched our expectations; we found 5 x 104 copies yielded a Cq of 
19.55 ± 0.04, the cycle increased by ~2 for every 4-fold dilution, and we detected the target 
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down to 3 copies. Compared with the 1% lysis buffer condition, we found that the reaction 
for the highest concentration (5 x 104 copies) was greatly impaired by 4.65 ± 0.13 (95% CI: 
4.33 – 4.97) cycles (Figure 2.3b). The delay worsened and variance increased as the NA 
concentration was decreased. At 3 copies/rxn, there was an 8.45 ± 0.94 (95% CI: 6.11 – 
10.79) cycle delay and all three triplicates amplified, but we needed to increase the number 
of cycles in this experiment in order to detect the delayed Cq. Our results showed that the 
presence of lysis buffer caused a decrease in the amplification efficiency with each cycle. 
This conclusion was also supported by the shallower amplification curves (Figure 2.15). 
 
 
Figure 2.3: (a-b) qPCR and (c-d) LAMP experiments targeting E. coli 23S rRNA 
gene, which shows increased impact of reaction inhibition at low NA 
concentrations. 
(a) qPCR and (c) LAMP spiked with 4-fold dilution series of E. coli 23S rRNA gene 
copies and comparing with and without Zymo Viral DNA/RNA Buffer. Each bar 
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represents the average of technical qPCR or LAMP triplicates (black circles). 
Numbers above a bar indicate the number of samples which amplified if not all 
triplicates were detected. Dashed boxes indicate axes for zoomed-in graphs of (b) 
qPCR and (d) LAMP. Numbers above each pair of bars indicate the difference in 
either Cq or TTP between the control and the reaction with added lysis buffer. 
Samples marked N.D. were not detected within either 60 cycles or 40 min. 
 
With LAMP, we also found that the delay as a result of buffer inhibitors was higher at lower 
NA concentrations (Figure 2.3c,d). Because LAMP was more sensitive to inhibitors than 
qPCR, we compared the control to 0.32% lysis buffer. The control reaction TTP was 7.61 ± 
0.08 min at 5 x 104 copies and the TTP increased with increasing dilutions up to 11.1 ± 0.7 
min at 195 copies. LAMP failed to amplify at higher concentrations of DNA than when using 
qPCR (amplification for 3 or fewer copies was stochastic). The addition of 0.32% lysis buffer 
caused a 0.95 ± 0.06 (95% CI: 0.80 – 1.10) min delay in TTP at the highest concentration (5 
x 104 copies/rxn), which increased as the E. coli DNA concentration was lowered to a 1.76 
± 0.19 (95% CI: 1.29 – 2.23) min delay at the lowest detectable concentration (780 
copies/rxn). At lower concentrations, amplification was stochastic. LAMP was unable to 
detect down to 195 copies/rxn in the presence of lysis buffer, indicating a loss in analytical 
sensitivity that was not observed with qPCR. Another difference between LAMP and qPCR 
is that although the LAMP TTP was delayed, the amplification rate and endpoint 
fluorescence in LAMP were not strongly affected (Figure 2.15). 
 
Identifying a suitable TPW 
Next, we identified a suitable wash buffer that would reduce the carryover of extraction 
buffer and integrate easily into existing protocols. The ideal wash buffer would be added 
after the final ethanol wash but prior to the elution and it would have the following properties: 
(1a) it would be non-inhibitory or (1b) it would not transfer to downstream assays such as 
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qPCR or LAMP, (2) it would remove previous washes from the column by an appropriate 
combination of solid-liquid and liquid-liquid interfacial properties and solubility of 
inhibitory components, and (3) it would not prematurely elute NAs from the column. We 
directly investigated criterion 1a by performing qPCR and LAMP reactions. We spiked 
reactions with λ phage DNA, diluted up to 10 µL, and we added an additional 1 µL of 
different wash buffer candidates to a total of 11 µL. As additional wash candidates, we tested 
increasing chain lengths of primary alcohols (or secondary alcohols if the primary form was 
unavailable), 5 centistokes (cSt) silicone oil, and FC-40 fluorocarbon oil (Figure 2.4a,b). As 
an experimental control, we tested a “No Additive” condition, which was a 10 µL reaction 
with optimized reaction conditions and no inhibitors. To control for the effects of a 1 µL 
dilution on the reaction, we also tested a “Water” condition which was an 11 µL reaction 
with no inhibitors. 
The “No Additive” control case showed a qPCR Cq of 20.09 ± 0.01 cycles (95% CI: 20.07 – 
20.12) and a LAMP TTP of 6.54 ± 0.05 min (95% CI: 6.42 – 6.66). We note that 1 µL in 11 
µL is a large fraction of the reaction mix (~9%), so we are overestimating buffer carry-over 
concentrations compared to normal operating conditions. The “Water” control showed no 
delay for qPCR and a 0.55 min delay for LAMP due to the dilution of LAMP reactants. For 
both qPCR and LAMP reactions, we found that long-chain alcohols with ≥ 9 chain lengths, 
silicone oil, and FC-40 were non-inhibitory for qPCR (within 1 cycle) and LAMP (within 1 
min) compared to the “No Additive” condition (Figure 2.4a,b). Octanol showed delays for 
qPCR (3.54 cycle difference) and LAMP (4.63 min difference), and only 2 out of 3 replicates 
amplified for qPCR. All alcohols with ≤ 8 chain lengths either had delayed amplification or 
the reaction was completely inhibited. Because long-chain alcohols, silicone oil, and FC-40 
showed little to no inhibition of qPCR and LAMP, these candidates fulfilled criterion 1a. 
These non-inhibitory wash candidates (long-chain alcohols, silicone oil, and FC-40), which 
we refer to as TPW, have low solubility in water (Table 2-7) and resulted in phase separation 
(Table 2-8). The TPW separates to either the top phase or the bottom phase (density 
dependent) while interacting minimally with the aqueous solution. As a result of reduced 
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interactions with the aqueous solution, the TPW is less toxic to downstream reactions. In 
LAMP reactions with added alcohols (Figure 2.4b), we also noticed that the TTP delay 
decreased as the solubility decreased (from 1-octanol to 2-dodecanol). The 1-octanol had the 
greatest delay (without completely inhibiting the reaction). We suspect that although 1-
octanol mostly occupied its own phase, some 1-octanol dissolved in the aqueous phase and 
disrupted polymerase activity. Furthermore, we also noticed that the TTP for the very low 
solubility TPWs matched the “No Additive” condition rather than the “Water” condition, 
implying the reaction mix was not diluted by the 1 µL of added TPW. 
 
 
Figure 2.4: Identifying the most effective TPW in (a) qPCR and (b) LAMP 
reactions and subsequent validation of 1-undecanol as a candidate TPW with 
(c) qPCR and (d) LAMP at low eluent dilutions. 
TPW candidates for (a) qPCR and (b) LAMP reactions were spiked with 5 x 104 
copies λ phage DNA and primers, made to 10 µL, and 1 µL of each wash candidate 
was added to yield 11 µL total. The number 2 next to the 1-octanol bar indicates that 
only two of the three replicates amplified. The dashed lines show the Cq or TTP of 
the uninhibited 10 µL “No Additive” control. (c) qPCR with 2.2x diluted eluent and 
(d) LAMP with 2x diluted eluent on a λ phage DNA sample extracted with a Zymo 
Quick-Viral DNA/RNA kit. Protocol was performed according to manufacturer 
instructions as provided or with an additional TPW (+1-undecanol) between the 
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ethanol wash and elution steps. Each bar represents the average of technical 
triplicates (black circles). We ran 6 extractions (3 silica columns x 2 conditions) and 
used the same eluent for both the qPCR and LAMP analyses. Samples marked N.D. 
were not detected within either 40 cycles or 40 min. NTC, no-template control. (a,b) 
We asked whether TPW candidates fell within the 99% CI of the “No Additive” 
control (qPCR: 20.01-20.17, LAMP: 6.25-6.83) with outliers indicated with a *. (d) 
We asked whether the average TTP was statistically different between the 
manufacturer protocol and the +1-undecanol condition using a t-test. 
 
Next, we evaluated criterion 1b (ensuring that the TPW does not transfer to qPCR and 
LAMP) as well as criterion 2 (the ability of the TPW to remove previous washes from the 
column) by running a NA extraction with or without TPW and adding the resulting eluent 
into qPCR and LAMP (Figure 2.4c,d). Of our TPW candidates, we selected 1-undecanol for 
further evaluation because (i) it was non-inhibitory for qPCR and LAMP reactions and (ii) 
as an alcohol, 1-undecanol may function similarly to ethanol- or isopropanol-based washes. 
In these experiments (testing criteria 1b and 2), we first diluted a commercially purified λ 
phage DNA sample to 2.5 x 106 copies and ran an NA extraction using the Zymo Quick-
DNA/RNA Viral Kit. We either followed the manufacturer protocol or added an additional 
300 µL 1-undecanol wash in between the Viral Wash Buffer and elution step. Using the 
manufacturer’s protocol, the resulting eluent is approximately 49 µL, but with the added 
TPW the resulting eluent is approximately 48 µL aqueous phase and ~1-2 µL 1-undecanol 
phase. Because we wanted to emphasize any potential inhibitory effects, we used a low 
dilution of eluent. For qPCR, we diluted 2.2x by adding 4.5 µL of eluent, 0.5 µL primers, 
and 5 µL qPCR reaction mix. For LAMP, we diluted 2x by adding 5 µL eluent, 0.5 µL 
primers, and 4.5 µL reaction mix. During the transfer of eluent into the reaction mix, we 
noticed that the phase separation yielded by the TPW resulted in minimal transfer of the TPW 
into downstream reactions (criterion 1b). The ~1-2 µL TPW separates from the aqueous 
phase and adheres to the walls of the tube, making it is easy to use a pipette to capture just 
the eluent. 
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Overall, we found that the addition of the 1-undecanol TPW greatly improved qPCR and 
LAMP performance at low dilution (Figure 2.4c-d). Without the inclusion of the TPW, 
qPCR run at low dilution of eluent, and following the manufacturer’s NA extraction protocol 
led to failed amplification in all 9 samples. However, with the TPW, the reaction completely 
recovered with a Cq of 18.46 ± 0.22 cycles. For LAMP and low dilution, we found that the 
manufacturer protocol amplified in 6.78 ± 0.17 min, whereas our modified TPW protocol 
amplified in 6.00 ± 0.04 min (Figure 2.4d). Not only was there a 0.78 min reduction in TTP 
(p < .01), variance was also reduced. Observing improvements for both qPCR and LAMP, 
we concluded there was reduced carryover of previous washes (criterion 2). 
To confirm our result that the 1-undecanol TPW with low eluent dilutions led to significant 
improvements in qPCR and LAMP, we repeated this experiment twice more and found 
similar results. In total (Figure 2.4-5), we ran 27 reactions (9 columns) following the 
manufacturer protocol and compared to 27 reactions (9 columns) with the added 1-undecanol 
wash. Each set of 3 columns showed a statistically significant (p < 0.01) difference 
comparing with and without 1-undecanol wash (p < 0.01) for qPCR and LAMP. For qPCR 
(triplicate) with the manufacturer protocol, we found 2/27 reaction wells with Cq between 
18-22 cycles, 3/27 wells were delayed by 4 or more cycles, and 22/27 wells did not amplify. 
Of the 5 wells that amplified, the average Cq and standard deviation was 28.6 ± 9.2 cycles. 
Meanwhile, adding the 1-undecanol wash resulted in 25/27 wells with Cq between 18-22 
cycles, 2/27 wells with a delayed Cq, and all reactions amplified. The average Cq with the 
added 1-undecanol wash was 19.7 ± 2.5 cycles. We emphasize that in addition to more 
samples amplifying, we found that the Cq dropped and the measured variance among samples 
was reduced, thereby improving the accuracy, speed, and robustness of the diagnostic assay. 
For LAMP (triplicates), all 27 wells with TPW (10.23 ± 0.06 min) had a faster TTP than all 
27 wells following manufacturer protocols (11.36 ± 0.27 min). Again, we find that the 1-
undecanol wash improved the speed and robustness (reduced variance) of the assay.  
Next, we investigated whether this result was specific to 1-undecanol or TPWs in general 
(Figure 2.5a,b,d,e). For this experiment, we chose 2-dodecanol because it is the longest 
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chain alcohol we tested, and 1-octanol because it is the shortest chain alcohol for which 
both qPCR and LAMP still amplified (Figure 2.4a,b). We expect 2-dodecanol to perform 
similarly to 1-undecanol because they are compositionally similar, and both were previously 
found to be non-inhibitory for qPCR and LAMP (Figure 2.4a,b). Accordingly, we expect 1-
octanol might perform worse given its higher solubility and previously observed delays. We 
also chose silicone oil and FC-40 to evaluate nonalcoholic forms of TPW. The result of our 
study found that all five TPW candidates outperformed the manufacturer protocol. In qPCR 
reactions, 7/9 reactions amplified with 2-dodecanol wash, 5/9 for 1-octanol, 5/9 for silicone 
oil, and 4/9 for FC-40, whereas without the TPW (following the manufacturer protocol) 
amplification often failed (5/27). For LAMP, all TPWs conditions amplified with a faster 
TTP than manufacturer protocol. (P < 0.01).  
We hypothesize 1-undecanol and 2-dodecanol performed best (greatest number of 
successfully amplified qPCR reactions and faster LAMP TTPs) because these two TPW 
candidates met all of our criteria (1a. non-inhibitory, 1b. low transfer to downstream assays, 
2. remove previous wash, and 3. do not elute NAs). Meanwhile, we hypothesize 1-octanol 
performs slightly worse because 1-octanol is inhibitory to qPCR and LAMP (criterion 1a). 
However, these inhibitory effects are minimal because 1-octanol phase-separated from the 
eluent and, as a result, only a small volume of 1-octanol was carried-over into the 
downstream reactions (criterion 1b). Lastly, we observed that both silicone oil and FC-40 
demonstrated slightly worse performance than the other TPW candidates. A potential 
explanation for the poor performance of silicone oil and FC-40 is that during the TPW step, 
the alcohols mixed with the previous ethanol-based wash, whereas silicone oil and FC-40 
did not (Table 2-8). As a result, this allows the alcohol-based TPWs to dilute and more 
effectively cleanse droplets of ethanol trapped in the column (criterion 2).  
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Figure 2.5: Comparing the performance of different TPWs with eluent at 2.2x 
dilution in qPCR (a,d), 2x dilution in LAMP (b,e), and 100x dilution in digital 
PCR (dPCR) (c,f). 
Samples were spiked with 2.5 x 106 copies λ phage DNA and extracted in 50 µL 
water with a Zymo Quick-Viral DNA/RNA kit. We compared each manufacturer’s 
protocol (Manuf. protocol) with the same protocol plus an additional TPW of either 
1-undecanol, 1-octanol, 2-dodecanol, silicone oil, or FC-40. To observe inhibition, a 
low eluent dilution was used in qPCR and LAMP with λ phage primers. To get a 
highly accurate quantification of NAs (for comparing these results), we ran each 
sample using dPCR with a high dilution of eluent (100x), which eliminates the effects 
of inhibitors. Each bar represents the average of qPCR or LAMP technical triplicates 
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(black circles) or single dPCR measurements. We ran 24 extractions (3 silica columns 
x 8 conditions) and the same eluent was used to run the qPCR, LAMP, and dPCR 
analyses. Where shown, numbers above a bar indicate the number of samples which 
amplified if not all triplicates were detected. Dashed lines (panels c and f) indicate 
the average NA recovery following manufacturer protocol. Samples marked N.D. 
were not detected within 40 cycles by qPCR or 40 min by LAMP. (a-f) For each of 
the five TPW candidates, we asked whether the mean value was statistically different 
from the manufacturer protocol by t-test. N.S. stands for not significant (P > 0.05). 
 
Next, we evaluated whether or not the TPW meets criterion 3 (NAs are effectively eluted 
from the column during the TPW or lost due to premature elution or incomplete elution) 
(Figure 2.5c,f). For this experiment, we used a 100x dilution to reduce buffer concentrations 
to non-inhibitory levels followed by digital PCR (dPCR); dPCR is a highly sensitive method 
for quantifying NAs that detects the same target (same primers) as qPCR. Although 
triplicates are commonly tested for qPCR and LAMP, for dPCR experiments we ran 
duplicates measurements each with more than 15,000 individual reactions. We merged the 
results from both experiments and used the Poisson distribution to calculate the final 
concentration using Bio-Rad’s QuantaSoft analysis software. We normalized all dPCR 
concentrations to the average concentration of the three extractions following the 
manufacturer protocols. We found that the TPW did not appreciably affect the NA recovery, 
fulfilling our final criterion (3) for an ideal wash buffer. Furthermore, all highly diluted dPCR 
measurements showed similar NA recovery between manufacturer protocol and TPW 
conditions, whereas low dilutions resulted in stark differences for both qPCR and LAMP, 
further confirming that inhibitors are responsible for delays in Cq and TTP. 
 
TPW validation for different kits with high and low dilution 
 
 
37 
To evaluate the generality of our approach and better understand the mechanism, we tested 
three extraction kit protocols with and without the added TPW. We also wanted to evaluate 
whether there is a difference in downstream amplification between high eluent dilution (10x) 
and low eluent dilution (2x or 2.5x). We evaluated Zymo’s kit D7021 using either the newer 
protocol (Zymo Quick-DNA/RNA Viral Kit) or the older protocol (Zymo ZR Viral 
DNA/RNA Kit). Although both protocols use the same buffers, the Zymo Quick Kit has 
three wash steps (two viral wash buffers and one ethanol wash), whereas the Zymo ZR kit 
has one viral wash buffer step. By default, the Zymo kits do not include a “dry spin.” The 
Qiagen QIAquick uses a different set of buffers, has one wash step, and by default includes 
a “dry spin.” In this experiment, all kits extractions were performed on pure water (there are 
no NAs during the extraction, Figure 2.9) to ensure we were only evaluating the effects of 
buffer inhibitors. The subsequent qPCR and LAMP reactions were then spiked with 5 x 104 
λ DNA copies. As a control, water was added to qPCR or LAMP (rather than kit extract) to 
represent the best-case reaction without inhibitors (“No Extract”). 
We did not observe inhibition at 10x dilution following manufacturer protocols (Figure 2.6), 
which confirmed that the standard 10x or more dilution into qPCR and LAMP prevents the 
inhibitory effects we see at lower dilutions. With a 10x dilution, we noticed that the “No Dry 
Spin” condition using the Qiagen kit with LAMP resulted in ~1 min delay. We note that the 
Qiagen kit manufacturer protocol requires the dry spin. Without the dry spin, we noticed the 
Qiagen kit extract had substantially more volume (~65 µL) than when the dry spin was 
included (~49 µL). This implies ~16 µL (25%) carryover of Buffer PE into the kit extract. 
The volume of kit extract from Zymo kits, however, was not noticeably affected by the 
addition of the dry spin (~49 µL with or ~49 µL without). 
 
TPW validation for different reaction mixes with high and low dilution 
To understand how different reaction mixes respond to buffer carry-over, we compared 
NEB’s SsoFast mix to NEB’s Luna mix and our manually prepared LAMP mix to NEB’s 
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pre-made LAMP mix. Using a Zymo Quick-DNA/RNA Viral Kit for extractions, we 
found that the Luna mix amplified at a 2.2x dilution of kit eluent, whereas the SsoFast mix 
did not (Figure 2.14a,b). This result implies that the Luna kit is more tolerant to the Zymo 
extraction buffer inhibitors than to those in the SsoFast mix. When we compared experiments 
with and without the TPW, we again observed that the inclusion of the TPW improved 
downstream assay performance, recovering amplification for the SsoFast mix and reducing 
the Cq from 19.1 to 18.4 cycles for the Luna qPCR assay. The manually prepared LAMP mix 
performed similarly to the pre-made LAMP kit, and again the TPW improved performance 
at low eluent dilution (2.86x). The TTP for the home-made mix was reduced from 7.4 to 7.0 
min, and the TTP for the pre-made mix was reduced from 7.9 to 7.4 min (Figure 2.14c,d). 
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Figure 2.6: Evaluation of TPW for different silica-column NA extraction kit 
protocols on pure water samples using (a-c) qPCR and (d-f) LAMP. 
All reactions were spiked with 5 x 104 copies λ phage DNA and primers. By 
manufacturer protocol, the (a,d) Zymo Quick-DNA/RNA Viral Kit and (b,e) Zymo 
ZR Viral DNA/RNA Kit do not include the dry spin (+dry spin), whereas the (c,f) 
Qiagen QIAquick PCR Purification Kit does. The left of each graph shows high 
dilution and the right shows low dilution. Each bar represents the result from a single 
qPCR or LAMP measurement. We ran 27 silica-column extractions (3 silica columns 
x 3 conditions x 3 extraction protocols), and the kit extract was shared between high 
and low dilutions of both qPCR and LAMP. Dashed lines show the Cq or TTP for a 
reaction without inhibitors (“No Extract”). Samples marked N.D. were not detected 
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within either 40 cycles or 40 min. (a-f) We asked whether the manufacturer protocol 
replicates (“No Dry Spin for Zymo kits, “+dry spin” for Qiagen kit) fell within the 
95% CI of the corresponding +1-undecanol condition for the low kit extract dilution 
case. The number of replicates that lie outside the 95% CI were indicated by the 
number of *s. 
 
However, when we used 2x or 2.5x dilutions, we observed significant inhibition (Figure 
2.6). With the Zymo kits and qPCR, there was no amplification whether or not an additional 
dry spin was added (Figure 2.6a,b), contradicting Zymo’s “no buffer contamination” claim. 
For the Qiagen kit (Figure 2.6c) and qPCR, the dry spin performs quite well, matching the 
No Extract control. With the Zymo kits and LAMP (Figure 2.6d,e), there are delays when 
following the protocol (no dry spin) but this is slightly improved by adding a dry spin. With 
the Qiagen kit and LAMP (Figure 2.6f), we observe total reaction inhibition without the dry 
spin and a 1.1 min delay following the manufacturer protocol. In summary, these results 
prove that inhibitors are carried into the elution, the additional dry step is helpful for 
removing wash buffers, and high dilution is the responsible for reducing concentrations to 
non-inhibitory levels. 
Lastly, we used our modified protocol utilizing 1-undecanol TPW and found substantially 
improved performance, even at low dilutions of the kit extract. We calculated the 95% 
confidence interval (C.I.) for each 1-undecanol condition at the low dilution and counted the 
number of outliers when following the manufacturer protocol. For all kits and combinations, 
we find that the TPW matches performance (Qiagen qPCR) or substantially improved 
performance (Zymo ZR and Zymo Quick qPCR, all LAMP conditions). The most drastic 
improvement is for the Zymo ZR kit and qPCR, which failed to amplify with the 
manufacturer protocol but completely recovered when we added the TPW (Figure 2.1c is a 
subset of Figure 2.6b showing “No Dry Spin” and “+1-undecanol”). Given the dramatic 
improvements and ease of adding the TPW, we recommend silica-column kit manufacturers 
further evaluate the TPW and consider inclusion with their kits. 
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We evaluated whether in some cases the TPW could be considered as an alternative for 
ethanol-based washes (Figure 2.16). As a comparison, we used the Zymo ZR kit, which only 
has one wash step (viral wash buffer). We either replaced the viral wash-buffer step with a 
dry spin (control), ethanol (control), or different TPW solutions. Briefly, we found that at 
least under these clean conditions, ethanol wash slightly outperforms the viral wash buffer, 
long-chain alcohol washes have the best performance, and non-alcohol washes (silicone oil 
and fluorocarbon oil) led to failed amplifications. 
 
TPW validation for magnetic-bead extractions 
We next tested whether TPW would improve magnetic bead extractions. Sur et al. previously 
found that transferring magnetic particles through a hydrophobic liquid effectively reduced 
PCR inhibitors 51. This method, termed immiscible phase filter (IPF), allowed for the 
replacement of multiple wash steps with a single pass through an immiscible liquid. At a 5x 
dilution of eluent into RT-qPCR, the IPF method showed no statistical difference in detected 
copies compared to commercial kits for HIV-1 spiked into plasma, Chlamydia and 
Gonorrhea spiked into urine, and proviral HIV-1 DNA integrated with peripheral blood 
mononuclear cells in whole blood. Another previous study conducted by Berry et al. 
described the IFAST (immiscible filtration assisted by surface tension) device 52, and further 
analyzed their method by examining surface tensions and energies associated with the 
aqueous phase, immiscible phase, and their device material. The IFAST device reduced total 
NA extraction operation time to less than 5 min while showing similar performance to 
commercial extraction kits with operation times between 15 to 45 min (eluent dilution 
unspecified). 
Here with test the TPW with a commercial magnetic bead extraction kit and evaluate both 
high and low dilution of eluent into LAMP and qPCR. A schematic of the magnetic-bead 
protocol is shown in Figure 2.1b. Using a Zymo Quick-DNA/RNA MagBead Extraction kit, 
we started with 1 x 106 copies λ DNA and eluted with 50 µL. By default, the protocol requires 
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a 10 min air dry step to allow residual ethanol from the wash step to evaporate. We tested 
the manufacturer protocol, protocol without the air dry step, and the protocol where the air 
dry step was replaced with a 1-undecanol TPW. At 10x dilution into qPCR (Figure 2.7a), 
omitting the dry step has no effect. Adding the 1-undecanol TPW led to a 1.1 cycle delay, 
which corresponds to a decrease in NA extraction efficiency (Figure 2.7c) rather than an 
inhibitory delay. At 10x dilution into LAMP (Figure 2.7b), omitting the air dry step causes 
a 1 min delay, and including the TPW leads to a 0.7 min TTP improvement. At low dilutions, 
the inhibitory effects are more drastic, and the TPW clearly outperformed the kit protocol 
with 2 of 3 manufacturer protocol samples performing worse by qPCR and 3 of 3 
manufacturer protocol non-detects.  
Further experimentation with the MagBead kit revealed that the greater the volume of 1-
undecanol carryover, the lower NA recovery we observed. In the experiment shown (Figure 
2.7), the three extractions had approximately 30 µL, 24 µL, and 22 µL of 1-undecanol 
carryover as measured by pipette. We found that following the initial 1-undecanol aspiration, 
a significant volume of 1-undecanol remains stuck to the magnetic beads and walls of the 
tube. To improve NA yield, we developed a modified protocol in which we aspirate the 1-
undecanol, wait at least 1 min, and aspirate any remaining 1-undecanol that slid down the 
tube due to gravity. This modification led to high yield of NAs after TPW for 1-undecanol 
(Figure 2.7c) and for other compounds (Figure 2.17). 
 
 
 
43 
 
Figure 2.7: Evaluating TPW for compatibility with Zymo Quick-DNA/RNA 
MagBead extraction with (a) qPCR, (b) LAMP, and (c) dPCR. 
Extraction performed on 1 x 106 λ phage DNA copies with either a 10 min air dry 
(Manuf. protocol), no air dry, or with the air dry replaced by a TPW (+1-undecanol) 
step. The resulting eluent is spiked at either high dilution or low dilution into (a) 
qPCR and (b) LAMP or 100x dilution into (c) dPCR. For dPCR (d), the bars to the 
right of the solid black line show the results for an extraction protocol with a +1-
undecanol wash using a high-yield protocol from a separate experiment (normalized 
to the no TPW control in that experiment). Bars represent single qPCR and LAMP 
or the merged result from a duplicate dPCR measurement. Dashed line in dPCR (c) 
indicates the average NA recovery following manufacturer protocol. We ran 9 
extractions (3 magnetic-bead extractions x 3 conditions), and the eluent was shared 
among qPCR, LAMP, and dPCR analyses. Samples marked N.D. were not detected 
within either 40 cycles for qPCR or 40 min for LAMP. (a-b) We asked whether the 
manufacturer protocol replicates fell within the 95% CI of the corresponding +1-
undecanol condition for the low eluent dilution case. The number of replicates that 
lie outside the 95% CI were indicated by the number of *s.  
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Figure 2.8: Measurement of reverse transcription (RT) efficiency on Neisseria 
gonorrhoeae RNA using 16S rRNA gene primers with (a) 10x dilution or (b,c) 
2x dilution of extractions from different commercial kits into RT reaction mix. 
NA concentration quantified by digital PCR after 100x dilution of post-transcribed 
RT mix. (c) We asked whether RT yield comparing with and without TPW was 
statistically different using a t-test. 
 
TPW validation for RT 
We next tested how extraction buffer carryover and TPW would affect RT. For applications 
requiring high sensitivity, the starting sample might only contain a few cells. In these 
scenarios, it is beneficial to detect RNA because many RNA copies can be made from a 
single DNA copy. To evaluate whether or not buffer carryover affects RT, we ran an RT 
experiment using RNA from N. gonorrhoeae, a pathogen with clinical and diagnostic 
relevance (Figure 2.8). First, a high concentration of RNA was extracted using a Zymo ZR 
Viral DNA/RNA Kit, and the extracted RNA was diluted 100-fold to reduce the 
concentration of inhibitors. Separately, we ran kit extractions on pure water samples for all 
previously examined NA extraction kits. We combined RNA with kit extractions into RT 
reactions containing WarmStart Rtx, NG 16S rRNA PCR primers, and other reaction 
components. We emphasize that all reactions contained equal concentrations of RNA, and 
were expected to produce equal levels of DNA. In each RT reaction, we either added 1 µL 
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kit extract to 9 µL reaction mix (10x) or 5 µL kit extract to 5 µL RT reaction mix (2x). For 
the “No Extract” condition, we added either 1 µL or 5 µL water. Following RT, the 
transcribed DNA was then diluted an additional 100x and added to dPCR mix (reaction mix, 
PCR primers) for quantitative analysis. By separating the RT reaction and quantification with 
dPCR, we can clearly investigate the effects of buffer inhibition on RT alone (whereas with 
a 1-step RT-dPCR reaction, it is difficult to determine whether inhibition affects RT or 
dPCR). We observed a clear trend: using kit extracts while following manufacturer protocols 
led to a reduction in the amount of DNA that was transcribed. This trend was observed even 
at a 10x dilution of kit extract into the RT reaction, implying that RT is more strongly 
inhibited than qPCR or LAMP (Figure 2.8a). However, when the TPW was added to the 
NA extraction kit, transcription efficiency was improved for all kits. These trends are even 
more pronounced when examining a 2x dilution of kit extract into the RT reaction (Figure 
2.8b). These results were further confirmed with greater sample size in a separate experiment 
for 2x dilution of kit extract into RT reaction (Figure 2.8c). We found that the TPW 
significantly improved the efficiency of the RT reaction. 
 
Conclusions 
In this chapter, we evaluated how the buffers from solid-phase silica-column centrifugation 
and magnetic-bead extraction kits are carried over into the eluent and inhibit downstream 
amplification reactions. Using kits from leading manufacturers, we repeatedly observed that 
as expected, a high (10x) dilution of eluent showed little to no inhibition of qPCR or LAMP 
reactions. However, carried-over extraction buffers caused delays or completely inhibited 
amplification and reverse transcription at low (2–2.5x) dilutions of eluent. We observed 
reaction inhibition using two different silica-column centrifugation kits (3 protocols: Zymo 
ZR, Zymo Quick, Qiagen QIAquick) and a magnetic-bead kit (Zymo MagBead) when using 
the manufacturer protocols. 
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We reduced the inhibition due to carryover by developing a TPW protocol that improved 
eluent purity and led to more efficient and reproducible reactions. We showed that the 
inclusion of a dry spin step, although helpful, still generated buffer carryover which inhibited 
qPCR and LAMP at low eluent dilutions. We discovered that the inclusion of a TPW step 
greatly reduced buffer carryover, and we found that low solubility compounds exhibited the 
best performance. Using the TPW protocol improved eluent purity, leading to more efficient 
(reduced delays in Cq or TTP) reactions. The addition of the TPW also improved the 
efficiency of RT reactions. 
Furthermore, TPW improved reproducibility of amplification reactions by reducing Cq and 
TTP variations between measurements (Figure 2.7a, 2.2x dilution), and at low target 
concentrations leading to more repeatable detection (Figure 2.7b, 2x dilution). 
Reproducibility is an important aspect of nucleic-acid assays in biological research and 
diagnostic assays. Given the high degree of sensitivity of reactions to levels of carryover 
(Figure 2.2), especially at low target NA concentrations (Figure 2.3), it is expected that 
slight variation in the extent of carryover can lead to high variation in the performance of a 
NA assay. High purity eluent from TPW was compatible with low dilutions into 
amplification mix, improving assay sensitivity because more NAs could be added to each 
reaction. 
We anticipate the addition of the TPW would improve NA extraction purity and performance 
of downstream assays in a variety of applications. We have demonstrated performance of 
TPW for a range of commercial extractions kits and a range of nucleic-acid targets. One 
limitation of this study is that it is not exhaustive: we have not tested every possible kit, every 
possible sample type, every possible NA reaction, and every possible nucleic-acid target. 
However, TPW is inexpensive and easy to incorporate into both silica-column (one 
additional spin) and magnetic-bead extractions (one additional aspiration), and therefore we 
encourage researchers and commercial suppliers to test TPW in their specific workflows and 
protocols. In particular, we expect to use the TPW extraction in combination with lyophilized 
reagents, which requires no dilution, and is highly desirable for point-of-care diagnostics. 
 
 
47 
Finally, the TPW will enable the field to develop new methods of sample preparation, such 
as pressure- or vacuum-based NA extractions, that are simpler, quicker, and more portable 
than current protocols. 
In addition to reducing extraction buffer carryover, we hypothesize the TPW could also 
reduce carryover of some compounds originating from the sample by removing them from 
the solid phase. For example, long-chain alcohols might remove nonpolar compounds better 
than traditional wash buffers (ethanol or isopropanol). This hypothesis remains to be tested 
in future work. Furthermore, we anticipate that improved eluent purity from the added TPW 
would enable high-sensitivity analyses that were previously difficult or impossible because 
high dilution of eluent has been the de facto standard. Improved eluent purity would be 
especially valuable for more challenging reactions, including long amplicons (DNA and 
RNA), targets with high GC content, and highly structured or chemically modified RNA 
targets (e.g. rRNA, tRNA). By enabling the use of lower dilutions, this method would 
enhance performance of NA analysis in applications where sensitivity and reproducibility 
are critical, including single-cell sequencing, cell-free circulating DNA analyses and SNP 
detection, and molecular diagnostics. 
 
Data Availability Statement 
Full dataset available through CaltechDATA, DOI: 10.22002/D1.1298; 
https://data.caltech.edu/records/1298 
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Supporting Information 
Kit extractions on “pure water” 
Typically, it makes sense to run controls with nucleic acids (NAs) spiked into the sample 
prior to the NA extraction step. However, in our “pure water” experiments we wanted to 
observe the effects of buffer carry-over independently of NA yield. We subsequently ran NA 
extractions on “pure water” samples to obtain eluent containing buffer carry-over (kit 
extract). We then used the original “pure water” sample as the non-inhibited control and 
compared to the kit extract (elution from kit extraction performed on pure water) in NA 
spiked downstream reactions. This approach was used to generate Figure 2.1c, Figure 2.6, 
and Figure 2.8. 
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Figure 2.9: Example protocol used for experiments performed on “pure water.” 
 
Full data set for buffer inhibitors in qPCR and LAMP 
Figure 2.10-13 show the full data set for buffer dilutions in qPCR and LAMP. The A-C 
panels of each figure (providing Cq and TTP data) were presented in the main text. Changes 
in the endpoint RFU were highly concordant with changes in Cq or TTP. The melting-
temperature (Tm) effects showed up at low concentrations of inhibitors, suggesting that Tm 
can be an effective indicator for the presence or absence of inhibitors in sample. 
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Figure 2.10: (a-c) Cq, (d-f) endpoint fluorescence, and (g-i) melting temperature 
for qPCR on 5 x 104 λ phage DNA copies in the presence of ethanol, Zymo Viral 
Wash Buffer, or Qiagen PE Buffer. 
Gray background indicates an average Cq delay of at least 0.5 cycles, RFU decrease 
of at least 500 RFU, or a melting temperature change of at least 0.5 °C compared 
with the 0% buffer condition.  
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Figure 2.11: (a-c) Cq, (d-f) endpoint fluorescence, and (g-i) melting temperature 
for qPCR on 5 x 104 λ phage DNA copies in the presence of Zymo DNA/RNA 
Shield, Zymo Viral DNA/RNA Buffer, or Qiagen PB Buffer. 
Gray background indicates an average Cq delay of at least 0.5 cycles, RFU decrease 
of at least 500 RFU, or melting temperature change of at least 0.5 °C compared with 
the 0% buffer condition. 
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Figure 2.12: (a-c) TTP, (d-f) endpoint fluorescence, and (g-i) melting 
temperature for LAMP on 5 x 104 λ phage DNA copies in the presence of 
ethanol, Zymo Viral Wash Buffer, or Qiagen PE Buffer. 
Gray background indicates an average TTP delay of at least 0.5 min, RFU decrease 
of at least 5000 RFU, or melting temperature change of at least 0.5 °C compared with 
the 0% buffer condition. 
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Figure 2.13: (a-c) TTP, (d-f) endpoint fluorescence, and (g-i) melting 
temperature for LAMP on 5 x 104 λ phage DNA copies in the presence of Zymo 
DNA/RNA Shield, Zymo Viral DNA/RNA Buffer, or Qiagen PB Buffer. 
Gray background indicates an average TTP delay of at least 0.5 min, RFU decrease 
of at least 5000 RFU, or melting temperature change of at least 0.5 °C compared with 
the 0% buffer condition. 
 
TPW validation for different reaction mixes with high and low dilution 
We compared NEB’s SsoFast EvaGreen Supermix to NEB’s Luna Universal qPCR master 
mix and a manually prepared LAMP mix to NEB’s pre-made WarmStart LAMP Kit. For the 
SsoFast mix, we used 500 nM primers (NEB recommended 300-500 nM), and for the Luna 
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mix we used 250 nM primers (NEB recommendation). The same primer concentration 
was used for the manually prepared LAMP mix and NEB’s pre-made mix. For the LAMP 
comparison, the lowest possible dilution was 2.86x because NEB’s pre-made LAMP mix 
required 65% of the reaction volume (WarmStart LAMP 2X master mix, 50x fluorescent 
dye, primers). 
 
 
Figure 2.14: Evaluation of extraction buffer inhibition on different assays and 
improvements due to the addition of a TPW. 
We compared the (a) NEB SsoFast mix to the (b) NEB Luna mix, and we compared 
a (c) manually prepared LAMP mix to an (d) NEB pre-made LAMP mix. Kit eluent 
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was obtained by performing a Zymo Quick-DNA/RNA Viral Kit on 2.5 x 105 copies 
λ phage DNA and eluting with 50 µL water. The left side of each graph shows high 
dilution and the right side shows low dilution. We ran six silica-column extractions 
in total, and the same kit extract was shared among the high and low dilutions of all 
assays. Samples marked “N.D.” indicate not detected within either 40 cycles (qPCR) 
or 40 min (LAMP). All negative controls were clean (not shown). For the low eluent 
dilution conditions, we asked how many replicates following the standard 
centrifugation protocol fell outside of the 95% confidence interval for the 
corresponding centrifuge +TPW condition (indicated by number of *). 
 
Buffer inhibitors in qPCR and LAMP 
We note that 3.2% Qiagen PE Buffer in LAMP caused a large delay (6.0 min ∆TTP), but 
this difference does not measure as statistically significant by t-test. This is due to a bias 
introduced by a single non-detect (8 out of 9 amplified) which greatly increased the measured 
standard deviation. If we exclude the non-detect from the analysis (rather than assigning the 
non-detect to a value of 46.7 min), the t-test measures a P-value of 0.002. Also of potential 
interest, Qiagen PB Buffer appears to have sped up LAMP at low concentrations (0.1% - 
1%). This result is unexpected, and further testing is required to validate this surprising result, 
which we hypothesize is not generalizable (e.g. could be primer or reaction mix dependent).  
Table 2-1: Summary of ethanol-based buffer dilutions for qPCR.  
The average and standard deviation were calculated from 9 replicates. The ∆Cq is 
calculated by subtracting the average value for a given buffer concentration from the 
water condition (0%). A positive value indicates a cycle delay when adding the 
buffer. P-values were calculated by a 1-tailed unequal variance t-test compared to the 
water condition (0%). A * indicates a delay of at least 0.5 cycles and P-value <0.05. 
Non-detects were assigned a value of 40 cycles. VWB = Zymo Viral Wash Buffer; 
PE = Qiagen PE Buffer. 
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Table 2-2: Summary of lysis buffer dilutions for qPCR. 
The average and standard deviation were calculated from 9 replicates. The ∆Cq is 
calculated by subtracting the average value for a given buffer concentration from the 
water condition (0%). A positive value indicates a cycle delay when adding the 
buffer. P-values were calculated by a 1-tailed unequal variance t-test compared to the 
water condition (0%). A * indicates a delay of at least 0.5 cycles and P-value <0.05. 
Non-detects were assigned a value of 40 cycles. PB = Qiagen PB Buffer. 
 
 
Table 2-3: Summary of ethanol-based buffer dilutions for LAMP. 
The average and standard deviation were calculated from 9 replicates. The ∆TTP is 
calculated by subtracting the average value for a given buffer concentration from the 
water condition (0%). A positive value indicates a cycle delay. P-values were 
calculated by a 1-tailed unequal variance t-test compared to the water condition (0%). 
A * indicates a delay of at least 0.5 min and P-value <0.05. Non-detects were 
assigned a value of 46.7 min. VWB = Zymo Viral Wash Buffer; PE = Qiagen PE 
Buffer. 
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Table 2-4: Summary of lysis buffer dilutions for LAMP. 
The average and standard deviation were calculated from 9 replicates. The ∆TTP is 
calculated by subtracting the average value for a given buffer concentration from the 
water condition (0%). A positive value indicates a cycle delay. P-values were 
calculated by a 1-tailed unequal variance t-test compared to the water condition (0%). 
A * indicates a delay of at least 0.5 min and P-value <0.05. Non-detects were 
assigned a value of 46.7 min. PB = Qiagen PB Buffer. 
 
 
 
Inhibitory effects on NA amplification curves 
We observed that qPCR reactions with lysis buffer (Figure 2.15a, dashed lines) had lower 
amplification efficiency with each cycle compared with reactions lacking lysis buffer 
(Figure 2.15a, solid lines). This experiment demonstrates that the presence of lysis buffer 
causes a delay in the Cq and a reduction in the endpoint fluorescence intensity. Meanwhile, 
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LAMP reactions with lysis buffer experienced an initiation delay, but the amplification 
rate and endpoint fluorescence intensity were not strongly affected (Figure 2.15b). 
 
 
Figure 2.15: (a) qPCR and (b) LAMP amplification curves with (dashed lines) 
or without (solid lines) Zymo Viral DNA/RNA Buffer for 4-fold dilutions of E. 
coli 23S rRNA gene copies. 
For qPCR we used 1% lysis buffer, and for LAMP we used 0.32% lysis buffer. Time-
to-positive (TTP) threshold of 200 RFU for qPCR or 1000 RFU for LAMP is drawn 
as a dotted black line. Legend indicates the number of E. coli 23S rRNA gene 
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copies/rxn. The qPCR amplification curves correspond to the experiment in Figure 
2.3 of the main text. 
 
TPW screen with qPCR and LAMP 
Table 2-5: TPW screen with qPCR. 
∆Cq calculated by subtracting the “No additive” control from each condition. 
 
Table 2-6: TPW screen with LAMP. 
∆TTP calculated by subtracting the “No additive” control from each condition. 
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Solubility table and ethanol phase separation for TPW candidates 
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Table 2-7: Solubility table for two-phase wash (TPW) candidates 
 
 
Table 2-8: Compounds were mixed at a 1:1 volume ratio. 
A “2” denotes phase separation into 2 distinct phases, whereas a “1” forms a single 
phase. VWB stands for Zymo Viral Wash Buffer, which contained 80% ethanol 
(v/v). 
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Evaluating a 3-step centrifugation extraction with TPW 
We wanted to see whether in some cases the TPW could be considered as an alternative to 
the ethanol wash for removing lysis buffer. Exchanging the ethanol wash for a TPW could 
be useful for applications in which the starting sample is already relatively pure. For this 
experiment, we used the Zymo ZR kit, which only has three centrifugation steps: lysis 
(sample, shield, lysis buffer), wash (ethanol-based viral wash buffer), and elution (water). 
We either followed the manufacturer protocol or replaced the viral wash buffer with a dry 
spin, ethanol, or TPW (Figure 2.16). We added 5 µL of the resulting eluent to 5 µL of LAMP 
reaction mix and amplified at 68C. Eluent from the manufacturer protocol amplified in 5.7 
min. The dry spin did not amplify, which is expected because lysis buffer was not removed 
by any wash steps, and lysis buffer is very inhibitory for LAMP. A 100% ethanol wash 
performed slightly better (earlier TTP) than the viral wash buffer, and both 1-octanol and 2-
dodecanol outperformed the wash buffer. Meanwhile, eluent from the silicone oil and FC-40 
wash conditions did not amplify. A dPCR experiment on heavy dilutions of the eluent show 
similar recovery for all conditions, with a slight reduction for the silicone oil wash. This 
demonstrates that 1-octanol and 2-dodecanol remove lysis buffer from the column. The 
simplicity of a 3-step protocol (bind, wash, elute) is compatible with point-of-care devices 
(few steps), and could be useful for applications with relatively clean samples. 
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Figure 2.16: Evaluation of TPW as a potential alternative to ethanol-based viral 
wash buffer in a Zymo ZR kit. 
(a) LAMP reaction with 2x dilution of eluent and (b) dPCR reaction with 100x 
dilution of eluent. Bars represent the average of technical LAMP triplicates or 
merged duplicate dPCR measurements. We ran 7 extractions (1 silica column x 7 
conditions), and same eluent was used LAMP and dPCR reactions. No template 
controls (n=3) and samples marked N.D. were not detected within 40 min. 
 
Evaluating a low-carryover, high-yield MagBead protocol 
The manufacturer protocol for the Zymo Quick-DNA/RNA Viral MagBead Kit led to 
significant extraction buffer carryover (as shown in Figure 2.7-8). To improve NA yield with 
the added TPW, we performed the initial TPW aspiration, waited at least 1 min, and aspirated 
any remaining TPW. This second aspiration collected a few microliters of residual buffer 
that dripped down from the walls of the tube or from the magnetic beads. To reduce carryover 
of all buffers, we also applied this 1 min wait and secondary aspiration to all steps 
(lysis/binding buffer, wash buffers). We evaluated this modified protocol for different TPWs, 
and the results are shown in Figure 2.17. At high dilutions of eluent, there were no visible 
indicators of inhibition for any of the samples. Our modified protocol greatly reduced 
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carryover overall, such that qPCR began to work even at low dilutions (whereas when run 
using the standard manufacturer protocol, we saw inhibition). The addition of the TPW 
further improved LAMP at low dilutions. Finally, NA recovery improved to 75-100%, 
achieving our original goal. 
When inhibitors are a major concern and time is not an issue, we recommend performing the 
MagBead protocol with secondary aspirations on each step, adding a 10-min dry step, and 
adding the TPW. For an approach balancing performance and assay time, we recommend 
following the manufacturer protocol, replacing the 10-min dry step with the TPW, and 
adding a secondary aspiration step just prior to the elution. 
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Figure 2.17: Evaluation of a modified Zymo Quick-DNA/RNA Viral MagBead 
Kit for reduced carryover with and without TPW by (a) qPCR, (b) LAMP, or 
(c) dPCR. 
All conditions were performed with a modified protocol for high NA yield when 
combined with TPW. MagBead extractions were performed on 2.5 x 106 λ phage 
DNA copies. Low and high eluent dilutions evaluated by qPCR and LAMP. A 100x 
eluent dilution into dPCR shows high yield with TPW. Bars represent single qPCR 
and LAMP reactions or merged duplicate dPCR measurements. We ran 21 
extractions (3 magnetic-bead extractions x 7 conditions), and the same eluent was 
used in qPCR, LAMP, and dPCR analyses. 
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Statistical analysis methods 
Confidence intervals were calculated assuming the populations to be normally distributed 
and using a t statistic. For buffer inhibition experiments, statistical analysis was performed 
by a 1-tailed unequal variance t-test (N=9) comparing the water condition (control) to each 
buffer concentration (H1: the mean is delayed). For the subsequent experiments, we used a 
2-tailed unequal variance t-test (H1: the means are different). Non-detects were assigned the 
maximum possible Cq measurement of 40 cycles or a TTP of 46.7 min to indicate the lack of 
amplification. Although this approach introduces some bias into the analysis, we believe this 
is the best representation for handling non-detects (other alternatives include excluding the 
non-detects or assigning non-detect values to the average of those that amplified). 
There are many potential sources of experimental variation (e.g. column-to-column, day-to-
day generation of master mix, buffer dilutions, and pipetting errors), and we tried to control 
for these by running triplicates for different variables (buffer/MM dilutions, columns, 
technical qPCR/LAMP assays). A priori, we would have assumed our independent variables 
to be differences in buffer dilutions or differences among columns, and we expected that our 
technical replicates would display a narrow distribution. Instead, we observed large 
variations among technical replicates (e.g. 2 out of 3 amplify). Because large variations 
appear at the level of the technical replicate, we treated each technical replicate as an 
independent sample in our statistical analysis.  
Familywise error rate across the reported statistical analyses was not controlled (e.g. 
Bonferroni correction). All data have been made publicly available and, to strengthen the 
findings of this study, we encourage further replication and validation, as there are numerous 
different potential applications and variables to examine (e.g. sample matrices, extraction 
kits, sequencing, etc.).  
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3 .  C h a p t e r  3  
COMMERCIAL STOCKS OF SARS-COV-2 RNA MAY REPORT 
LOW CONCENTRATION VALUES, LEADING TO ARTIFICIALLY 
INCREASED APPARENT SENSITIVITY OF DIAGNOSTIC 
ASSAYS 
 
E. Jue and R.F. Ismagilov. 2020. medRxiv. pre-print. doi: 10.1101/2020.04.28.20077602  
 
Abstract 
In response to the rapidly evolving COVID-19 pandemic, the U.S. Food and Drug 
Administration (FDA) has rapidly issued 49 emergency use authorizations (EUAs) for 
SARS-CoV-2 in vitro diagnostic test-kits. A critical metric in the performance evaluation for 
a diagnostic test kit is the analytical sensitivity, which is measured by the limit of detection 
(LOD). Commercial RNA stocks with known titers are used to determine LOD. We 
identified a problem with the titer reported for the commercial stocks when examining the 
analytical sensitivity of the reverse transcription quantitative PCR (RT-qPCR) protocol that 
is recommended by the Centers for Disease Control and Prevention (CDC) using plasmid 
DNA from Integrated DNA Technologies (IDT), synthetic RNA from BEI Resources (BEI), 
and extracted genomic RNA from BEI. We detected 3/3 positives for reactions containing 
synthetic RNA at a concentration of 0.1 copies/reaction (based on the supplier’s label 
concentration). The apparent better-than-single-molecule performance is a statistically 
highly unlikely event, indicating a potential inaccuracy in the supplier’s quantification of the 
stock material. Using an ultrasensitive and precise assay, reverse transcription digital PCR 
(RT-dPCR), we independently quantified concentrations of commercial SARS-CoV-2 
plasmid DNA and SARS-CoV-2 RNA stocks. For plasmid DNA, the actual concentration 
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measured by RT-dPCR was 11% of the nominal label concentration. For synthetic RNA, 
the actual concentration measured by RT-dPCR for one lot was 770% of the label 
concentration, and for a different lot was 57% of the label concentration. For genomic RNA, 
the concentration measured by RT-dPCR for one lot was 240% of the label concentration, 
and for a different lot it was 300% of the label concentration. This SARS-CoV-2 genomic 
RNA from BEI Resources has been used in at least 11 approved FDA Emergency Use 
Authorizations as of April 27, 2020. Such deviations of reported RNA or DNA stock 
concentrations from true concentrations can result in inaccurate quantification and 
calculation of LOD. Precise and accurate reporting of DNA and RNA stock concentrations 
by commercial suppliers will enable accurate quantification of assay performance, which is 
urgently needed to improve evaluation of different assays by diagnostic developers and 
regulatory bodies. 
 
Introduction 
As of April 27, 2020, the COVID-19 pandemic has reached 185 countries/regions, with more 
than 3 million infected individuals, and more than 210,000 deaths.[1, 2] The rapid spread of 
SARS-CoV-2 (the virus that causes COVID-19) and the large proportion of asymptomatic 
infected individuals has led to widespread demand for diagnostic test kits. To meet the 
massive demand, on February 4, 2020, the U.S. Department of Health and Human Services 
(HSS) secretary declared that circumstances exist justifying the authorization of emergency 
use of in vitro diagnostics for detecting SARS-CoV-2.[3] Since then, the U.S. Food and Drug 
Administration (FDA) has fast-tracked 49 Emergency Use Authorizations (EUAs) for 
SARS-CoV-2 test-kit manufacturers and commercial laboratories.[4]  
The application to receive an EUA requires a description of the assay and an evaluation of 
its performance.[5] A key metric in evaluating assay performance is the analytical sensitivity, 
which describes the ability of a test to detect very low concentrations of the target analyte. 
Analytical sensitivity is typically measured using the limit-of-detection (LOD), which is the 
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concentration of target analyte that can be consistently detected at least 95% of the time 
(19 of 20 replicates are positive). It is important for test kits to demonstrate a low LOD, 
which indicates good sensitivity of the test and the ability to detect samples containing very 
low viral RNA concentrations. Thus far, many diagnostic test kits for SARS-CoV-2 RNA 
have reported good LODs, with some reporting down to as low as 40 copies/mL.  
We obtained SARS-nCoV-2 plasmid DNA from IDT, synthetic SARS-nCoV-2 RNA from 
BEI, and genomic RNA from SARS-nCoV-2, isolate USA-WA1/2020 from BEI. In a well-
functioning assay (i.e., perfect transcription of RNA), we would expect to observe the same 
LOD for all 3 stocks. Instead, using the quantitative reverse transcription polymerase chain 
reaction (RT-qPCR) protocol recommended by the Centers for Disease Control and 
Prevention (CDC), we found substantial discrepancies, leading us to question the accuracy 
of the reported stock concentrations from the commercial suppliers.   
In this manuscript, we aimed to resolve the discrepancies in the LODs obtained with the three 
SARS-CoV-2 NA stocks by performing our own quantification of each stock concentration 
using a highly sensitive digital quantification method, reverse transcription digital PCR (RT-
dPCR).[6, 7] 
 
Results and Discussion 
Half-log dilutions of NA stocks in RT-qPCR 
We first performed half-log dilutions on each SARS-CoV-2 NA stock (plasmid DNA from 
10,000 to 3.16 nominal copies/reaction and synthetic RNA and genomic RNA from 100 to 
0.0316 nominal copies/reaction) using the CDC-recommended RT-qPCR protocol (Figure 
3.1). A priori, we expect all NA stocks to have similar LOD. We also expect that the RNA 
LOD may be slightly worse than the DNA LOD because RNA must be transcribed prior to 
amplification. Contrary to these expectations, we observed that both RNA stocks 
outperformed the DNA stock. The first non-detects (reactions failing to amplify) appeared at 
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3.16 copies/reaction for plasmid DNA (Figure 3.1A), at 0.0316 copies/reaction for 
synthetic RNA (Figure 3.1B), and at 0.316 copies/reaction for genomic RNA (Figure 3.1C). 
We also observed lower Cq values for synthetic RNA compared with genomic RNA at the 
same input dilution (using the supplier’s label concentration). 
Of particular interest, when quantifying the synthetic RNA, we detected 3/3 positives at a 
dilution of just 0.1 copies/reaction, indicating a virtually impossible better-than-single-
molecule assay performance. An RT-qPCR reaction requires a minimum of 1 RNA copy as 
a template to exponentially amplify and generate a detectable signal. Better-than-single-
molecule assay performance is highly unlikely based on statistics. Using the Poisson 
distribution,[8] which accounts for the stochasticity in loading a reaction well, when loading 
a solution into a well at an average target RNA concentration of 0.1 copies/reaction, there is 
a ~9.5% chance that a reaction well actually contains at least one RNA copy. If testing a set 
of 3 reaction wells, the probability that all 3 wells contains at least one RNA copy each drops 
to 0.086% (0.0953). 
 
Figure 3.1: Better-than-statistically-likely performance of reverse-transcription 
quantitative PCR (RT-qPCR) protocol recommended by the CDC using half-
log dilution series of SARS-CoV-2 nucleic-acid targets. 
Plots show number of quantitation cycles (Cq) for half-log dilutions of (A) plasmid 
DNA lot 508728 from Integrated DNA Technologies (IDT), (B) synthetic RNA lot 
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70033953 from BEI Resources (BEI), and (C) genomic RNA lot 70033700 from 
BEI. No-template controls (n=24) did not amplify after 80 cycles. 
 
Re-quantification of NA stocks with RT-dPCR 
To resolve the differences in LOD and understand the apparent better-than-single-molecule 
performance of the CDC assay, we re-quantified the NA stocks using an RT-dPCR protocol 
(Bio-Rad dPCR EvaGreen Supermix with added WarmStart Rtx (NEB) (Figure 3.2). We 
first ran 16 no-template controls and measured an average background concentration of 1.9 
± 1.0 copies/µL. We defined the assay detection limit (99.7% confidence) as the background 
concentration plus 3 standard deviations of the background,[9] and calculated the assay 
detection limit of RT-dPCR to be 4.9 copies/µL. To quantify each stock concentration, we 
first diluted the NA stock down to a concentration within the digital quantification range (10 
- 120,000 input copies of target) and measured with RT-dPCR.[10] We then took the 
concentration obtained from the RT-dPCR measurement, subtracted the background 
concentration, and multiplied the result by the dilution factor to calculate our RT-dPCR 
measured stock concentration.  
We ran a dilution series for each SARS-CoV-2 NA stock. For plasmid DNA (IDT, lot 
508528), we observed that all RT-dPCR quantifications were systematically lower than the 
concentration we expected from the supplier’s label concentration, except when our 
measurements dropped below the assay detection limit (Figure 3.2A). To further validate 
our results, we performed 2 additional dilutions down to what should have been 633 
copies/µL. Of the three measurements taken at 633 copies/µL, two were performed using 
RT-dPCR, and the third was performed using dPCR (no reverse transcription). The RT-
dPCR measurements were 69 and 66 copies/ µL, and the dPCR measurement was 65 
copies/µL. As expected for DNA, there was no difference in our measurements when using 
the dPCR assay with or without reverse transcription. To reduce the contributions of Poisson 
noise and background signal on our quantification, we used the highest concentration that 
we tested to quantify the stock concentration. Using the dilution for which we expected 2000 
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plasmid DNA copies/µL, we actually measured 220 copies/µL. From this measurement, 
we calculated a stock concentration of 2.2x104 copies/µL, which is 11% of the supplier’s 
label concentration of 2x105 copies/µL.  
For synthetic RNA (BEI, lot 70033953), we observed that all RT-dPCR quantifications were 
systematically higher than the supplier’s label concentration of 5x105 copies/µL (Figure 
3.2B). We performed two additional dilutions (three in total) down to what should have been 
6.33 copies/µL and observed that all three values were higher than expected (54, 67, and 66 
copies/µL). In a separate experiment, we performed dPCR (no reverse transcriptase) and 
observed that the signal was below background levels, which is expected because no 
amplification should occur in an RNA sample in the absence of reverse transcriptase. Using 
the dilution for which we expected 2000 copies/µL (based on the label concentration), we 
actually measured 15,000 copies/µL. From this measurement, we calculated a stock 
concentration of 3.9x106 copies/µL, which is 770% of the supplier’s label concentration of 
5x105. 
For genomic RNA (BEI, lot 70033700), we observed that all RT-dPCR quantifications were 
systematically higher than the supplier’s label concentration of 5.5x104 copies/µL (Figure 
3.2C). We performed two additional dilutions (three in total) down to what should have been 
6.33 copies/µL and observed that all three values were higher than expected (19, 15, and 23 
copies/µL). The genomic RNA in a dPCR (no reverse transcription) experiment also 
measured below the background signal. Using the dilution for which we expected 63.3 
copies/µL, we actually measured 155 copies/µL. From this measurement, we calculated a 
stock concentration of 1.3x105 copies/µL, which is 240% of the supplier’s label 
concentration of 5.5x104. 
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Figure 3.2: Quantification of different SARS-CoV-2 nucleic acid targets using 
an RT-dPCR protocol. 
Plots show measured concentration (circles) for half-log dilutions of the label 
concentrations (triangles) based on supplier-reported values of (A) plasmid DNA (lot 
508728 from IDT), (B) synthetic RNA (lot 70033953 from BEI), and (C) genomic 
RNA (lot 70033700 from BEI). Individual dilution series were repeated twice more 
for the 633 copies/µL dilution with plasmid DNA and the 6.33 copies/µL dilution for 
both RNA stocks. The background (solid line) was calculated by averaging no-
template controls (n=16), and the assay detection limit (dashed line) was calculated 
as the background signal in no-template controls plus 3 standard deviations of the 
background signal (99.7% confidence).[9] 
 
We next investigated potential differences among lots of stock SARS-CoV-2 RNA. We 
obtained an additional lot of synthetic RNA (lot 70034198) and an additional lot of genomic 
RNA (lot 70033320) from the same supplier (BEI). For each, we diluted the label 
concentration down to what should have been 63.3 copies/µL and measured the 
concentration with RT-dPCR (n=1). The synthetic RNA stock (lot 70034198) measured 38 
copies/µL. From this, we calculated a concentration of 1.7x105 copies/µL, which is 57% of 
the label concentration of 2.9x105 copies/µL.  We note that lot 70034198 was much closer 
(57%) to the label value as compared with lot 70033953 (770%). The genomic RNA stock 
(lot 70033320) measured 193 copies/µL. From this measurement, we calculated a 
concentration of 1.4x105 copies/µL, which is 300% of the label concentration of 4.8x104 
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copies/µL. We found that the RT-dPCR measurements for genomic RNA stocks were 
similarly higher (240% for lot 70033700, 300% for lot 70033320) than the supplier’s label 
concentration. 
 
Dilutions of NA stocks in RT-qPCR with RT-dPCR correction 
Next, we selected concentrations near the LOD for each NA stock, and reran RT-qPCR with 
greater sample size (N=10 for each of three dilutions of each stock, Table 3-1). If we use the 
suppliers’ label concentrations to understand the RT-qPCR results, we observed large 
deviations (orders of magnitude differences) from expected values. For example, 3 of 10 
wells turned positive for a label concentration diluted to 0.0316 copies/reaction with 
synthetic RNA (lot 70033953), whereas we would expect (based on statistical calculations) 
for 3 out of 100 wells to be positive. We also note that only 7 of 10 wells turned positive for 
a label concentration diluted to 31.6 copies/reaction with plasmid DNA (lot 528728), 
whereas statistically we expect all 10 wells to turn positive (assuming single-molecule 
detection). By Poisson distribution, we would expect 1 out of every 5x1013 wells to be 
negative at this concentration.  
If we instead use our RT-dPCR measured concentrations to understand our RT-qPCR results, 
the observed results are statistically more likely for all 3 NA stocks.  The highest tested 
concentrations of plasmid DNA (lot 5208728), synthetic RNA (lot 70033953), and genomic 
RNA (lot 70033700) were measured by RT-dPCR to have concentrations of 3.45, 2.44, and 
2.42 copies/reaction respectively. We observed 70%, 100%, and 90% positives for these 
conditions, which is a reasonable result considering that the Poisson distribution 
corresponding to 3 copies/reaction predicts an expected value (most likely) of 95% positives. 
For the tested concentrations measured by RT-dPCR to be near 1 copy/reaction with an 
expected value of 63% positives, we observed 30%, 80%, and 60% positives. Lastly, for the 
lowest tested concentrations measured by RT-dPCR to be near 0.3 copies/reaction with an 
expected value of 26% positives, we observed 20%, 30%, and 60% positives. 
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Table 3-1: Analytical performance near the limit of detection (LOD) for 
different SARS-CoV-2 targets in the CDC-recommended RT-qPCR protocol. 
Each nucleic acid stock was diluted, and we selected 3 different concentrations to 
spike into RT-qPCR reaction wells (10 replicates for each condition). Measured 
concentrations were used to convert the label concentrations based on the RT-dPCR 
measurements reported in Figure 3.2. Positives were counted as detected if they 
amplified within 40 cycles. No-template controls (N=6) did not amplify after 80 
cycles. 
 
Conclusions 
In this chapter, we observed vast discrepancies in the analytical sensitivity of the CDC-
recommended RT-qPCR protocol based on which commercial NA stock was used. 
Performing an ultrasensitive digital PCR method, RT-dPCR, revealed there are likely errors 
in the supplier-reported concentrations. Specifically, using RT-dPCR, the measured 
concentration of plasmid DNA (IDT, lot 508728) was 11% of the label concentration. For 
synthetic RNA (BEI), the measured concentration by RT-dPCR was 770% of the label 
concentration for lot 70033953, whereas it was 57% of the label concentration for lot 
70034198. For genomic RNA (BEI), the measured concentration by RT-dPCR was 240% of 
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the label concentration for lot 70033700 and 300% of the label concentration for lot 
70033320. An underreporting of the stock concentration could lead to an artificially 
improved LOD for a diagnostic assay. Such discrepancies in how NA suppliers quantify their 
stock can introduce significant biases and impair proper development and evaluation of in 
vitro diagnostics being considered for regulatory approvals and mass production. 
The inaccurate quantification of the SARS-nCoV-2 genomic RNA concentration is 
concerning because our analysis of EUA documents indicated that this RNA stock (BEI, NR-
52285) has been used in at least 11 EUAs: Lyra SARS-CoV-2 Assay, Abbott RealTime 
SARS-CoV-2 assay, AvellinoCoV2 test, NxTAG CoV Extended Panel Assay, NeuMoDx 
SARS-CoV-2 Assay, COV-19 IDx assay, BioGX SARS-CoV-2 Reagents for BD MAX 
System, ARIES SARS-CoV-2 Assay, Logix Smart Coronavirus Disease 2019 (COVID-19) 
Kit, Smart Detect SARS-CoV-2 rRT-PCR Kit, BD SARS-CoV-2Reagents for BD MAX 
System, and Curative-Korva SARS-Cov-2 Assay.[4] We note that the GeneFinder COVID-
19 Plus RealAmp Kit and the STANDARD M nCoV Real-Time Detection Kit both report 
using genomic RNA, but we could not determine whether or not BEI was the supplier. Of 
the kits that used BEI genomic RNA, the majority did not report the lot or starting stock 
concentration (which could be used to deduce the lot number).  
Discrepancies in stock quantification can be attributed to multiple factors, including 
differences in quantification method, reaction conditions, reverse transcriptase efficiency, 
polymerase efficiency, etc. We acknowledge that no assay is perfect (ours included), and it 
is virtually impossible to obtain a “true“ count of an underlying NA concentration. 
Nevertheless, it is possible to come close using an assay which yields the highest NA 
concentration, has low background, and produces statistically plausible results. For this, here 
we have successfully used ultrasensitive digital RT-dPCR.  We suggest that RT-dPCR or a 
similarly improved methodology is implemented for quantification of all RNA stocks used 
for SARS-CoV-2 assays being submitted for emergency use authorization or equivalent 
regulatory approval.  We also encourage independent evaluations of in vitro diagnostic assay 
performance using the same quantified standards by unbiased sources.[11] 
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Materials and Methods 
Stocks and Dilutions 
A DNA plasmid control (2019-nCoV, research-use only) was purchased from Integrated 
DNA Technologies (IDT; Coralville, Iowa, USA; Cat#148365270, Lot 0000508728; 2x105 
copies/µL). Quantitative Synthetic RNA from SARS-Related Coronavirus 2, NR-52358 (Lot 
70033953, 5x105 genome equivalents/µL; Lot 70034198, 2.9x105 genome equivalents/µL) 
and Genomic RNA from SARS-Related Coronavirus 2, Isolate USA-WA1/2020, NR-52285 
(Lot 70033700, 5.5x104 genome equivalents/µL; Lot 70033320, 4.8x104 genome 
equivalents/µL) were obtained from BEI Resources (Manassas, VA, USA). All stocks were 
aliquoted and stored at -80 C. For all dilution series, an aliquot was thawed and serially 
diluted in 1x TE buffer with 0.05% Tween-20 in 1.5 mL DNA LoBind Tubes (USA 
Scientific Incorporated; Ocala, FL, USA).   
RT-qPCR 
qPCR was performed using protocol recommendation from the CDC’s Real-Time RT-PCR 
Panel for Detection of 2019-Novel Coronavirus.[12] Briefly, 5 µL TaqPath 1-Step RT-qPCR 
Master Mix (ThermoFisher Scientific, Waltham, MA, USA) was added to 1.5 µL combined 
primer/probe mix (N1; Lot 0000509022 from IDT’s 2019-nCoV CDC qPCR Probe Assay), 
and 8.5 µL nuclease-free water. Master-mix was added to a 96-well plate (thin-wall clear 
well, HSP9641, Bio-Rad), and 5 µL of template was mixed by pipette in individual wells. 
The 96-well plate was sealed (Microseal B, MSB1001, Bio-Rad) and spun briefly in a Mini 
Plate Spinner Centrifuge (14-100-141, Fisher Scientific) to bring down droplets. 
Thermocycling and real-time imaging were performed on the Bio-Rad CFX96 Touch Real-
Time PCR Detection System (Bio-Rad Laboratories, Hercules, CA, USA) by heating to 25 
°C for 2 min, 50 °C for 15 min, 95 °C for 2 min, and cycling 80 times between 95 °C for 3 s 
and 55 °C for 30 s. 
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RT-dPCR 
RNA was quantified with reverse transcription droplet digital polymerase chain reaction 
(RT-dPCR). Reaction mix contained 1X Bio-Rad EvaGreen ddPCR Mix, 200 nM forward 
and backward COVID primers (N1 primers purchased from IDT, re-suspended in NF-
H2O),[13] 1 U/µL Riboguard RNase inhibitor (Lucigen Corp., Madison, WI, USA), and 300 
U/mL WarmStart RTx (New England Biolabs, NEB; Ipswich, MA, USA). Template was 
added at 10% of the reaction mix and the original concentration calculated from the dilution 
series. All samples were made to 50 µL, and duplicates were run by adding 22 µL to two 
sample wells in the DG8 Cartridge (1864008, Bio-Rad). Dilutions were quantified using the 
QX200 droplet digital PCR system (Bio-Rad), and droplet generation, droplet transfer, and 
foil sealing followed manufacturer’s instructions. Thermocycling took place on a C1000 
Touch Thermal Cycler (Bio-Rad) with an RT step at 55 °C for 10 min, pre-melt at 95 °C for 
3 min, 40 cycles of 95 °C for 30 s, 60 °C for 30 s, and 68 °C for 30 s, and a stabilization at 
4 °C for 5 min, 90 °C for 5 min, and a hold at 12 °C until droplet analysis. A temperature 
ramp rate of 2 °C/s was used for temperature transitions. Droplets were read according to 
manufacturer’s instructions. Analysis thresholds were manually set to 10,000. Final 
concentrations were determined using the merge setting on the QuantaSoft analysis software 
(Bio-Rad). Measured stock concentrations were calculated by subtracting background 
(signal average of 16 no-template controls) and multiplying by the dilution factor. 
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Abstract 
This chapter evaluates the potential of 3D printing, a semi-automated additive prototyping 
technology, as a means to design and prototype a sample-to-device interface, amenable to 
diagnostics in limited-resource settings, where speed, accuracy, and user-friendly design are 
critical components. As a test case, we built and validated an interlock meter-mix device for 
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accurately metering and lysing human urine samples for use in downstream nucleic acid 
amplification. Two plungers and a multivalve generated and controlled fluid flow through 
the device and demonstrate the utility of 3D printing to create leak-free seals. Device 
operation consists of three simple steps that must be performed sequentially, eliminating 
manual pipetting and vortexing to provide rapid (5 to 10 s) and accurate metering and mixing. 
Bretherton's prediction was applied, using the Bond number to guide a design that prevents 
potentially biohazardous samples from leaking from the device. We employed multi-material 
3D printing technology, which allows composites with rigid and elastomeric properties to be 
printed as a single part. To validate the meter-mix device with a clinically relevant sample, 
we used urine spiked with inactivated Chlamydia Trachomatis and Neisseria gonorrhoeae. 
A downstream nucleic acid amplification by quantitative PCR (qPCR) confirmed there was 
no statistically significant difference between samples metered and mixed using the standard 
protocol and those prepared with the meter-mix device, showing the 3D-printed device could 
accurately meter, mix, and dispense a human urine sample without loss of nucleic acids. 
Although there are some limitations to 3D printing capabilities (e.g. dimension limitations 
related to support material used in the printing process), the advantages of customizability, 
modularity and rapid prototyping illustrate the utility of 3D printing for developing sample-
to-device interfaces for diagnostics. 
 
Introduction 
We evaluate multi-material 3D printing for the design and prototyping of an interlock meter-
mix device that meters and lyses human urine samples for a workflow compatible with 
limited-resource settings (LRS) and point of care (POC) diagnostic testing. 3D printing 
comprises a set of additive manufacturing techniques that allows the formation of complex 
3D structures with minimal restrictions. The emerging technological capabilities of 3D 
printing bring exciting advancements in the fabrication of micro- and macrofluidic devices, 
enabling architectures that would be difficult with conventional fabrication techniques such 
as soft lithography.1,2 A primary advantage of 3D printing is the ability to rapidly prototype 
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and iterate new designs, without needing to tool expensive molds.3 3D printing reduces 
the design and prototyping time from weeks and months down to hours and days, making 
prototyping more cost-effective and therefore more accessible—particularly for research labs 
where needs may change frequently. Because 3D printing is semi-automated, it minimizes 
assembly time, the requirements for labor, and reproducibility issues, therefore reducing 
many of the barriers that currently prevent some research labs from prototyping complex 3D 
parts.2 The customizable design files generated in computer-aided design (CAD) software 
can be easily modified in coordination with experiments. 3D-printed materials also exhibit a 
wide range of properties, with varying levels of rigidity, surface roughness, optical clarity, 
and biocompatibility to fit a diverse range of device requirements.4 In combination, all of 
these advantages make 3D printing attractive for prototyping fluidic devices relevant to lab-
on-a-chip and diagnostics fields.  
The sample-to-device interface for diagnostics is a critical component of nucleic acid 
amplification testing (NAAT) in LRS, and remains an unsolved challenge.5,6 Many NAAT 
technologies are not amenable to LRS, because NAAT is an intrinsically multistep process 
involving sample metering, lysis, nucleic acid (NA) purification, amplification, and 
detection.7 To be useful in clinical practice in POC or LRS, the entire NAAT workflow 
should be fully automated, user-friendly (without training or pipetting steps to meet CLIA-
waiver), rapid, equipment-free, sensitive, and specific. To equip a portable device with 
complete sample-in to answer-out functionality requires the appropriate consideration of all 
upstream and downstream processes. While many efforts have been taken to automate 
nucleic acid (NA) purification and amplification, sample metering must always be addressed 
because a user in LRS or at the POC cannot be asked to pipette accurately. Furthermore, 
combining sample transfer with the step in which the sample is mixed with the lysis buffer 
is attractive, because it has the advantage of minimizing the cost and complexity of an 
integrated diagnostic device, and could benefit such devices being developed in research 
labs, including our own.8-11 Precise metering is especially critical in NAAT testing of 
sexually transmitted diseases (STDs), such as Chlamydia trachomatis (CT) and Neisseria 
gonorrhoeae (NG).12 In 2013, there were 1,401,906 and 333,004 reported cases of CT and 
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NG, respectively, in the United States, with many more cases unreported and 
undiagnosed.13 The Centers for Disease Control and Prevention (CDC) estimates 20 million 
new STD infections per year in the US, accounting for $16 billion in healthcare costs.13 The 
CDC now recommends NAAT for CT/NG diagnosis14 because these tests are sensitive, 
accurate, and use non-invasive urine samples. Many of these tests need to be done under LRS 
or POC settings.   
Currently, there is no standardized way to deliver a known amount of sample mixed with 
lysis buffer to an LRS- or POC-compatible NAAT diagnostic device. A method for doing so 
is subject to the following constraints: (i) meter a precise volume of urine with <5% 
coefficient of variation (CV), (ii) mix urine with premeasured, preloaded lysis buffer at a 
specific ratio (as determined by the extraction chemistry), (iii) transfer the lysed urine without 
dripping potentially infectious solution, (iv) perform these operations quickly, in a user-
friendly, equipment-free manner that minimizes potential user errors, and (v) maintain the 
sensitivity and specificity of the overall assay (no loss of nucleic acids to 3D-printed surfaces, 
contamination, or leachates).  
Here, we evaluate the capabilities of multi-material 3D printing to design and prototype a 
single-use disposable macrofluidic device that meets the above constraints. We also discuss 
the advantages and disadvantages of 3D printing as a research tool for device development. 
Multi-material printing, wherein different materials are combined into a single printed part, 
offer expanded capabilities, so we chose to specifically investigate multi-material 3D 
printing as a tool for building sample-to-device interfaces. We have previously demonstrated 
the utility of multi-material printing in the development of a pumping lid for interfacing with 
microfluidic devices,15 however, the pumping lid we developed was only used to compress 
air, and did not contact fluids directly. Here, we expand on the ability to use multi-material 
printed parts to generate sealed fluid cavities through the development of a multivalve and 
plungers used within our device. 
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Results and Discussion 
Interlock design and meter-mix device operation 
To operate the meter-mix device (see ESI† video), the user performs three simple steps: 1. 
insert urine suction tube into patient sample and pull urine plunger; 2. remove from patient 
sample and slide multivalve; and 3. push lysis buffer plunger to eject the mixed solution. The 
device can then be easily disposed in biohazardous waste. Furthermore, the user of the device 
cannot accidentally perform these three operations out of order due to the presence of 
interlock features attached to the plungers. In the initial position, the urine plunger interlock 
blocks the sliding of the multivalve, and the multivalve blocks the movement of the lysis 
buffer plunger (Figure 4.1A). When the user pulls up on the urine plunger, urine is aspirated 
through the suction tube, through the valve, and into the urine chamber. Pulling up on the 
urine plunger also releases the interlock that was blocking the multivalve (Figure 4.1B-C). 
The user then slides the multivalve, which disconnects the urine suction tube inlet while 
generating two new outlets to a static mixer, one outlet urine and the other for lysis buffer 
which has been pre-stored on the device. By pre-storing the lysis buffer on device, we 
eliminate many manual pipetting steps and reduce user error.16 The sliding of the multivalve 
also creates openings for the urine plunger interlock and the lysis buffer plunger interlock 
(Figure 4.1C). In the final step, the user pushes down on the lysis buffer plunger, which also 
pushes the urine plunger, ejecting both urine and lysis buffer through the static mixer (Figure 
4.1D). The total user operating time is between 5 and 10 s. 
The meter-mix device is composed of eight assembled parts: 1. main enclosure, 2. lysis 
buffer plunger, 3. urines plunger, 4. two plunger stoppers, 5. multivalve, 6. urine suction 
tube, 7. static mixer elements, and 8. static mixer case (Figure 4.2). All parts were designed 
using 3D CAD software (Solidworks 2015 Education Edition) and fabricated using an Objet 
260 multi-material 3D printer (Stratasys, Eden Prairie, MN, USA). We judiciously selected 
two semi-transparent photopolymer materials, Veroclear and TangoPlus, corresponding to a 
rigid plastic, analogous to poly(methyl methacrylate) (PMMA), and a soft, elastomeric 
material, analogous to rubber, respectively. By utilizing translucent materials, fluids are 
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visible as they are transported among chambers of the device, providing visual feedback 
during operation. All of the parts were composed of Veroclear, providing a strong structure. 
The plunger heads, stoppers, and the multivalve were printed with a combination of 
Veroclear and TangoPlus, which enabled us to design sliding surfaces and generate seals. 
With the exception of the plunger stoppers, each part underwent between seven and 25 
unique design iterations. In the Figure 4.2 demonstration, which shows the entire device 
assembly and operation, 1150 µL 0.05% (v/v) Sky blue Ateco dye (August Thomson Corp., 
Glencove, NY, USA) was preloaded into the lysis buffer chamber and 0.1% Lemon yellow 
Ateco dye was manually loaded into the urine chamber. These two dye solutions were run 
through the device and combined to form a green mixed solution (Figure 4.2D). 
 
Figure 4.1: Schematic overview of the design and operation of the 3D-printed 
interlock meter-mix device for metering and mixing a urine sample with lysis 
buffer. 
(A) The multivalve has 5 holes which are labeled accordingly. (B) Lysis buffer (blue) 
is preloaded into the lysis buffer chamber, where the topmost position of the lysis 
buffer plunger (left, grey) is pre-determined by stoppers (tan). The urine plunger 
interlock rod (right, beige) is positioned within the multivalve, preventing the valve 
from sliding and simultaneously blocking the lysis buffer plunger interlock rod. The 
user pulls up on the urine plunger (C) until it contacts and is stopped by the lysis 
buffer plunger, aspirating urine and simultaneously removing the urine plunger 
interlock rod from the multivalve. The user slides the multivalve (D), closing off the 
urine suction tube, opening the lysis buffer and urine outlets to the mixer, and 
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providing openings for both interlock rods. In the final step, the user pushes down on 
the lysis buffer plunger (E), ejecting urine and lysis buffer through a static mixer, 
wherein the solutions are well mixed before finally being ejected from the tip of the 
mixer. Red blocks at the bottom of each panel show a top-down view of the 
multivalve. Black circles and rings indicate holes in the multivalve. Slashed circles 
indicate the presence of a feature that is blocked by the multivalve. Colored circles 
indicate the presence of an interlock rod or an open channel for the flow of a solution.   
 
Designing and prototyping leak-proof connections 
To ensure reliable device operation, all of the seals on the device need to be hermetically 
sealed. We accomplish this using the capability of Multi-jet 3D printing to generate materials 
jointly composed of hard plastic (Veroclear) and soft rubber-like material (TangoPlus). We 
used multi-material printing for fabricating both plungers and the multivalve. The challenge 
with creating leak-proof connections is determining the appropriate dimensions, overlap, and 
the ratio of soft:hard material to create a strong leak-proof connection that is still easy to 
move by hand. We took advantage of the rapid prototyping capabilities of 3D printing to 
quickly converge on functional designs. For the urine chamber, we found a good fit using an 
8 mm diameter hole and an 8 mm diameter plunger head, where the inner diameter of the 
plunger head consisted of 7.2 mm Veroclear surrounded by a 0.4 mm (5%) thick layer of 
TangoPlus. For the lysis buffer chamber, we found good fit using an 11.31 mm diameter hole 
and an 11.31 mm diameter plunger head (surrounded by a 5% TangoPlus layer). These 
parameters made hermetically sealed connections capable of generating and holding a 
vacuum. We selected the dimensions of the chambers in the main enclosure to provide the 
desired air volumes and mixing ratios (see Accurate Dispensing). To generate the multivalve 
seal, an open cavity was designed through the side of the main enclosure, with raised ridges 
around each hole for the inlets and outlets. The multivalve was 2.7 mm thick, with 0.54 mm 
TangoPlus (20%) layered on the top and 0.54 mm on the bottom. At the points of contact 
between the multivalve and the inlet/outlet ridges, there was a 0.2 mm overlap where the 
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ridge pushed into the TangoPlus layer (by 3D CAD design). To assist sealing and sliding, 
we applied silicone oil to lubricate all contact points at movable interfaces (plunger heads, 
chambers, and the multivalve). 
 
Figure 4.2: Photographs of the device at different stages of operation. 
(A) In the initial position, blue dye representing lysis buffer is preloaded and the urine 
plunger is down. (B) In the second position, the urine plunger contacts the lysis buffer 
plunger and a specific volume of yellow dye representing urine is metered. (C) In the 
third position, the multivalve was slid 5 mm to the right, simultaneously closing and 
opening new connections. (D) In the final position, both plungers are down, 
dispensing a green solution out through the static mixer (inset). 
 
Plunger system and accurate metering 
To accurately meter urine, we designed a plunger system with predetermined start and stop 
positions. During device operation, the urine plunger is pulled up until it contacts the 
underside of the lysis buffer plunger. The volume displaced by the plunger was calculated in 
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CAD software, providing an estimate for the volume of urine aspirated into the device. To 
precisely calibrate metering, the working design was iterated by testing prototypes of the 
device by aspirating deionized water, weighing the device, and modifying the height of the 
plunger stoppers to adjust the volume displaced by the plunger. To accurately meter lysis 
buffer, we use a pipettor to preload the meter-mix device. When the device is set to the initial 
configuration, lysis buffer is sealed on both sides by the lysis buffer plunger and multivalve. 
This is advantageous for a disposable LRS and POC device because the filling step can be 
performed during manufacturing and assembly. In this way, the end-user does not need to 
consider handling of the lysis buffer during device operation. 
With diagnostic devices, it is important to minimize dead volumes to avoid wasting reagents, 
losing sample, or introducing a source of variability. One strength of 3D printing is that 
potential sources of dead volume can be identified and reduced during the design process. 
During our design process, we identified four potential sources of dead-volume: urine lost in 
the suction tube, urine lost in the urine chamber, lysis buffer lost in the lysis buffer chamber, 
and mixed solution remaining in the static mixer. We recognize that patient urine is abundant, 
and that it is acceptable for the meter-mix device to overfill urine; however, the final volume 
of urine ejected from the device must be consistent between runs. To ensure accurate, 
consistent ejected volumes, the dead-volume of the urine suction tube was taken into account 
while modifying the positions of the plunger stoppers. It should be noted that dead-volume 
can be reduced by changing the design of the suction tube as required. For our meter-mix 
device, we were concerned with dead volumes of urine remaining in the urine chamber and 
the static mixer, which could contribute to differences in the volumes of urine ejected 
between runs. In particular, a user who sees liquids trapped in the static mixer may be inclined 
to shake the meter-mix device, introducing error which affects the accuracy of downstream 
quantitative processes. To remove this dead volume, we leave a pocket of air that sits above 
the lysis buffer within the lysis buffer chamber. After urine is aspirated into the device, we 
designed the system so that the heights of the pocket of air are roughly equal (the air initially 
residing in the suction tube is incorporated into the device during the aspiration step). These 
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two pockets of air produce a blow-out volume of air which removes the dead volumes of 
urine and lysis buffer that would otherwise remain in the chambers and static mixers. 
We wanted to ensure that after urine is aspirated into the urine chamber, urine is unable to 
leak out through the tip of the urine suction tube. Bretherton previously examined this 
problem, and found the dimensionless bond number, Bo (which relates gravity to surface 
tension), to be a guiding parameter.17 The bond number is related to the density difference 
between the liquid and air, the diameter of the tube, and the surface tension of the liquid. He 
predicted that for a vertical tube that is sealed at one end, a bubble contained within will not 
rise if Bo < 0.842.17 Thus, in our meter-mix device, if the bond number is low, and a bubble 
enters the urine suction tube, the bubble will be immobile, preventing solution from dripping 
out through the tip of the urine suction tube. Bretherton's prediction suggests that we want to 
minimize the bond number, which we can do simply by reducing the diameter of the 3D-
printed urine suction tube. We would not, however, want to make the diameter so small that 
it generates a high resistance to flow, as this would generate a noticeable delay in the filling 
time and negatively affect the user experience. Tube diameter is constrained with our 3D 
printing methods because as tube diameter decreases, it becomes increasingly difficult to 
remove the support material and clean inside the tube. For our device, we limited our testing 
to >1.5 mm diameter sized suction tubes. At the millimeter scale, there was no noticeable 
delay between pulling up on the urine plunger and filling of the urine chamber. 
We tested the Bretherton prediction using 3D-printed parts. A simple plunger system was 
designed along with suction tubes of varying diameters. In multi-material 3D printing, the 
printing of support material can be avoided for some geometries and configurations. We 
printed straight suction tubes in the vertical configuration, which does not print support 
within the suction tube and therefore does not require support cleaning. While some support 
can be avoided, one limitation of our multi-material printer is that it always prints support 
material for the bottom layer in contact with the 3D printer's build plate. When one side of 
the model is printed in contact with support and the other parts of the model are located on 
the exterior sides of the device, there may be minor differences between dimensions and 
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surface roughness. For example, we found that when printing straight tubes upright, the 
diameter on the side of the tube in contact with the 3D printer's build plate was slightly 
smaller than the opposite opening. A discrepancy between parts of the model in contact with 
the build plate and open to air is not an exclusively multi-material 3D printing characteristic, 
but is common to many types of 3D printers. Care was taken to always use the side of the 
tube in contact with the build plate for the connection to the body of the plunger system. 
Table 4-1: Bretherton's prediction tested using 3D-printed tubes of varying 
diameter. 
 
To test the prediction, we used the opposite side of the suction tube to aspirate solution into 
the tube. The suction tube was manually disturbed through tapping the tip in order to 
introduce bubbles, mimicking a real-world user experience where the user bumps the device. 
We found that there was general agreement between bond number and the Bretherton 
prediction (Table 4-1). Using water, for bond number <= 0.416, no bubbles entered the 
device and no fluid dripped from the tip. For bond numbers between 0.544 and 0.688, a 
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bubble entered the tube releasing some drops, but the bubble did not rise and the liquid-
air interface at the tip regained stability. Close to the Bretherton prediction at Bo = 0.850, 
bubbles entered the tube and both rise and no rise of the bubble were observed, which seemed 
to depend on the size of the bubble incorporated. Finally, for a large bond number (1.028), 
drops were released when the bubble initially entered the tube, the liquid-air interface at the 
tip regained stability, and we saw bubble rise as predicted by Bretherton. The experiment 
was repeated using ethanol with similar results. We also observed that for very large bond 
numbers (Bo >/= 2.155), once the ethanol-air interface at the tip was disturbed, a column of 
air entered the suction tube, spilling all of the solution out of the tip. Accounting for 
Bretherton's prediction, the limitations of cleaning support material, and accounting for the 
pocket of air for blow-out, we selected a suction tube diameter of 2.3 mm in the final design. 
The surface tension of urine from healthy patients ranges from 48–70 mN/m.18 Using the 
low value of surface tension at 48 mN/m, a density of 1.01, and a 2.3 mm diameter gives a 
Bo = 0.272. 
 
Accurate dispensing 
The flow rate of each solution is determined by the design of the device chambers, plungers, 
and outlets. We designed each chamber of the device to undergo the same driving pressures 
over the entire dispensing operation. We can accomplish this by matching the solution height, 
air pocket height, and plunger heights in both chambers. For example, a 2:1 volume ratio can 
be obtained by making the area of one chamber twice the area of the second chamber. The 
cross-sectional area of the channels and outlet valves should also be maintained at the 2:1 
ratio to obtain the flow resistance and corresponding volumetric flow rate. Our device was 
designed with a 2:1 volume ratio between lysis buffer and urine, but we were cognizant of 
the potential for flow irregularities near the beginning and end of the flow regime. If slight 
inaccuracies during filling cause urine to enter the static mixer prematurely or after all of the 
lysis buffer has gone through, this could leave some urine unmixed and unlysed. This could 
lead to inaccuracies during downstream quantification, and unlysed bacteria are a biohazard. 
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To address these concerns, we slightly overfilled the lysis buffer compartment leading to 
a final lysis buffer to urine volume ratio of 2.2:1. 
We evaluated the dispensing accuracy of our device using water, green dye, spectrophometer 
measurements, and a balance. To examine inter-device variability, we tested three different 
device prototypes each run in triplicate (Table 4-2). There was no significant difference 
among devices for aspiration volume (P = 0.46) or the volume expelled (P = 0.44). Sample 
aspiration was found to accurately meter ~790 µL (<1% CV). As previously described, the 
blow-out volume of air is responsible for ejecting the final volumes of urine and lysis buffer 
remaining in the chambers and the static mixer. We found that pushing the plunger down 
over the course of 1–2 s led to relatively little error in the final ejection volume (<2% CV). 
However, pushing the plunger down faster (in <1 s) pushed bubbles through the static mixer 
and greater volumes of liquid remained in the device, resulting in reduced ejection volumes 
(~1350 µL). In real-world applications, it is important to minimize differences resulting from 
user operation. Future designs can address the issue of plunger speed affecting dead volume 
by reducing the diameter of the outlets to prevent bubbles from escaping before the fluid. 
The ratio of solution ejected from the lysis buffer chamber and the urine chamber was 
calculated by measuring the absorbance of the final ejected solution and comparing it to the 
green dye loaded into the lysis buffer chamber. We found that dispensed volumes out of the 
lysis buffer chamber and urine chamber were similar, with percent deviations of 2.5% and 
6.6%. 
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Table 4-2: Evaluation of metering and dispensing accuracy of the meter-mix 
device. 
 
 
Static mixer design and mixing evaluation 
To simplify user experience and eliminate mixing by pipetting or vortexing, we designed an 
on-device Kenics static mixer (KMS), a common mixer used for a variety of industrial 
applications.19 We had previously designed the flow rates of urine and lysis buffer to exit the 
outlets at a consistent flow rate. We predicted that a KMS mixer placed after the lysis buffer 
and urine outlets would be an efficient way to mix the two streams. The static mixer is 
composed of alternating left- and right-hand 180° helical twists with 90° offsets between 
elements. This immobile structure encased within a tube guides the flow of solutions from 
the center of the tube to the wall of the tube and from the wall to the center. Each element 
splits and recombines streams of flow, rapidly homogenizing the fluid, similar to mixing by 
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chaotic advection in moving plugs.14,20,21 We designed a KMS static mixer composed of 
eight elements, with a diameter of 5 mm, and a length:diameter ratio of 1.25:1. Limited by 
the requirements of removing support material from 3D-printed parts, it was not feasible to 
print the entire mixer and tube enclosure as a single unit. Instead, we used a modular 
approach, printing the mixer elements and the mixer case as separate pieces. Both parts were 
printed in the upright configuration.  
When static mixer elements were printed with the glossy finish setting, only the topmost 
element was glossy and had different surface roughness and dimensions than the other 
elements (remaining parts had the matte finish because they were printed in contact with 
supporting material). To address this issue, we printed the static mixer elements with the 
matte finish (Figure 4.3A). The static mixer elements and the static mixer case were cleaned 
separately and assembled carefully because the static mixer elements were very prone to 
breaking (Figure 4.3B–D). 
To evaluate mixing quality, a starch iodine-thiosulfate decolorization was used. The 
decolorization reaction is a preferred method to evaluate mixing because any pockets of 
unmixed regions will be visible.22 The initial decolorization reaction occurs quickly in a 1:1 
iodine:thiosulfate ratio, although a secondary reaction leads to the reappearance of color so 
higher ratios of iodine:thiosulfate (e.g. 1:1.2 or 1:1.4) can be used.23-25 For the meter-mix 
device, we used a 1:1.05 ratio because the design enables rapid mixing within the timescale 
of the device operation. The starch iodine solution was loaded into the urine chamber through 
the suction tube, and the sodium thiosulfate was preloaded into the lysis buffer chamber. The 
device mixed the two solutions within the first three to four elements (Figure 4.3G). As a 
control, to confirm that the loss of color is due to mixing and not an artifact of the chemical 
or optical properties of the 3D-printed part, we also show the static mixer element fully filled 
and while mixing with a solution that does not cause decolorization. We ran the meter-mix 
device with starch iodine indicator loaded into both chambers (Figure 4.3E) and in a separate 
experiment with starch iodine loaded into the urine chamber and water loaded into the lysis 
buffer chamber (Figure 4.3F). 
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Figure 4.3: Assembly of the static mixer (A–D) and a demonstration of its use in 
the meter-mix device (E–G). 
(A) Freshly printed static mixer elements before cleaning. (B) Static mixer elements 
after a 15 min cleaning step to remove support material. (C) Static mixer case. (D) 
Assembled static mixer with elements inserted into case. (E) Iodine– starch indicator 
loaded into both chambers and ejected through the static mixer. (F) Iodine–starch 
indicator mixing with water to show a dilution. (G) Iodine–thiosulfate de-colorization 
reaction demonstrating rapid mixing within the first few static mixer elements. 
 
Function and biocompatibility 
We evaluated the meter-mix device for compatibility with a routine nucleic acid extraction 
kit by comparing the metering and mixing steps performed by the device with standard 
approaches for metering and mixing (manual pipetting and vortexing). Two concerns are the 
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potential for nucleic acids to bind to 3D-printed surfaces, and the potential for compounds 
from 3D-printed materials to leach into the solutions, both of which can negatively affect 
downstream analysis of nucleic acids. We preloaded the device with 1150 µL lysis buffer 
and aspirated urine spiked with 104 cells/mL of either C. trachomatis (CT) or N. gonorrhoeae 
(NG) through the suction tube. The multivalve was slid, and the plungers were pushed 
manually, ejecting the solutions through the static mixer and into a 2 mL polypropylene tube. 
An off-device sample was tested in parallel, with 1100 µL lysis buffer and 500 µL spiked 
urine (see Table 4-2) metered by a pipettor and the solution mixed by vortex. We also ran 
no-template controls containing clean urine for both on and off-device conditions. After 
mixing, all samples were processed in parallel according to the manufacturer's instructions 
using the QIAamp Viral RNA Mini kit (recommended for purification of bacterial DNA 
from urine). Following extraction, nucleic acid concentrations were compared using routine 
quantitative polymerase chain reaction (qPCR) with primers previously evaluated for the 
detection of C. trachomatis26 or N. gonorrhoeae.27 The threshold cycle for vortex and device-
mixed samples were not statistically different, indicating that there was no significant loss of 
nucleic acids and or material leaching that inhibited downstream analysis. No-template 
negative controls showed no amplification after 35 cycles. 
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Figure 4.4: qPCR threshold cycles on DNA extracted from urine spiked with 
either inactivated Chlamydia trachomatis (CT) or Neisseria gonorrhoeae (NG). 
Sample metering and mixing with lysis buffer was performed with either the meter-
mix device (light green bars) or standard pipette and vortex (dark green bars). The 
remainder of the extraction protocol was identical for both conditions. 
 
Experimental 
Meter-mix device cleaning and assembly 
Printed parts were cleaned using pipette tips or copper wire and rinsed with water. The urine 
plunger, lysis buffer plunger, multivalve, and both chambers of the main enclosure chambers 
were lubricated with viscous silicone oil (Dimethylpolysiloxane 12,500 cSt, Sigma Aldrich, 
St. Louis, MO, USA). To assemble, first the urine plunger was inserted into the urine 
chamber of the main enclosure followed by the lysis buffer plunger into the lysis buffer 
chamber. The two plunger stoppers were then inserted, locking the topmost position of the 
lysis buffer plunger. The multivalve was inserted into the main enclosure from the side, and 
pushed into its final position to preload 1150 uL lysis buffer through the outlet. The 
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multivalve was then moved into its starting position, the urine plunger pushed to the 
bottom of the chamber, and the urine suction tube and static mixer were attached. For these 
joints, the outer diameter of the static mixer case (8 mm) and the outer diameter of the urine 
suction tube (4.5 mm) sized exactly to the diameter of adapters on the main enclosure. After 
cleaning, a thin layer of support material remains at the junctions of the main enclosure. 
Because this support material is shed from the joints during device use, we used silicone oil 
to enhance the seal.  
 
Characterization of metering and dispensing 
To evaluate metering and dispensing, we loaded into the lysis buffer chamber 1150 µL 0.5% 
(v/v) green food color dye (The Kroger Co., Cincinnati, OH, USA) diluted in deionized water 
was aspirated into the urine chamber through the urine suction tube, and mass measured to 
obtain the aspirated volume (using water density of 1 g/mL). The multivalve was pressed 
and the solution ejected into a pre-tared conical tube to obtain the mass of the solution ejected 
from the device. The resulting solutions were well-mixed through vortexing. The original 
0.5% (v/v) green dye and each resulting solution was diluted by 20x, loaded into a cuvette, 
and measured with a UV-vis spectrophotometer (Nanodrop 2000c, Thermo Scientific, 
Wilmington, DE, USA). Measurements were taken at the wavelength where the absorbance 
was maximal (630 nm), and the ratio was used to determine the volume of solutions ejected 
from each chamber. 
 
Iodine-thiosulfate decolorization reaction 
Iodine, starch indicator, and sodium thiosulfate solutions were prepared according to the 
Handbook of Industrial Mixing.22 Briefly, 1150 µL sodium thiosulfate nonahydrate (0.5 mM, 
ThermoFisher Scientific, Waltham, MA, USA) was loaded into the the lysis buffer chamber. 
Starch indicator was prepared by adding 100 mg starch, soluble potato, powder (J.T. Baker, 
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Center Valley, PA, U.S.) and 20 g potassium iodide to 10 mL deionized water. 50 µL of 
this starch solution was added to a 1 mL solution of iodine (1 mM, Alfa Aesar, Ward Hill, 
MA, USA), coloring the solution dark bluish-purple. The final ratio of iodine:thiosulfate was 
0.95:1. A video was taken using the Samsung Galaxy S4 camera, and frames extracted during 
device operation when the flow fully filled the static mixer (Figure 4.3E-G). 
 
Qiagen extraction and qPCR experiment 
In order to test device compatibility with biological samples and ensure that downstream 
nucleic acid analysis was not negatively affected, we compared samples that were metered 
and mixed on-device against traditional vortex mixing using a commercial nucleic acid 
extraction kit (QIAamp Viral RNA Mini Kit, 52904). Lysis buffer was loaded with 2 ng/µL 
carrier DNA (salmon sperm DNA, Thermo Fisher AM9680). Non-infectious CT and NG 
samples were obtained from ZeptoMetrix Corp. (NATNG-ERCM, NATCT(434)-ERCM, 
Buffalo, NY, USA). Quantitative PCR was performed on a Roche LightCyler 96. PCR 
reactions consisted of 5 µL SsoFast EvaGreen Supermix (BioRad cat no. 1725200), 2.0 µL 
of template (extracted spiked urine), 0.5 µL of 20X primer stocks, and 2.5 µL nuclease-free 
water. The primers used26,27 were previously evaluated for the detection of either CT or NG. 
Final primer concentration in the reaction was 500 nM. Thermal cycling consisted of a 3 min 
initial denaturation step at 95 ˚C, followed by 40 cycles of 20 s at 95 ˚C, 20 s at 62 ˚C, and 
20 s at 72 ˚C. Melt analysis confirmed specific product for all reactions. 
 
Conclusions 
We showed that multi-material 3D printing can be used to prototype a disposable interlock 
meter-mix device that accurately meters urine and completely mixes it with lysis buffer in a 
format that meets the requirements for a downstream NAAT compatible with LRS and POC 
settings. The 3D-printed device accurately aspirated predetermined volumes into a urine 
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chamber with a coefficient of variation of 0.8%. Urine and lysis buffer were dispensed 
through a KMS static mixer at a 2.2:1 mixing ratio. Printing with translucent materials 
enabled visual confirmation of fluid movement and showed that mixing occurred within the 
first few elements of the static mixer, with homogenization and lysis later verified by qPCR. 
Printing with a multi-material 3D printer enabled us to use a combination of composites to 
create airtight seals that slide without leaking or losing vacuum pressure. Using a 3D printer 
also helped address the potential for sample dripping, a biohazardous concern when working 
with bodily fluids and potentially dangerous solutions, as we were able to test Bretherton's 
prediction for bubble rising through several prototype iterations and identify optimal tube 
dimensions that ensured the sample did not drip.  
The 3D-printed device was designed to optimize the user's experience: operation is simple 
(three steps); interlock features protect against user error; neither pipetting nor vortexing are 
required; and the entire device operation is completed within 5 to 10 s (see ESI† video). We 
validated our device by lysing urine samples spiked with CT/NG and performed downstream 
processes to quantify nucleic acids through qPCR. These results confirmed that the 3D-
printing materials (Veroclear and TangoPlus) were biocompatible; we observed no loss of 
nucleic acids and devices performed equally well compared with the standard protocol of 
pipettor metering and vortex mixing in a polypropylene tube. Finally, we demonstrated that 
the performance of the meter-mix device matched the performance of standard laboratory 
protocols for metering and mixing, with a substantially shorter time period for device 
operation. 
The meter-mix device described here is not limited to mixing urine with lysis buffer. A 
common operation in biology, chemistry, and medicine is to mix two solutions of known 
volume. Due to the customizability of 3D printing and CAD design, it is easy to adapt the 
meter-mix device to different volumes or configurations. In some applications, it may be 
desirable to meter two different solutions at the time of use. In this example, the meter-mix 
device could be reconfigured with an additional suction tube appended to the lysis buffer 
chamber. Given the versatility of the meter-mix device, it may be useful in a variety of 
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applications such as sequencing, dilutions, or chemical syntheses. Because the meter-mix 
device simplifies and accelerates workflow, protects against user error, and provides a user-
friendly experience, we foresee its future application in research labs and limited-resource 
settings. For example, time-sensitive laboratory measurements may require metering and 
mixing on the timescale of single digit seconds rather than the tens of seconds required for 
pipetting. In commercial applications, an important advantage of a single-use disposable 
device is that it can be assembled and pre-loaded with lysis buffer before it is shipped, 
eliminating a pipetting step for the end user. 
Throughout the course of device development, the 3D printing workflow was a major 
advantage over analogous forms of prototyping, such as soft lithography. Prototyping with 
3D printing was rapid, enabling us to design, test, redesign, and reprint a prototype in the 
period of a single day. For small parts that can be printed in less than a few hours, it is possible 
to iterate multiple designs within in a single day. The ease with which parts can be modified 
after having developed the initial design allowed us to print multiple variations of the meter-
mix device at once and determine the optimal architecture of each part in a single experiment. 
This was useful for determining the diameter of the suction tube, setting the parameters for 
the static mixer, and adjusting the fit for the seals. Another advantage with 3D printing is that 
the 3D CAD models which are developed during the design stage can also be utilized and 
adapted for injection molding. This is important in commercial applications when large 
quantities are required, since injection molding has higher start-up costs but lower costs per 
part than 3D printing. We also found modularity to be an important advantage with 3D 
printing. Parts can be built as separate components and later reassembled, reducing build 
time (which relies heavily on z-axis height). It is also easier, and less expensive, to validate 
and iterate with individual components than to redesign and reprint an entire device. Of 
course, the final cost of producing these devices using standard manufacturing methods 
(injection molding) will be even lower than prototyping costs. 
The greatest limitation we faced with multi-material 3D printing pertained to the support 
material. We faced three specific issues: (i) wherever support material is printed in contact 
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with the model, the printer produces a matte finish with different surface characteristics 
and dimensions compared with the glossy finish of parts that do not contact the support 
material; (ii) it can be difficult to remove the support material for some geometries, so care 
needs to be taken during the design to account for cleaning; and (iii) removal of the support 
material takes time, requiring ~45 min to clean all of the components for a single device. As 
new support material is developed, this limitation will diminish. For example, some 
companies have developed new dissolvable support materials that can be removed in a soak-
and-rinse process, however, these processes are still diffusion-limited and may be difficult 
to implement when cleaning long, narrow channels relevant to microfluidic devices. Despite 
some limitations, we conclude that 3D printing is an attractive prototyping technology with 
great potential for solving the sample-to-device interface problem in diagnostics, especially 
in resource-limited settings. 
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5 .  C h a p t e r  5  
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Abstract 
Digital single-molecule technologies are expanding diagnostic capabilities—enabling the 
ultrasensitive quantification of targets, such as viral load in HIV and hepatitis C infections, 
by directly counting single molecules. Replacing fluorescent readout with a robust visual 
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readout that can be captured by any unmodified cell phone camera will facilitate the 
global distribution of diagnostic tests, including into limited-resource settings where the need 
is greatest. This chapter describes a methodology for developing a visual readout system for 
digital single-molecule amplification of RNA and DNA by: (i) selecting colorimetric 
amplification-indicator dyes that are compatible with the spectral sensitivity of standard 
mobile phones, and (ii) identifying an optimal ratiometric image-process for a selected dye 
to achieve a readout that is robust to lighting conditions and camera hardware and provides 
unambiguous quantitative results—even for colorblind users. We also include an analysis of 
the limitations of this methodology, and provide a microfluidic approach that can be applied 
to expand dynamic range and improve reaction performance, allowing ultrasensitive, 
quantitative measurements at volumes as low as 5 nanoliters. We validate this methodology 
using SlipChip-based digital single-molecule isothermal amplification with lambda DNA as 
a model and hepatitis C viral RNA as a clinically relevant target. The innovative combination 
of isothermal amplification chemistry in the presence of a judiciously chosen indicator dye 
and ratiometric image processing with SlipChip technology allowed the sequence-specific 
visual readout of single nucleic acid molecules in nanoliter volumes with an unmodified cell 
phone camera. When paired with devices that integrate sample preparation and nucleic acid 
amplification, this hardware-agnostic approach will increase the affordability and the 
distribution of quantitative diagnostic and environmental tests. 
 
Introduction 
This chapter shows that single nucleic acid molecules confined in nanoliter volumes in 
microfluidic devices can be detected and counted by an unmodified cell phone camera, in 
combination with isothermal amplification chemistry, a judiciously chosen indicator dye and 
ratiometric image processing. We describe a novel methodology that can be used to develop 
a visual readout for digital single-molecule amplification of sequence-specific RNA and 
DNA that can be used with any camera phone—without modifications or attachments. 
Single-molecule visual readout has never been achieved before. Diagnostic tests that 
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incorporate such a visual readout will greatly expand the applicability of emerging digital 
single-molecule technologies, including into limited resource settings (LRS). Ultrasensitive 
and quantitative detection of nucleic acid molecules is of particular interest for infectious 
disease diagnosis in LRS, such as the quantification of viral load for human 
immunodeficiency virus (HIV) and hepatitis C virus (HCV),1-3 as many of these infections 
occur far from centralized laboratories where diagnostic tests are routine. Increasing 
diagnoses in these locations will lead to faster and more appropriate treatment and have a 
major impact on disease burden4,5 Most point of care (POC) tests are not amenable to LRS 
because they don’t meet the World Health Organization’s ASSURED criteria of being 
affordable, sensitive, specific, user-friendly, rapid, robust, equipment-free, and deliverable.5 
The tests that do meet the requirements for LRS (e.g. immunochromatography to detect 
antigens or antibodies in a dipstick or lateral-flow format; or the visualization of antigen-
antibody lattice formation) have poor reported sensitivities and thus are unable to detect and 
quantify analytes at low concentrations.4,6 Nucleic acid amplification tests (NAATs), such as 
PCR, have the desired high sensitivity and target specificity, providing accurate 
quantification, but these technologies are costly, time-consuming, and require skilled 
technicians and laboratory settings.7  
Of the NAATs, isothermal amplification methods (e.g. loop-mediated isothermal 
amplification, LAMP) are among the most attractive for LRS because they do not require 
thermocycling or capital equipment and can be run in water baths, using simple heaters or 
with exothermic chemical heating that does not require electricity.8-11 Still, acquiring 
quantitative and ultrasensitive measurements outside of the lab remains challenging because 
the methods are not robust to variability in reaction conditions, and readouts rely on precise 
measures of fluorescence intensity. Running isothermal amplification chemistries in a digital, 
single-molecule format maintains the high sensitivity and quantification capabilities 
typically achieved only in lab settings.12-15 In digital single-molecule isothermal 
amplification, single, stochastically confined DNA or RNA molecules are randomly 
distributed among discrete nanoliter or picoliter volumes and amplified under controlled 
conditions.16-18 This creates relatively high local concentrations of target DNA or RNA, 
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making digital amplification more efficient and robust compared to bulk reactions with 
the same number of starting target molecules. Nucleic acid amplification of even a single 
target molecule produces a clear fluorescent signal, and the results of digital amplification 
can be read by a modified cell phone (e.g. a phone camera with an optical filter) under dim 
lighting.14 
Microfluidic technology has been an instrumental tool in developing single nucleic acid 
molecule capabilities,19-27 and the integration of sample-preparation modules into portable 
microfluidic devices will further enable their use by untrained users in any setting.28-30 To 
bring these emerging technological capabilities to LRS, however, such devices capable of 
ultrasensitive, quantitative measurements should provide a rapid, visual readout that can be 
captured easily—e.g. by any mobile phone without modifications or attachments. Cell phone 
cameras provide a convenient, nearly universal tool to pair with emerging diagnostic 
technologies to transform global healthcare as ~7 billion mobile cellular subscribers exist 
worldwide and 70% of users live in developing countries.31 Mobile devices are emerging as 
a powerful platform to create cost-effective alternatives for molecular diagnostics in LRS32-
42 and colorimetric diagnostics based on unmodified cell phones have been used before,38,43-
46 but not in a digital format, where the short path lengths and nanoliter volumes have 
constrained visual-based methods. Here, we describe an approach that enables visual readout 
of single nucleic acid molecule amplification by (i) selecting an appropriate colorimetric 
indicator dye based on spectral properties that align well with the RGB sensitivities of 
common cell phone camera sensors and (ii) identifying the optimal ratiometric image-
processing for the selected dye to achieve a readout that is robust to lighting conditions and 
camera hardware. Using this approach, after sequence-specific single-molecule isothermal 
amplification, a visual readout is captured by an unmodified camera phone, and the resulting 
image is analyzed using a ratiometric approach, wherein the measured intensities of two of 
the three RGB color channels are divided to provide a binary result (a positive or negative 
reaction) for each well. The automation of this ratiometric analysis provides a clear, reliable 
digital readout without requiring the user to differentiate color change by eye or manipulate 
lighting (Figure 5.1a). We further show how limitations related to reaction inhibition by the 
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readout dye can be solved with SlipChip microfluidics technology to decouple the 
amplification and readout steps. We validated our visual readout method with SlipChip-
based digital single-molecule isothermal amplification reactions using phage lambda DNA 
as a model and HCV RNA as a clinically relevant target, in reaction volumes as low as 5 nL, 
using a variety of common cell phones and a range of illumination conditions. 
 
Results and discussion 
Selecting an indicator dye 
To eliminate the need for a fluorescent readout in single-molecule amplification and produce 
a readout that can be imaged by any cell phone camera under various illumination conditions, 
one can use a nucleic acid amplification-indicator dye that changes color in response to 
amplification. A robust colorimetric readout balances two opposing requirements: the 
indicator dye must be sufficiently concentrated (or present in a large enough volume) to 
provide readable absorbance (i.e. smaller volumes and shorter path lengths require greater 
concentrations of dye for sufficient absorbance to be detected), but not so concentrated that 
the dye interferes with the amplification reaction. To optimize a visual readout system for 
single-molecule counting with an unmodified cell phone camera, we first identified the 
factors that contribute to hypothetical limitations of a visual readout system, including the 
range of reaction volumes (or path lengths) at which a particular indicator could be used to 
monitor amplification and the range of indicator concentrations that would not interfere with 
the amplification reaction. Where these ranges overlap are the optimal volumes and dye 
concentrations at which a reaction is not inhibited and can provide a change in absorbance 
that is sufficient for readout with an unmodified camera phone (dotted green region of Figure 
5.1b). 
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Figure 5.1: A visual readout approach for digital single-molecule isothermal 
amplification for use with an unmodified cell phone camera. 
(a) A workflow for visual readout of digital single-molecule amplification. Single 
nucleic acid molecules and indicator dye are compartmentalized on a microfluidic 
device and followed by isothermal nucleic acid amplification. Positive reaction 
solutions are blue; negative reactions are purple. After ratiometric image processing, 
positive reactions become white and negative reactions become black—an 
unambiguous binary result. The number of positive wells is then used to quantify the 
concentration of the input target. (b) A diagram for delineating the optimal range of 
dye concentrations as a factor of path length (reaction volume) and the threshold for 
reaction inhibition. The green-shaded region indicates the range of acceptable dye 
concentrations for visualization with an unmodified cell phone camera. 
Concentrations to the left of the green region are too low for visualization; 
concentrations to the right of the green region are too high. Within this green region, 
the dotted area indicates dye concentrations that both enable readout with an 
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unmodified cell phone camera and do not inhibit the amplification reaction. The area 
to the right of the red line indicates dye concentrations that interfere with 
amplification making accurate quantification based on real-time data challenging. 
 
We validated this visual readout approach using loop-mediated isothermal amplification 
(LAMP)47,48 (Supporting Information Table 5-1, Table 5-2) because this method has been 
well characterized and validated previously for single-molecule analyses.12,14-17,49 LAMP 
chemistry is based on an auto-cycling strand displacement reaction performed at a constant 
temperature to synthesize large amounts of amplified product; a LAMP reaction generates 
more than 109 copies of template within 1 h of incubation at 60–65 °C.48 We used a cubic 
reaction volume of 8 nL (200 x 200 x 200 µm3), which is in the range of volumes used in 
digital experiments.12,14,15,17,49 We assume that an appropriate indicator of an amplification 
reaction will have a change in absorbance that equates to a change of extinction coefficient 
of ~25,000 L mol-1 cm-1 upon reaction (this number approaches the maximum achievable 
change in absorbance for small-molecule dyes). We use the Beer-Lambert law (A = Ɛ(A), 
which describes the relevant parameters to consider for visualization, wherein A = 
absorbance (the percentage of light absorbed); Ɛ = extinction coefficient (L mol-1 cm-1); L = 
length of the light's path through the solution (cm); c = concentration of absorbing species 
(mol/L). At a path length of 0.2 mm, an estimated ~2 mM concentration of the dye is required 
to reach a change of absorbance of 1 unit. Given these parameters, to obtain a readout that 
can be captured by an unmodified mobile phone, we predicted that an appropriate indicator 
dye would be one that responds to each nucleotide incorporation (present in mM 
concentrations), as opposed to responding only to the number of produced molecules 
(amplicons), which would not exceed primer concentration (present in the µM range).  
Colorimetric approaches to visual detection of nucleic acid amplification typically measure 
absolute changes in color intensity,50-54 however distinguishing color change—e.g. purple vs. 
blue—is difficult and therefore not an appropriate way to quantify readout under variable 
conditions, such as in LRS. Ratiometric measurements, which take the ratio of two 
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independent measurements under the same conditions, improve the robustness of a 
colorimetric approach, converting results to a yes/no binary outcome, eliminating the need 
for the user to differentiate colors. We hypothesized that a cell phone camera’s sensor, which 
reads in three color channels (red, green, and blue, RGB) could provide suitable information 
for using a ratiometric approach to read amplification reactions at the single molecule level. 
The example we considered here is the back-illuminated Exmor R CMOS image sensor55 
used on popular cell phones such as the Samsung Galaxy 4, iPhone 4S, and iPhone 5, which 
has a sensitivity maxima of ~520 nm (green), ~459 nm (blue), and ~597 nm (red) (Table 
5-2a).  
To illustrate our methodology for a hardware-agnostic visual readout with a ratiometric 
approach, we selected eriochrome black T (EBT), a magnesium ion indicator that meets the 
aforementioned dye specifications and has been used previously for visualization of LAMP 
products.56,57 During an isothermal amplification reaction, as nucleotides are incorporated, 
protons and bi-product pyrophosphate ions (P2O7
4−) are produced, and these ions can 
strongly bind metal ions (e.g. Mg2+ ions) and form insoluble salts, decreasing the 
concentration of metal ions in the reaction solution. Before the amplification reaction, EBT 
is bound to magnesium ions and the reaction solution is purple. As a LAMP reaction proceeds 
in the presence of target nucleic acid, it is suggested that EBT is deprived of Mg2+ by newly 
generated pyrophosphate ions, and the reaction solution turns blue.  
We hypothesized that EBT would be amenable to colorimetric analysis with a cell phone 
camera because, in RGB terms, in a positive LAMP reaction containing EBT dye, there is 
higher transmittance in the blue channel (blue LAMP reaction solution), while in a negative 
LAMP reaction transmittance remains high in the blue and red channels (purple LAMP 
reaction solution) (Figure 5.2a). These observed changes in transmittance between positive 
and negative reactions can be captured by the Exmor R optical sensor (Figure 5.2a), which 
match well with the observed differences between positive and negative transmittance 
profiles of LAMP reactions containing EBT (Figure 5.2a). 
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Figure 5.2: Predicted values and experimental validation of the first step of the 
ratiometric approach. 
(a) Measured spectral transmittance (%) in the range of visible light (400−700 nm) 
for positive (solid blue line) and negative (solid purple line) RT-LAMP reaction 
solutions, each containing 0.7 mM of eriochrome black T (EBT) as the amplification 
indicator dye. Dashed lines correspond to normalized spectral responses for red (R), 
green (G), and blue (B) channels of an Exmor R CMOS sensor, a common sensor in 
cell phone cameras. (b−e) Analysis of the three possible RGB ratiometric 
combinations for positive and negative RT-LAMP reaction solutions. (b) The 
predicted RGB values and corresponding colors for positive and negative LAMP 
amplification reactions obtained by convoluting the transmittance spectrum and 
Exmor R spectral responses described in panel a. (c) The cropped and enlarged color 
images collected with an Apple iPhone 4S for positive and negative RT-LAMP 
reaction solutions containing 90 μM of EBT dye. (d) Predicted images and 
ratiometric values for positive and negative amplification reactions processed for 
each ratiometric combination, G/R, B/R, and G/B. (e) Experimental images and 
ratiometric values for positive and negative amplification reactions for each 
combination: G/R, B/R, and G/ B. All experiments were performed with HCV RNA 
as template. 
 
Selecting the optimal ratiometric approach 
We tested whether the suitability of an indicator dye can be evaluated for a ratiometric 
approach prior to experimental validation by predicting the RGB values read by a cell phone 
camera for a positive and a negative reaction. First, we took the transmittance spectra for 
positive and negative amplification reactions containing EBT and convoluted them with the 
normalized spectral responses for each of the RGB channels in an Exmor R CMOS sensor58 
providing six curves (a positive and negative for each of the three color channels). Next, we 
calculated the area under each curve and took its square root (to correct for the standard 
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square-root scaling that occurs when an image data is compressed to be stored in the 
memory card of a cell phone), providing the predicted RGB values (Figure 5.2b) for positive 
(R=185, G=197 and B=209) and negative (R=219, G=190 and B=212) RT-LAMP reaction 
solutions in the presence of EBT at this particular concentration. These values can then be 
evaluated to select the optimal ratiometric approach for this particular indicator dye. In an 
RGB color scheme, there are three possible combinations for ratiometric analysis: G/R, B/R, 
or G/B. The predicted RGB values for a positive and a negative reaction are used to calculate 
the ratios for each channel combination (Figure 5.2d); the ratio with the greatest difference 
between positive and negative outcomes (G/R in this example) is predicted to be the most 
robust ratiometric analysis. 
Using the approach described above, we predicted the RGB ratios for a positive and negative 
RT-LAMP reaction in the presence of two additional indicator dyes: hydroxynaphthol blue 
(HNB) and calmagite. HNB is being reported increasingly in the literature for LAMP 
visualization,50,59-62 and calmagite is an analogue of EBT dye with the nitro group absent 
(more stable version).63 A side-by-side comparison showed that the greatest predicted 
difference between positive and negative RT-LAMP reactions, as captured by an unmodified 
cell phone camera, would be achieved using EBT as the indicator dye and G/R as the 
ratiometric combination (Figure 5.17). Based on these predicted ratios, we decided to 
validate our methodology using EBT as the indicator dye. We confirmed the storage stability 
of the EBT dye stock solution in the dried state (Figure 5.19), as this is a critical requirement 
for the use of a dye in real point-of-need diagnostic applications. EBT serves as our validation 
dye in this paper, however our methodology is designed to be applicable to alternative dyes. 
To experimentally validate this approach to predicting an optimal ratiometric combination, 
we performed an RT-LAMP reaction for HCV RNA containing EBT as the indicator dye 
and captured an image of the readout with an unmodified camera phone (iPhone 4S) (Figure 
5.2c). We processed the readout image; color channels of the original image were split, and 
all three channel ratios (G/R, B/R, G/B) were calculated to derive a ratiometric image for 
each ratiometric combination. These experimental ratios obtained with an unmodified cell 
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phone camera (Figure 5.2e) matched well with the predicted values (Figure 5.2d) for 
each of the three ratiometric combinations, confirming the predictive power of this approach. 
The G/B ratio was identified as less appropriate for distinguishing positive and negative 
reactions because the values for positive and negative reactions were similar; G/R and B/R 
ratios were identified as suitable because there was sufficient contrast between the values for 
positive and negative reactions. For the G/R combination, the ratio obtained after a negative 
reaction was 0.91, and the ratio from a positive reaction was 1.03—a difference of 0.12 
(Figure 5.2e). For the B/R combination, the ratios for negative and positive reactions were 
0.98 and 1.07—a difference of 0.09 (Figure 5.2e). Therefore, we selected the G/R 
combination for our subsequent validation experiments. Counting positives is a more 
intuitive approach, so the B/R ratio (where the positive ratio had the greatest difference from 
the background) can be a useful and attractive method. However, it is generally more 
desirable to select a ratio that includes the green channel because most single-chip digital 
image sensors used in digital cameras, including cell phones, utilize a Bayer filter mosaic 
pattern that is composed of 50% green, 25% red, and 25% blue pixels.64 
To test the robustness of our approach to different hardware and illumination conditions, we 
used HCV RNA amplified by RT-LAMP at two-fold increasing concentrations of indicator 
dye ranging from 10.9 µM to 1.4 mM (for a total of eight dye concentrations). After RT-
LAMP amplification, 50 µL of each reaction solution were transferred to 96-well plates (path 
length of ~1.5 mm), and the readout was imaged with cameras from four common cell phone 
models: Apple iPhone 4S (Figure 5.3a), HTC inspire 4G (Figure 5.3b), Motorola Moto G 
(Figure 5.3c), and Nokia 808 PureView (Figure 5.3d). Under fluorescent light and using the 
G/R ratiometric process (green channel divided by red channel followed by a threshold 
adjustment to generate a binarized black and white image), we determined that EBT 
concentrations lower than 0.175 mM provided an insufficient color change for detection with 
a cell phone camera (Figure 5.3, region I, white background), while concentrations of 1.4 
mM inhibited the amplification reaction (Figure 5.3, region III, red background). For this 
particular indicator dye, the range of concentrations at which color change could be detected 
by an unmodified cell phone camera and no inhibition was observed at the endpoint of the 
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reaction (Supporting information, Figure 5.7) was identified as 0.175 mM to 0.7 mM 
(Figure 5.3, region II, green background). Some cell phone cameras were more sensitive 
(e.g. HTC inspire 4G was able to distinguish a positive result at EBT concentrations as low 
as 0.0875 mM) (Figure 5.3b), but all four cell phone models distinguished a positive reaction 
at concentrations between 0.175–0.7 mM (Figure 5.3, region II, green background). We 
then chose one cell phone with the most representative performance (Apple iPhone 4S) to 
test the robustness of the G/R approach to different lighting conditions. Under all conditions 
tested: incandescent light (Figure 5.3e), direct sunlight (Figure 5.3f), and indirect sunlight 
(Figure 5.3g), the optimal EBT concentration range that we identified under fluorescent light 
(0.175–0.7 mM) could be read clearly, confirming the robustness of the ratiometric approach 
to variations in illumination. 
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Figure 5.3: Validation of the robustness of the G/R ratiometric approach to 
different hardware (cell phone cameras) and lighting conditions. 
(a−g) Enlarged and cropped color images (top two rows of each individual panel) 
captured by an unmodified cell phone camera from positive (+) and negative (−) RT-
LAMP reactions at 2-fold increases in EBT concentration from 10.9 μM to 1.4 mM 
(1 = 0.011 mM; 2 = 0.022 mM; 3 = 0.044 mM, 4 = 0.088 mM, 5 = 0.175 mM; 6 = 
0.35 mM; 7 = 0.7 mM; 8 = 1.4 mM). Positive wells are blue and negative wells are 
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purple. After G/R ratiometric processing (bottom two rows of each individual panel), 
negative wells are black. Regions I, II, III in each panel indicate the effect of dye 
concentration: (II) acceptable concentration range for visualization (green regions); 
(I) concentrations too low for visualization (white regions); and (III) concentrations 
too high for visualization (red regions). (a−d) Images captured by four common cell 
phones under fluorescent light: (a) Apple iPhone 4S, (b) HTC inspire 4G, (c) 
Motorola Moto G, and (d) Nokia 808 PureView. (e−g) Images captured by an Apple 
iPhone 4S under three additional light conditions: (e) incandescent light, (f) direct 
sunlight, and (g) indirect sunlight. All experiments were performed with HCV RNA 
as a clinically relevant target. All images were acquired with unmodified cell phone 
cameras. Detailed information for the G/R ratiometric process (Figure 5.8) and 
additional cell phone camera images (Figure 5.9) are provided in the Supporting 
Information. 
 
One-step method for digital visual readout 
Microfluidic devices enable ultrasensitive digital quantification. Small well volumes are 
valuable because they enable faster reactions (because concentrations are high in single 
wells), minimize the effects of inhibitory materials (due to their isolation into wells), and 
expand the upper limit of the dynamic range (because single molecules can be confined from 
samples containing high template concentrations).18,65,66 However, as well volumes (and path 
lengths) decrease, color visualization becomes challenging for a mobile phone. To 
compensate, the concentration of the indicator dye can be increased, however high 
concentrations of some dyes inhibit amplification reactions. Thus, there are inherent physical 
limits to a colorimetric approach. To validate that this visual readout approach could be 
applied to single-molecule amplification at nanoliter volumes, we used digital LAMP 
(dLAMP) and phage lambda DNA (λDNA) as a target. We specifically aimed to resolve 
three questions: (i) Can we obtain a visual readout for amplified single molecules that can be 
 
 
128 
captured by an unmodified cell phone camera? (ii) Is volume a factor in achieving a 
digital visual readout? (iii) Does ratiometric processing work for small volumes? 
To answer these questions, we designed a multivolume rotational SlipChip device containing 
1,240 wells of eight volumes ranging from 15 nL to 50 nL (Figure 5.10-11). We loaded these 
devices with LAMP reaction solution containing an appropriate target concentration in the 
middle of the device’s dynamic range, a fluorescent DNA-detecting intercalation dye (Syto 
9), and EBT dye at 0.7 mM (the highest non-inhibiting concentration identified in Figure 
5.3). We imaged this device with a house-built real-time fluorescence imager, with a Leica 
stereoscope (optimal imaging conditions), and with an Apple iPhone 4S. The number of 
positive counts based on fluorescence was 261, while 260 positives were counted using the 
indicator dye and G/R process both with the stereoscope and the cell phone (Figure 5.4). 
This experiment showed that the G/R method could be used in place of fluorescence readout 
to count amplified single molecules and that the readout capture and G/R processing 
performed on an unmodified cell phone matched the results obtained under optimal lighting 
conditions (stereoscope). Additionally, using a device containing 800 wells of 27 nL, we 
observed excellent correlation among positive counts obtained from the stereoscope, 
fluorescence imager, and cell phone camera (Figure 5.12). 
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Figure 5.4: Readout from single-molecule digital LAMP reactions performed 
with λ DNA on a multivolume rotational SlipChip device imaged by (a) a 
stereoscope, (b) a fluorescence microscope, and (c) an unmodified cell phone 
camera. 
(e−g) Callouts are magnified to show visual correlation among the three imaging 
methods. (d) The results of the ratiometric processing for the stereoscope G/R-
processed image and (h) the cell phone G/R-processed image. Colors were enhanced 
in these figures for clarity of publication; raw images were used in all ratiometric 
analyses. These devices contained 1240 wells of eight volumes ranging from 15 to 
50 nL. 
 
While investigating the limits that reaction volume may impose on visual readout, we 
observed that the estimated template concentration determined from each of the eight well 
volumes produced similar Most Probable Numbers (MPN) of molecules (mean 8,500  1,500 
copies/mL) (Figure 5.5a) (estimated concentration from all volumes are within 95% 
confidence interval at each volume, detailed in Figure 5.13). In addition, all SlipChip 
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devices, analyzed independently, gave similar target concentrations (8,400  500 
copies/mL) (Figure 5.5b), suggesting that the selected indicator dye did not impair 
quantification of single molecules in well sizes 15–50 nL and that these well volumes can be 
imaged reliably with either a stereoscope or an unmodified cell phone camera. However, the 
cell phone camera images of well volumes of 15 nL were less clear than those obtained from 
the stereoscope, suggesting that volumes of ~15 nL may approach the limit of colorimetric 
imaging with current camera phone sensors, although as higher quality sensors are integrated 
into commercial cell phones, this limit would change. 
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Figure 5.5: Robustness of digital visual readout at different well volumes. 
Concentration of lambda DNA was estimated by digital LAMP using five 
multivolume rotational SlipChip devices, each of which contained eight well 
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volumes ranging from 15–50 nL. (a) Measured template concentration for each well 
volume averaged over five devices. (b) Mean template concentration for each of five 
rotational SlipChip devices. Concentrations were calculated using MPN theory,65 and 
error bars represent standard deviation. Images were captured by a stereoscope and 
processed with the ratiometric approach (G/R process). 
 
Two-step method for digital visual readout 
We next developed a method to apply the visual readout approach to digital devices that 
contain smaller well volumes. To be able to image at small volumes (e.g. 5 nL) on a 
microfluidic device, one must balance the need for greater indicator color intensity for 
visualization with the need to keep dye concentrations below the level of inhibition (Figure 
5.3 region III) for an amplification reaction. High concentrations of indicator dye can 
completely halt an amplification reaction, and we knew from performing real-time bulk 
experiments that even when reactions are positive, an indicator dye can still interfere to some 
extent with isothermal nucleic acid amplification—for both RNA and DNA we observed 
delays in the time-to-positive, and this delay increased at greater concentrations of the 
indicator dye, even though reactions were positive (Figure 5.14). We hypothesized that we 
could prevent inhibition completely by decoupling the amplification step from the readout 
step. To do this, we designed a two-step SlipChip device (based on previous SlipChip 
designs)13 (Figure 5.15-16) in which the amplification solution and the detection solution 
are loaded into separate wells (Figure 5.6a). We validated this two-step protocol with a 
clinically relevant target, purified HCV RNA, using digital reverse transcription-LAMP 
(dRT-LAMP). First, we performed digital isothermal amplification in the set of small (5 nL) 
amplification wells (in the absence of the indicator dye) (Figure 5.6a (i)). After 
amplification, a “slip” was performed and the amplification wells came into contact with a 
second set of larger (9.5 nL) wells, which contained the indicator dye—for a total well 
volume of 14.5 nL (Figure 5.6a (ii)). After mixing, negative wells lacking target molecules 
stayed purple and wells containing positive reactions turned blue (Figure 5.6a (iii)). Counts 
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obtained by a house-built real-time imaging instrument (to read fluorescence), and counts 
obtained by G/R processing from an image captured by an unmodified cell phone camera 
were significantly correlated (Pearson’s Corr = 0.9998; R2 = 0.9996) (Figure 6h), showing 
that this two-step SlipChip-based protocol provides a suitable visual readout for digital 
single-molecule amplification for devices containing wells of small volumes. 
Devices shown in this manuscript were not designed to achieve clinically relevant 
concentrations in the lower detection limit of quantification (LDL) because larger well 
volumes do not represent a challenge when imaging with a mobile phone. Instead, we studied 
the performance of our approach with wells of small volumes to ensure that this method 
meets the ULQ required for clinical relevance. The upper limit of quantification (ULQ) is 
determined by the total number of wells with the smallest volume. As an example, for 
SlipChip devices with 800 wells of 5 nL the ULQ is 1,162,413 copies/mL, while a SlipChip 
device with 10,000 wells of 5 nL the ULQ is 1,622,660 (calculations performed according 
to Kruetz, et al. 2011.65 
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Figure 5.6: Experimental validation of two-step SlipChip devices for single 
molecule counting with an unmodified cell phone camera. 
(a) A flow-chart of detection of single molecules in two-step SlipChip: (i) 5 nL 
amplification wells are loaded with amplification reaction solution (RXN), and 9.5 
nL detection wells are loaded with indicator dye (DYE). (ii) After amplification, a 
slip is performed and the RXN and DYE wells are combined. (iii) Immediately after 
mixing, positive reaction solutions become blue, while negative reactions remain 
purple. The readout is imaged by an unmodified cell phone camera. (iv) Ratiometric 
image processing (G/R process) provides a single binary result (positive or negative). 
(b) Stereoscope and (c) fluorescence images of the device before the amplification 
and readout wells are merged (arrow designates direction of slip). (d) Stereoscope 
and (f) cell phone camera images after the device is slipped and the wells are merged. 
(e) Stereoscope and (g) cell phone camera images after G/R image processing. (h) 
Correlation between fluorescence counts and cell phone (G/R processed) counts. 
Colors were enhanced in figure panels (b, c, d, and f) for clarity of publication; raw 
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images were used in all ratiometric analyses. In these experiments, HCV RNA was 
amplified by dRT-LAMP. 
 
Conclusions 
Here we show that single nucleic acid molecules can be detected and counted with an 
unmodified cell phone camera by employing microfluidic technology, sequence-specific 
isothermal amplification, and a judiciously chosen amplification-indicator dye. We further 
show that ratiometric processing of the cell phone image enables robust quantification 
without the need for a user to differentiate colors. The general methodology we developed 
can be used as a guideline to enable others to develop their own cell phone based single-
molecule counting approach. The methodology includes the following steps: First, an 
appropriate amplification indicator should be selected. Indicators should respond optically to 
each nucleotide incorporation event (as opposed to responding to number of produced 
molecules) resulting in a change in the transmittance profile in the wavelength range of 
visible light (400–700 nm). The indicator dye should have a change in absorbance matched 
to the spectral sensitivity of the image sensor in an unmodified cell phone; for ratiometric 
processing, the solution should have a large relative change in transmittance in color channels 
for which the camera’s image sensor is most sensitive. Second, the color ratio used in the 
ratiometric approach is chosen based on the spectral sensitivity of the image sensor in an 
unmodified cell phone. This step can be done in silico to identify the dye with the ratio that 
provides an unambiguous binary readout of positive and negative reactions that is robust to 
illumination and hardware conditions. We hope others will use this algorithm to identify even 
better dyes that will move this field forward. Third, the selected dye and ratiometric approach 
should be validated using the desired amplification chemistry. Experiments should be 
performed to establish the range of dye concentrations and well volumes at which an 
amplification reaction is not inhibited and at which imaging can be done with an unmodified 
cell phone. For some indicator dyes, the range of suitable well volumes and concentrations 
will be too narrow. In such situations, an alternative approach is to use a two-step device that 
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separates the amplification and readout steps. Processing can be done directly on a cell 
phone or uploaded wirelessly to a cloud server to swiftly communicate results, as we have 
shown previously.14 We anticipate that the capabilities of visual readout for counting single 
molecules will extend further as cell phone camera technology advances, as additional 
indicators are available (e.g. metal ions, pH indicators) and as additional types of 
amplification reactions are developed. Devices that integrate sample preparation, nucleic 
acid amplification, and a visual digital readout that can be captured easily will be a critical 
breakthrough toward bringing quantitative, ultrasensitive measurements outside of central 
laboratories—a key step for in vitro diagnostics, pandemic surveillance and environmental 
monitoring. We hope this work will stimulate regulatory agencies such as the FDA to 
consider the use of cell phones as valuable diagnostic components. 
 
Materials and Methods 
Chemicals and materials.  
All chemicals were purchased from commercial sources. The LoopAmp® RNA 
amplification kit (Eiken Chemical Co., Ltd., Japan) was purchased from SA Scientific (San 
Antonio, TX, USA). The LoopAmp® RNA amplification kit contains 2X Reaction Mix 
(RM) (40 mM Tris-HCl pH 8.8, 20 mM KCl, 16 mM MgSO4, 20 mM (NH4)2SO4, 0.2% 
Tween20, 1.6 M Betaine and dNTPs 2.8 mM each), Enzyme Mix (EM) (mixture of Bst DNA 
polymerase and AMV reverse transcriptase), and distilled water (DW). Bovine serum 
albumin (BSA) was purchased from Roche Diagnostics (Indianapolis, IN, USA). Phage 
lambda DNA (500 µg), SUPERase In RNase Inhibitor (20 U/μL), Eriochrome Black T 
(EBT) dye, mineral oil (DNase, RNase, and Protease free), tetradecane, Costar™ Clear 
Polystyrene 96-Well Plates, Corning® Universal Optical Microplate Sealing Tape, and 
DEPC-treated nuclease-free water were purchased from Thermo Fisher Scientific (Hanover 
Park, IL, USA). Chelex® 100 resin was purchased from Bio-Rad (Hercules, CA, USA). 
Trehalose Solution (1 M) was purchased from Amersham Life Science (Cleveland, Ohio, 
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USA). Tris-HCl buffer stock solution (1 M, pH 8.0) was purchased from Affymetrix 
(Santa Clara, CA, USA). All primers were produced by Integrated DNA Technologies 
(Coralville, IA, USA). Dichlorodimethylsilane was purchased from Sigma-Aldrich (St. 
Louis, MO, USA). SYTO® 9 Stain and AcroMetrix® HCV High Control were purchased 
from Life Technologies (Grand Island, NY, USA). Nucleic acid extraction kit QIAamp Viral 
RNA Mini kit was purchased from QIAGEN Inc. (Valencia, CA, USA). Eppendorf 
Mastercycler Gradient PCR Themal Cycler was purchased from Eppendorf (Hamburg, 
Germany). POLARstar Omega microplate reader was purchased from BMG Labtech 
(Durham, NC, USA). Leica MZ Fl III stereoscope with PLAN 0.5x lens was purchased from 
Leica Microsystems (Bannockburn, IL, USA). Photomasks were designed in AutoCAD 
2013 and ordered from CAD/Art Services, Inc. (Bandon, OR, USA). Soda-lime glass plates 
coated with layers of chromium and photoresist were ordered from the Telic Company 
(Valencia, CA, USA). 
 
SlipChip device design.  
The multivolume rotational SlipChip device design was used to demonstrate the one-step 
method for digital visual readout; this device was composed of 1,240 microfluidic wells, with 
the following volumes: 160 wells x 15 nL, 160 x 17.5 nL, 160 x 20 nL, 160 x 22.5 nL, 160 
x 25 nL, 160 x 40 nL, 160 x 45 nL, 120 x 50 nL (Figure 5.10). The total combined volume 
of all wells was 35.6 µL. For loading, one inlet hole (in the middle ring structure) and four 
oil escape holes (in the outer ring structure) were drilled in the top plate. The two-step 
SlipChip device was used to demonstrate a two-step method for digital visual readout; this 
device was based on previously published SlipChip designs.13 For the two-step SlipChip 
design used in this study, the device was modified in the following ways: (i) the number of 
each type of well was reduced to 800; (ii) space was added between the arrays to allow for 
the incubation conformation; (iii) the sequence of well loading was reversed (the smaller 5 
nL wells are loaded before the larger 9.5 nL wells). See Figure 5.15 for more details. 
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SlipChip multivolume designs for HCV and HIV viral load quantification at clinically 
relevant dynamic ranges67-69 is provided in the SI (Table 5-3). 
 
SlipChip device fabrication.  
The procedure for fabricating the multivolume rotational SlipChip and two-step SlipChip 
devices was based on previous work.70 The device features were etched to a depth of ~100 
µm for the multivolume rotational SlipChip devices and ~67 µm for the two-step SlipChip 
devices. After etching and drilling access holes, both devices were subjected to the same 
glass silanization process, previously described,66 where the glass plates were first 
thoroughly cleaned with piranha mix,dried sequentially with 200-proof ethanol and nitrogen 
gas, then oxidized in a plasma cleaner for 2 min, and immediately transferred into a vacuum 
desiccator for 1.5 h for silanization with dimethyldichlorosilane. After silanization, the 
devices were rinsed thoroughly with chloroform, acetone, and ethanol, and dried with 
nitrogen gas before use. When a glass SlipChip device needed to be reused, it was first 
cleaned with acid Piranha Solution and then subjected to the same silanization and rinsing 
procedure described above.  
 
Assembling and loading SlipChips.  
The SlipChips used for both the dLAMP and the dRT-LAMP reactions were assembled 
under degassed oil (mineral oil: tetradecane 1:4 v/v). Both top and bottom plates were 
immersed in the oil phase and placed face to face. The two plates were aligned under a 
stereoscope (Leica, Germany) and stabilized using binder clips. Through-holes were drilled 
into the top plate to serve as fluid inlets and oil outlets in dead-end filling. The reagent 
solutions were loaded through the inlets by pipetting. 
 
 
 
139 
HCV viral RNA purification from AcroMetrix® HCV High Control.  
200 µL plasma containing HCV RNA (viral load estimate provided by the company: 1.1 
IU/mL – 3.5 IU/mL) was extracted using the QIAamp Viral RNA Mini Kit (QIAGEN Inc, 
Valencia, CA, USA) according to the manufacturer’s instructions. The elution volume was 
60 μL. The purified HCV viral RNA was analyzed immediately or stored at -80 °C until 
further analysis. 
 
Preparation of EBT solution.  
The EBT stock solutions were prepared by dissolving EBT dye in deionized water. The 
aqueous solution was sonicated for 10–20 min, and the free volume was filled with argon 
gas and mixed on a rotator at 65 C for 1 h. To remove any potential impurities from the 
EBT dye, Chelex® 100 ion exchange resin was added to the resulting solution (5% w/v) and 
placed on rotator for 1 h. Resin was centrifuged at 3,000 rpm for 5 min, and the top fraction 
was collected in a Falcon tube, flushed with argon, and stored at room temperature for no 
more than 2 days. A comparison of EBT, HNB, and calmagite indicator dye stock solutions 
before and after treatment with Chelex® 100 is provided in the SI (Figure 5.18). 
 
Storage stability of amplification indicator dyes by drying in the presence of stabilizer 
trehalose 
EBT, HNB, and calmagite stock solutions at 0.7 mM were prepared by dissolving the dyes 
in 20 mM Tris-HCl buffer (pH 8.8) and adding 30 mM of trehalose. The solutions were 
sonicated for 10 min and mixed on a rotator at room temperature for 1 h. Chelex® 100 ion 
exchange resin was added (5% w/v) and placed on rotator for 1 h. Resin was centrifuged at 
3,000 rpm for 5 min and the top fraction was collected in a Falcon tube. The resulting stock 
solutions were transferred to a Costar™ Clear Polystyrene 96-Well Plate (40 μL per well) 
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and sealed with Corning® Universal Optical Microplate Sealing Tape before 
spectrophotometric analysis (time 0 h). Immediately after analysis, the sealing cover was 
removed and the plate was placed in a desiccator under vacuum overnight until the dye stock 
solutions were completely dry. Then, at 24-hour time points over the next 120 h (for a total 
of 5 time points), three wells of each dried amplification indicator solution were resuspended 
with 40 μL of deionized water and spectrophotometric analyses were performed. After each 
measurement, the plate was sealed again (to prevent hydration of the dried solutions in the 
other wells) and kept in the dark at room temperature. The absorption spectra analyses were 
performed by using the POLARstar Omega microplate reader with Omega Data analysis 
software. Absorbance in the range of 400–700 nm was recorded at 2-nm intervals. Blank 
solutions (20 mM Tris-HCl buffer with 30 mM Trehalose) were also loaded at time 0 h, 
desiccated after the first measurement, and treated as the rest of the solutions. The measured 
spectral absorbance from these control solutions was subtracted at each time point from the 
plotted data (Figure 5.19). 
 
RT-LAMP amplification of HCV RNA in-tube 
The purified HCV RNA described above was used for in-tube RT-LAMP amplification. The 
RT-LAMP mix contained the following: 20 μL of RM, 2μL of EM, 2 μL of SYTO® 9 Stain 
from a 40 μM stock, 4 μL of LAMP primer mixture (20 μM BIP/FIP, 10 μM LB/LF, and 2.5 
μM B3/F3), 1 μL of SUPERase In RNase Inhibitor (20 U/L), EBT solutions of various 
concentrations and with various amounts of RNA template solution, and enough nuclease-
free water to bring the volume to 40 μL. The solution was loaded into 0.2 mL PCR tubes and 
heated at 63 °C for 50 min and 85 °C for 5 min (heat inactivation) on an Eppendorf 
Mastercycler Gradient PCR Themal Cycler. 
 
Spectrophotometric analysis for positive and negative RT-LAMP reactions 
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Fifty-µL of positive and negative RT-LAMP reaction solutions containing 0.7 mM of 
EBT, HNB, and calmagite dyes were transferred to a Costar™ Clear Polystyrene 96-Well 
Plates, the plate was sealed with a Corning® Universal Optical Microplate Sealing Tape and 
then used for spectrophotometric analysis. An absorption spectra analysis was performed by 
using the POLARstar Omega microplate reader with Omega Data analysis software. The 
instrument was first set to zero at 700 nm for distilled water, and absorbance in the range of 
400 nm to 700 nm was recorded at 2-nm intervals. Transmittance was calculated from 
absorbance values using the following equation: 𝑇 = 10(2−𝐴). 
 
Prediction of RGB values 
Predicted RGB values for a positive and negative LAMP amplification reaction containing 
EBT were calculated as follows: (i) The spectral response curves for a Exmor R CMOS 
image sensor were available only in a graphical format, so data was extracted using Plot 
Digitizer (ver. 2.6.6) and new plots were generated. (ii) The area under the curve for each of 
the three color channel spectra was normalized (selecting 1,000 arbitrary values under each 
curve). Uniform white-balanced light source was assumed. (iii) Convolution of the spectral 
transmittance spectral profiles of the indicator dye for a positive and a negative LAMP 
reaction solution (experimentally obtained) with the normalized spectral responses from the 
Exmor R CMOS image sensor was performed. We ignored the light scattering caused by 
pyrophosphate release during the amplification reaction. As a result, six curves were 
generated (a positive and negative for each of the three color channels). (iv) The area under 
each curve was calculated and its square root taken, providing the predicted RGB values for 
positive and negative RT-LAMP reaction solutions in the presence of EBT at this particular 
concentration. 
 
dLAMP amplification of phage lambda DNA on multivolume rotational SlipChip devices 
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To amplify lambda phage DNA using dLAMP method, the LAMP mix contained the 
following: 20 μL of RM, 2 μL of EM, 2 μL of SYTO® 9 Stain from 40 μM stock, 4 μL of 
primer mixture (20 μM BIP/FIP, 10 μM LB/LF, and 2.5 μM B3/F3), 2 μL of BSA (20 
mg/mL), various amounts of DNA template solution, 4.7 µL of 6 mM EBT dye (0.7 mM 
final concentration), and enough nuclease-free water to bring the volume to 40 μL. The 
solution was loaded onto a multivolume rotational SlipChip device and heated at 63 °C for 
50 min on flat block PCR machine (Eppendorf Mastercycler). Five minutes of heating at 85 
°C was used to stop the reaction. 
 
Real-time dRT-LAMP of HCV RNA on two-step SlipChip devices 
To amplify HCV viral RNA using dRT-LAMP method on house-built real-time instrument, 
the RT-LAMP mix contained the following: 20 μL of RM, 2 μL of EM, 2 μL of SYTO® 9 
Stain from 40 μM stock, 4 μL of primer mixture (20 μM BIP/FIP, 10 μM LB/LF, and 2.5 
μM B3/F3), 2 μL of BSA (20 mg/mL), 1 μL of SUPERase In RNAase inhibitor, various 
amounts of RNA template solution, and enough nuclease-free water to bring the volume to 
40 μL. The solution was loaded into the 5 nL wells of two-step SlipChip devices. Other set 
of wells (9.5 nL) were loaded with 2.4 mM solution of EBT solution (1.57 mM final 
concentration). SlipChips were heated at 63 °C for 50 min on a house-built real-time 
instrument; reactions were stopped by heating to 85C for 5 min.  
 
House-built real-time instrument imaging 
Experiments were performed on a Bio-Rad PTC-200 thermocycler with a custom machined 
block. The block contains a flat 3” x 3” portion onto which the devices are placed ensuring 
optimal thermal contact. The excitation light source used was a Philips Luxeon S (LXS8-
PW30) 1315 lumen LED module with a Semrock filter (FF02-475). Image acquisition was 
performed with a VX-29MG camera and a Zeiss Macro Planar T F2-100mm lens. A Semrock 
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filter (FF01-540) was used as an emission filter. Images acquired were analyzed using 
LabVIEW software.  
 
House-built real-time instrument data analysis 
Fluorescent images were analyzed using self-developed Labview software. The data were 
analyzed by first creating a binary mask that defined the location of each reaction volume 
within the image. The masked spots were then overlaid on the stack of images collected over 
the course of the experiment, and the average intensity of each individual masked spot was 
tracked over the course of the stack. Background subtraction of the real-time trace was 
performed by creating a least mean square fit of each individual trace. Threshold was then 
manually set at the half height of the averaged maximum intensity, and the time-to-positive 
of each reaction was then determined as the point at which the real-time curve crossed the 
defined threshold. 
 
Bright-field image acquisition 
A mobile phone was used to capture the readout under standard fluorescent light, using the 
camera’s default autofocus and autoexposure settings. Photographs of the 96-well plate were 
also taken using alternate commercial cell phones and under different lighting conditions 
(Figure 5.3 and Figure 5.9). Stereoscope imaging was done using Leica MZ Fl III 
stereoscope with a PLAN 0.5x lens. The stereoscope was equipped with a Diagnostic 
Instruments color mosaic model 11.2 megapixel camera, and images were acquired using 
Spot imaging software. An automatic white-balance adjustment was done for each image 
using Spot software. Multiple images were acquired to capture all wells in the device, and 
assembled to form a complete image of the device to compare with the image acquired from 
the cell phone camera by using the freeware Image Composite Editor (ver. 2.0). 
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Bright field image processing and data analysis 
Images acquired with cell phone and stereoscope were processed using open source Image J 
software (ver.1.49) according to the standard procedure. Briefly: (i) white balance was 
corrected as needed, (ii) color channels of the original image were split and, (iii) one channel 
was divided by a second channel (e.g., green channel divided by the red channel in the G/R 
approach) to derive a ratiometric image; and (iv), automatic thresholding was applied to 
make a binary (black and white) image. Semi-automatic counting on the two-step Slipchip 
images was accomplished using a freeware Fiji image processing. Acquired bright field 
images for the multivolume rotational SlipChips were counted manually. 
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Supporting Information 
 
Figure 5.7: DNA gel electrophoresis for RT-LAMP product. 
Lanes 1, 10, and 19 are 100 bp DNA ladders. Lanes 2–9 are positive (HCV RNA) 
RT-LAMP reactions at two-fold increased EBT solution concentration (from 0.011 
to 1.4 mM). Lanes 11–18 are negative RT-LAMP reactions at two-fold increased 
EBT solution concentration (from 0.011 to 1.4 mM). Lane 9 shows an inhibited RT-
LAMP reaction in the presence of 1.4 mM EBT solution. 
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Figure 5.8: Each step of the G/R process algorithm. 
This experiment was performed with HCV RNA as a clinically relevant target, and 
the raw image was acquired with an Apple iPhone 4S under fluorescent light. The 
top row of each panel (eight wells) shows a positive RT-LAMP reaction containing 
EBT solution at two-fold increasing concentrations from 10.9 µM to 1.4 mM (from 
left to right). The bottom row of each panel (eight wells) shows negative RT-LAMP 
reactions containing EBT solution at two-fold increasing concentrations from 10.9 
µM to 1.4 mM. a). A raw image acquired by a cell phone camera. b) The same image 
after white balance correction. c) Red, green, and blue color channels separated. d) 
Resulting image after green channel is divided by red channel. e) The binary image 
after a threshold correction. Positive reactions (originally blue) are white and 
negative reactions (originally purple) are black. Image processing was performed 
with Image J (ver. 1.49). 
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Figure 5.9: Original and G/R-processed images acquired with unmodified cell 
phone cameras. 
Original color images show negative (bottom two rows) and positive (top two rows) 
RT-LAMP reactions. From left to right, EBT concentration is increased in two-fold 
increments between 10.9 µM to .088mM (bottom row) and .175mM to 1.4mM 
(second row from the bottom). Positives contained HCV RNA, and the same EBT 
concentration pattern was repeated. Negative wells are purple and positive wells are 
blue. Ratiometric G/R-processed images show the binary result in which the negative 
wells become black and the positive wells become white. (1–4) Images collected with 
four common cell phones under fluorescent light: (1) Apple iPhone 4S, (2) HTC 
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inspire 4G, (3) Motorola Moto G, and (4) Nokia 808 PureView. (5–7) Images 
collected with Apple iPhone 4S under different light conditions: (5) incandescent 
light, (6) direct sunlight, and (7) indirect sunlight. Image processing was performed 
with ImageJ (ver. 1.49). 
 
 
Figure 5.10: Schematic of the top (left) and bottom (right) plates of the 
multivolume rotational SlipChip device used in the one-step digital LAMP 
experiments before being assembled. 
The top plate shows the direction of the rotational 4.5° slip. 
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Figure 5.11: Schematic of the multivolume rotational SlipChip device used for 
one-step digital LAMP experiments after being assembled. 
Drawing shows the layout of top and bottom piece of the entire device on the right 
and a zoomed-in region (black box) on the left. a) Relative position of the two pieces 
when they are aligned to allow loading of solution through the channel, and b) the 
relative position of the two pieces when they are slipped (top slide rotated 4.5°) to 
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separate droplets from one another and form compartments. Features shown are 
before isotropic glass etching. 
 
 
Figure 5.12: Positive counts obtained from single-molecule digital LAMP 
reactions performed with lambda DNA on a one-step SlipChip device imaged 
by a house-built real-time fluorescence microscope, a Leica MZ Fl III 
stereoscope, and an unmodified cell phone camera (Apple iPhone 4S) under 
fluorescent light. 
One-step visual readout was performed on SlipChip devices composed of 800 wells 
of 27 nL volumes. LAMP amplification mix contained 0.7 mM eriochrome black T 
dye solution, SYTO® 9 Stain, and phage lambda DNA. Automated counting was 
performed by self-developed Labview software for fluorescent images and freeware 
Fiji image processing for bright field G/R processed images. Data are mean positive 
counts and error bars are S.D. (N = 3). Student’s t-tests were used for statistical 
comparisons, showing no significant differences among counts obtained by the three 
imaging methods (P values > 0.05). 
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Figure 5.13: Five multivolume experiments were performed, and the 
concentration of each volume was calculated based on the methods of Kreutz et 
al. 
Gray boxes denote the 95% confidence interval for the set of experiments at each 
volume. Concentrations calculated at each volume are consistent, and there is no bias 
based on the volume in which the reaction is performed. 
 
 
Figure 5.14: Performance of bulk LAMP reactions at increasing concentrations 
of the amplification indicator dye eriochrome black T (EBT). 
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All reactions performed in 10 L volumes with concentrations of EBT solution 
ranging from 0.0 to 0.7 mM, SYTO® 9 Stain and either 1,000 copies of HCV RNA 
(red) or 1,000 copies of phage lambda DNA (blue). All reactions were run in 
triplicate. 
 
 
Figure 5.15: Schematic of the two-step SlipChip device before assembly. 
Drawings show the top (a) and bottom (b) device plates with a selected region (black 
box) magnified on the left to show locations of the 5 nL and 9.5 nL wells. Features 
are shown before isotropic glass etching. The design of the two-step SlipChip device 
was based on previously published SlipChip designs.13 
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Figure 5.16: Schematic of the two-step SlipChip device after assembly and its 
operation. 
Drawings show the layout of the top and bottom plates on the right and a magnified 
region (black box) on the left. (a) Loading conformation for the first set of wells (5 
nL each). (b) Loading conformation for the second set of wells (9.5 nL each). (c) 
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Incubation conformation. (d) Final mixing conformation ready for imaging with a 
cell phone camera. Features are shown before isotropic glass etching. 
 
Table 5-1: Sequence of primers used in RT-LAMP experiments for detection of 
hepatitis C RNA.15 
 
 
Table 5-2: Sequence of primers used in LAMP experiments for detection of 
lambda phage DNA.17 
 
Table 5-3: Multivolume device designs for viral load quantification. 
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The lower detection limit (LDL) is defined as the concentration which would have a 95% 
probability of generating at least one positive well. The upper limit of quantification (ULQ) 
is defined as the concentration where the probability of all wells being positive is 5%. DR: 
dynamic range. Calculations were performed according to the equations and algorithms 
found in Kreutz JE, Munson T, Huynh T, Shen F, Du W, Ismagilov RF. “Theoretical design 
and analysis of multivolume digital assays with wide dynamic range validated 
experimentally with microfluidic digital PCR.” Anal Chem. 2011 83(21):8158-68. 
 
 
Figure 5.17: (a, c and e) Measured spectral transmittance (%) in the range of 
visible light (400–700 nm) for positive (solid purple line) and negative (solid blue 
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line) RT-LAMP reaction solutions, each containing 0.7 mM of eriochrome black 
T, hydroxynaphthol blue or calmagite as the amplification indicator dye. 
Dashed lines correspond to normalized spectral responses for red (R), green (G), and 
blue (B) channels of an Exmor R CMOS sensor, a common sensor in cell phone 
cameras. (b, d, and f) Predicted ratiometric values for positive and negative LAMP 
amplification reactions processed for each ratiometric combination, Green/Red, 
Blue/Red, and Green/Blue. Tables show absolute differences (positive – negative), 
and the relative difference (in %) between positive and negative ratiometric values 
are shown. All experiments were performed with HCV RNA as a template. Dye stock 
solutions were prepared as described in the Methods section, “Preparation of EBT 
solution.” 
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Figure 5.18: Comparison of the spectral absorbance (Absorbance Units) of 
untreated indicator dye stock solutions (dashed orange lines) and solutions 
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treated with Chelex® 100 resin (solid red lines) for (a) eriochrome black T 
(EBT), (b) hydroxynaphthol blue (HNB) and (c) calmagite indicator dyes. 
The EBT, HNB, and calmagite stock solutions were prepared by dissolving the dyes 
in 20 mM Tris-HCl buffer (pH 8.8) at 0.7 mM. The solutions were sonicated for 10 
min and mixed on a rotator at room temperature for 1 h. The solutions were split into 
two equal volumes for the comparison; one volume was treated with Chelex® 100 
ion exchange resin (5% w/v). 
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Figure 5.19: Storage stability of amplification indicator dyes by drying the stock 
solutions in the presence of stabilizer trehalose. 
Measured spectral absorbance (Absorbance Units) in the range of visible light (400–
700 nm) for (a) eriochrome black T (EBT), (b) hydroxynaphthol blue (HNB), and (c) 
calmagite indicator dyes solutions. Time “0 h” is the spectral absorbance of the dye 
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stock solution prior to drying in a dessiccator under vacuum. The following time 
points correspond to the length of time the dye stock solution was maintained in its 
dried state before being resuspended in distilled water. Full protocol is in the Methods 
section, “Storage stability of amplification indicator dyes by drying in the presence 
of stabilizer trehalose.” 
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6 .  C h a p t e r  6  
REAL-TIME, DIGITAL LAMP WITH COMMERCIAL 
MICROFLUIDIC CHIPS REVEALS THE INTERPLAY OF 
EFFICIENCY, SPEED, AND BACKGROUND AMPLIFICATION AS 
A FUNCTION OF REACTION TEMPERATURE AND TIME 
 
J.C. Rolando, E. Jue, N.G. Schoepp, and R.F. Ismagilov. 2018. Analytical Chemistry. 91(1):1034–
1042. doi:10.1021/acs.analchem.8b04324 
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Real-time, isothermal, digital nucleic acid amplification is emerging as an attractive 
approach for a multitude of applications including diagnostics, mechanistic studies, and 
assay optimization. Unfortunately, there is no commercially available and affordable real-
time, digital instrument validated for isothermal amplification; thus, most researchers have 
not been able to apply digital, real-time approaches to isothermal amplification. Here, we 
generate an approach to real-time digital loop-mediated isothermal amplification (LAMP) 
using commercially available microfluidic chips and reagents, and open-source components. 
We demonstrate this approach by testing variables that influence LAMP reaction speed and 
the probability of detection. By analyzing the interplay of amplification efficiency, 
background, and speed of amplification, this real-time digital method enabled us to test 
enzymatic performance over a range of temperatures, generating high-precision kinetic and 
endpoint measurements. We were able to identify the unique optimal temperature for two 
polymerase enzymes, while accounting for amplification efficiency, non-specific 
background, and time to threshold. We validated this digital LAMP assay and pipeline by 
performing a phenotypic antibiotic susceptibility test on 17 archived clinical urine samples 
from patients diagnosed with urinary tract infections. We provide all the necessary 
workflows to perform digital LAMP using standard laboratory equipment and commercially 
available materials. This real-time digital approach will be useful to others in the future to 
understand the fundamentals of isothermal chemistries—including which components 
determine amplification fate, reaction speed, and enzymatic performance. Researchers can 
also adapt this pipeline, which uses only standard equipment and commercial components, 
to quickly study and optimize assays using precise, real-time, digital quantification—
accelerating development of critically needed diagnostics. 
 
Introduction 
In this chapter, we describe a methodology to use commercially available chips, reagents, 
and microscopes to perform real-time digital LAMP. We use this methodology to perform a 
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mechanistic study of digital isothermal amplification, and apply the lessons learned to 
perform a phenotypic antibiotic susceptibility test (AST).  
Microfluidics-based diagnostics for infectious diseases are advancing as a result of using 
nucleic acid testing—making them amenable to the point of care (POC) and limited-resource 
settings where they will have clinical impact. Isothermal amplification methods in particular 
show promise for simplifying nucleic-acid-based POC diagnostics by circumventing the 
stringent thermal cycling requirements of PCR.1 One isothermal method that is being actively 
pursued in bioanalytical chemistry and the field of diagnostics is loop-mediated isothermal 
amplification (LAMP).2-6  
LAMP and other isothermal technologies are fast and sensitive, but when performed in a 
bulk format in microliter volumes (e.g. in a tube), they provide only semi-quantitative (log-
scale) resolution or presence/absence measurements.7-15 As a result, when optimizing an 
assay, it is difficult to quantify how small changes in assay conditions (e.g. in primers, 
reagents, or temperature) impact the reaction’s speed and analytical sensitivity. To reliably 
understand these effects with high precision would require hundreds of bulk experiments per 
condition.16 For the field to be able to take full advantage of the capabilities of LAMP, 
researchers need to be able to optimize reaction conditions by understanding and testing the 
variables that may influence reaction speed and probability of detection. Furthermore, the 
semi-quantitative measurements yielded by bulk isothermal methods are insufficient for 
analyses requiring precise quantification, such as phenotypic antibiotic susceptibility 
testing.17,18  
These problems can be solved using “digital” approaches, which partition single target 
molecules in large numbers of compartments and give a binary (presence/absence) readout 
for each compartment. These “digital” approaches thus allow determination of the efficiency 
of the amplification reaction19 and provide absolute quantification with high resolution. 
Digital isothermal measurements have been used to quantify viral load for HCV,16,20,21 
HIV,19,20 and influenza,22 perform bacterial enumeration,23-25 optimize primers,16 and test for 
phenotypic antibiotic susceptibility18 using LAMP18-28 and RPA.29 
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Real-time digital formats are especially valuable for examining the variables that mostly 
affect non-specific amplification and the speed of amplification. Many excellent approaches 
for end-point19,20,22-28 and real-time16,18,21 digital LAMP (dLAMP) have been published. 
Despite the value that real-time dLAMP can bring to diagnostics, this method is difficult to 
implement—especially for those without a background in micro-electro-mechanical systems 
or microfluidics—because there is no commercial system for real-time, digital isothermal 
amplification. To achieve statistical significance, a meaningful study might require dozens 
of experiments; such studies are difficult to perform without a commercial source of chips. 
Consequently, the few LAMP mechanistic studies that have been performed were not done 
with high precision. Further, those who would most benefit from optimized digital isothermal 
reactions (e.g. those working on POC diagnostics) cannot efficiently improve them.  
Here, we demonstrate how to generate high-precision kinetic and endpoint measurements 
using a real-time dLAMP assay that is performed completely with commercially available 
and open-source components (Figure 6.1). We use this real-time information to investigate 
dLAMP reactions mechanistically, including the interplay of efficiency, speed, and 
background amplification as a function of reaction temperature and time on two enzymes. 
To illustrate one application of using real-time dLAMP to improve a clinically relevant assay, 
we optimized the assay conditions for a phenotypic AST using the real-time dLAMP pipeline 
and used the optimized protocol to compare our AST of 17 clinical urine samples to the gold-
standard method. 
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Figure 6.1: A schematic of the pipeline for performing multiplexed, real-time, 
digital loop-mediated isothermal amplification (LAMP) using only 
commercially available and/or open source components. 
Microfluidic chips and reagents (e.g. primers, enzymes, buffer composition) can be 
purchased commercially. Multiple instrument configurations can be used to capture 
results. e.g. a customized real-time instrument (instructions for building publicly 
available30) or any commercial microscope. Data analysis is automated using a 
MATLAB script (Supporting Information, S-I). 
 
Experimental 
Microfluidic chips used in this paper were sourced from Applied Biosystems, Foster City, 
CA, USA) Ref A26316, "QuantStudio 3D Digital PCR 20k Chip Kit V2."  
LAMP reagents  
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Our amplification target was the E. coli 23S ribosomal gene, which we used previously 
as a target to perform rapid AST on clinical samples.18 Primers were purchased through 
Integrated DNA Technologies (San Diego, CA, USA) and were described previously.18 Final 
primer concentrations were identical for all experiments: 1.6 μM FIP/BIP, 0.2 μM FOP/BOP, 
and 0.4 μM LoopF/LoopB.  
LAMP experiments using Bst 3.0 (Figure 6.2; Figure 6.3b d, e, f, h-j; Figure 6.4) contained 
the following final concentrations, optimized previously18: 1x Isothermal Amplification 
Buffer II (New England BioLabs (NEB), Ipswich, MA, USA; Ref. B0374S; containing 20 
mM Tris-HCl 10 mM (NH4)2SO4 150 mM KCl, 2 mM MgSO4, 0.1% Tween 20 pH 8.8 at 
25 °C), 4 mM additional MgSO4 (beyond 2 mM from buffer), 1.4 mM Deoxynucleotide 
Solution Mix, primers: 1.6 μM FIP/BIP, 0.2 μM FOP/BOP, and 0.4 μM LoopF/LoopB, 1 
mg/mL BSA (New England BioLabs, Ref B90005), 320 U/mL Bst 3.0, Ambion RNAse 
cocktail (ThermoFisher, Waltham, MA, USA; Ref AM2286, 5 U/mL RNase A, 400 U/mL 
TNase T1), 2 μM SYTO 9 (ThermoFisher, Reference S34854), and approximately 660 
copies/μL template in Ambion nuclease-free water (ThermoFisher, Ref AM9932). 
LAMP experiments using Bst 2.0 (Figure 6.3a, c, e, g) contained the following final 
concentrations, optimized as shown in Figure 6.7: 1x Isothermal Amplification Buffer (New 
England BioLabs, Ref. B0537S; containing 20 mM Tris-HCl 10 mM (NH4)2SO4, 50 mM 
KCl 2 mM MgSO4 0.1% Tween 20 pH 8.8 at 25 °C), additional 6 mM MgSO4 (New 
England BioLabs, Ref. B1003S), 1.4 mM Deoxynucleotide Solution Mix (New England 
BioLabs, Ref N0447S), primers: 1.6 μM FIP/BIP, 0.2 μM FOP/BOP, and 0.4 μM 
LoopF/LoopB, 1 mg/mL BSA (New England BioLabs, Ref B90005), 320 U/mL Bst 2.0 
(New England BioLabs, Ref M0537S), Ambion RNAse cocktail (ThermoFisher, Ref 
AM2286, 5 U/mL RNase A, 400 U/mL TNase T1), 2 μM SYTO 9 (ThermoFisher, Ref 
S34854), and approximately 660 copies/μL template in Ambion nuclease-free water 
(ThermoFisher, Ref AM9932).  
Template E. coli DNA was extracted from exponential-phase cultures grown in BBL Brain-
Heart Infusion media (BD, Franklin Lakes, NJ, USA; Ref. 221813) using QuickExtract DNA 
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Extraction Solution (Lucigen, Middleton, WI, USA; Ref. QE09050) as described 
previously.18 Serial 10-fold dilutions were prepared in Tris-EDTA buffer (5 mM Tris-HCl, 
0.5 mM EDTA, pH 8.0) containing 2 U/mL RNase A and 80 U/mL RNase T1 
(ThermoFisher, Ref AM2286). DNA dilutions were quantified as described previously18 
using the QX200 Droplet Digital PCR (ddPCR) system (Bio-Rad Laboratories, Hercules, 
CA, USA). 
 
Phenotypic antibiotic susceptibility testing (AST) on clinical samples  
For the phenotypic AST, we adopted a workflow described previously,17,18 and used archived 
nucleic-acid extractions from a previous study.18 Briefly, clinical urine samples from patients 
with urinary tract infections (UTI) were split and diluted into equal volumes of media with 
or without the presence of an antibiotic. Samples were incubated for 15 min at 37 °C, a 
nucleic-acid extraction was performed, and these samples were archived at -80 °C until use. 
LAMP was performed on the archived samples to quantify the number of copies of the E. 
coli 23S ribosomal gene.  
We tested our optimized assay on 17 archived clinical UTI samples containing ≥5 × 104 
CFU/ml E. coli that had been categorized previously using the gold-standard broth 
microdilution AST (5 ciprofloxacin-susceptible, 5 ciprofloxacin-resistant, 4 nitrofurantoin-
susceptible, and 3 nitrofurantoin-resistant).  
We assessed samples as phenotypically “resistant” or “susceptible” by calculating the ratio 
of the concentration of 23S in the control and antibiotic-treated sample, which we call the 
control:treated (C:T) ratio. The C:T ratio was calculated 10 min after beginning to heat the 
LAMP reaction. A threshold of 1.1 was established previously,17,18 so samples with C:T 
ratios >1.1 indicated that there was DNA replication in the untreated (control) group but not 
in the antibiotic-treated samples; these samples were identified as susceptible to the 
antibiotic. Samples with C:T ratios of <1.1 indicated that DNA replication occurred in both 
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the control and antibiotic-treated samples; these samples were identified as resistant to 
the antibiotic. 
 
Results and discussion 
Workflow summary of real-time digital LAMP  
To evaluate a pipeline for real-time dLAMP experiments, we chose commercially sourced 
microfluidic chips sold for endpoint digital PCR applications. The chips consist of an array 
of 20,000 uniform partitions (Figure 6.1), each 60 μm in diameter and an estimated 0.75 nL 
internal volume, which is similar to the volumes typically used in dLAMP.16,18,20-23,25,26,28 
These chips are loaded by pipetting the sample mixture (in our case containing the LAMP 
reagents: buffer components, enzymes, template, and primers) into the plastic “blade” 
provided with the chips, and dragging the blade at a 70–80° angle to the chip to load the 
sample mixture by capillarity. This is followed by drying and evaporation of the surface layer 
for 20 sec at 40 °C, and application of the immersion fluid. Manual loading requires some 
skill, though a machine can be purchased to perform the task; typically, we were able to load 
~18,000 out of the 20,000 partitions. We performed our evaluation using two different 
enzyme mixtures, Bst 2.0 and Bst 3.0. Our amplification target (Figure 6.1) was the E. coli 
23S ribosomal gene that we previously used as a target to perform rapid AST on clinical 
samples.18 
The instrumentation requirements for real-time isothermal capabilities include a heater that 
can hold a stable temperature, and optical components with high spatial resolution that are 
capable of imaging the fluorescence intensity of the 20,000 individual partitions of the chip 
over time (Figure 6.2a). Here, we investigated two approaches: using a standard laboratory 
microscope (Leicia DMI-6000B), and using the RTAI,30 which is composed of a 
thermocycler, optical components, a camera, and a light source. 
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We generated a custom MATLAB script to analyze the digital real-time data (details in 
Supporting Information, S-I). The software follows the change in fluorescence in 
individual partitions over time. From these data, we extract each partition’s time to a 
fluorescence intensity threshold and calculate the bulk template concentration. In our 
demonstration, we loaded the acquired images into FIJI31 as a time-stack series and 
manually separated the images of the individual chips to be analyzed separately. To process 
each chip’s image stack, we used the custom MATLAB script that tracks the mean intensity 
of each partition over the course of each experiment. This script could be run with only minor 
modifications with images obtained from different instruments. 
To calculate the bulk template concentration over time, we (1) identified the partitions that 
did or did not contain reaction solution, (2) tracked the partitions that met a minimum 
fluorescence intensity, and (3) used the previous information to calculate the concentration 
of template in the bulk solution. 
A summary of the script is as follows: (i) load the images into memory, (ii) count the total 
number of partitions before heating, (iii) identify positive partitions after the conclusion of 
the experiment, (iv) track the intensity of positive partitions for each image frame, (v) apply 
Gaussian smoothing and baseline subtraction, (vi) save the data, and (vii) repeat for each 
image stack. The output of the script contains: the raw traces of individual partitions over 
time, baseline corrected traces of individual partitions over time (Figure 6.2b), the number 
of partitions exceeding the manually defined minimum fluorescence intensity threshold with 
time (Figure 6.2f), and the maximum relative rate in RFU per 30 sec for individual partitions 
(Figure 6.2d). These data provide all the necessary information to conduct the analyses 
detailed in Figure 6.2. 
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Figure 6.2: Experimental demonstration of the real-time digital LAMP 
(dLAMP) approach using the commercially available enzyme Bst 3.0. 
Experiments were run at 70 °C and imaged using a commercial microscope. 
(a) A time course of fluorescence images from a subset of 350 partitions out of 20,000 
partitions undergoing dLAMP reactions. (Intensity range 920-1705 RFU). (b) 
Fluorescence intensity for a subset of partitions over time. Blue traces indicate 
partitions containing template; red traces indicate fluorescence in the absence of 
template (i.e. non-specific amplification). Partitions turn “on” at the time point when 
the curve passes the threshold at 250 RFU. Vertical traces correspond to time points 
illustrated in panel (a) and generate endpoint measurements. (c) An “endpoint” 
measurement taken on a subset of partitions at 25 min. Bin width is 100 RFU. 
Fluorescence threshold is 250 RFU. (d) A histogram of the maximum observed 
change in fluorescence of individual partitions using the full chip. Rate threshold is 
45 RFU/30 sec. (e) Change in observed bulk concentration over time from the full 
chip using fluorescence intensity as threshold (solid lines) and rate (dashed lines). (f) 
Time at which individual partitions in panel (b) cross the fluorescence intensity 
threshold. (g) Maximum rate per partition plotted by time to fluorescence intensity 
threshold. 
 
Digital, real-time experiments to quantify LAMP performance  
We next sought to experimentally evaluate this pipeline (Figure 6.1). First, we established 
whether the fluorescence from LAMP reactions could be reliably measured from individual 
partitions over time (Figure 6.2a). We used LAMP reagents for Bst 3.0, commercial chips, 
a resistive heater held at 70 °C, and a commercial microscope. Although the microscope is 
capable of collecting all 20,000 partitions on one chip in a single image, for simplicity, in 
Figure 6.2a, we cropped the image to include only 350 of the 20,000 partitions. Before 
turning on the heater (t = 0), we measured the autofluorescence from SYTO 9 to quantify the 
total number of partitions loaded with reaction solution. (To calculate template concentration 
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using the Poisson distribution,32,33 we must know the total number of partitions 
containing the reaction mixture.) Autofluorescence from SYTO 9 decreases as the chip is 
heated and is completely eliminated within 3 min. The heater used on the microscope reaches 
reaction temperature within 120 sec. In less than 10 min, an increase in fluorescence was 
observed within some of the individual partitions, indicating amplification of individual 
template molecules inside those partitions. Due to the stochastic nature of amplification 
initiation, some of the partitions fluoresced later. 
In the negative-control (no template) partitions, fluorescence was not observed for the first 
45 min. However, we began to observe non-specific amplification after ~60 min. In these 
experiments, the negative control contains only 0.05x Tris-EDTA buffer in place of template 
and represents a best-case scenario. We attribute amplification in the absence of template to 
primer dimers and other non-specific LAMP products.  
Second, we asked if the signal from non-specific amplification was sufficiently delayed to 
differentiate it from the signal arising from specific amplification in the presence of template. 
To answer this question, we generated real-time fluorescence curves by plotting the change 
in fluorescence of individual partitions as a function of time (Figure 6.2b). We observed 
specific amplification (blue curves) beginning to initiate at ~7 min and non-specific 
amplification beginning to initiate at ~50 min (red curves) and concluded that we could 
discriminate specific and non-specific amplification by time. 
Third, we asked whether enzymatic heterogeneity16,21,34 of specific amplification can be 
quantified to differentiate specific from non-specific amplification. We plotted the maximum 
change of fluorescence achieved by each partition of the full chip per 30-sec interval (Figure 
6.2d). For the negative-control sample (red bars), we observed non-specific amplification 
following a bimodal distribution of rates, with a first peak with little to no rate of fluorescence 
increase and a second peak at ~25 RFU per 30 sec. For the sample containing template (blue 
bars), rates for specific amplification were heterogeneous and centered around a rate of 70 
RFU/30 sec. We note that in PCR, which is gated by temperature cycling, there is no 
equivalent concept of “rate” as long as replication of DNA occurs faster that the duration of 
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each elongation step. We found in our dLAMP experiments that the rate of specific 
amplification was greater than non-specific amplification. Hence, tracking amplification in 
real-time made it possible to distinguish true positives from false positives (non-specific 
amplification). 
Fourth, we asked if the distribution in time to fluorescence threshold is sufficiently narrow 
to discriminate specific and non-specific amplification. By plotting the number of “on” 
partitions (i.e. partitions that crossed the fluorescence intensity threshold defined in Figure 
6.2b) against time, we generated a distribution curve (Figure 6.2f) that illustrates the number 
of partitions that turn on per time point. This is related to the derivative of the change in 
concentration over time. This plot contains the time to threshold of all partitions within the 
entire chip, rather than a subset, to minimize sampling bias. In the sample containing template 
(blue curve), most partitions reached the threshold in 7–20 min, whereas the negative-control 
sample (red curve) had little non-specific amplification until approximately 60 min.  
Graphing time to threshold illustrates the overall reaction’s speed (defined as the location of 
the peak or mode time to threshold) and efficiency (proportional to the area under the curve 
and illustrated in Figure 6.2f as the calculated concentration). In our experiment, the peak of 
the sample containing template was narrow and well separated from the non-specific 
amplification of the negative control (Figure 6.2f), indicating sufficiently low heterogeneity 
in amplification rate and time to initiation of the reaction. 
Fifth, we asked how the calculated bulk concentration changes over time. To answer this 
question, we generated endpoint-style measurements for each 30-sec time point, and 
calculated how the concentration changed over time. To demonstrate how to generate a single 
endpoint-style measurement, we selected one time point (25 min) and plotted RFU as a factor 
of the number of partitions (Figure 6.2c). Partitions were classified as either “on” (>250 
RFU threshold) or “off” (<250 RFU threshold). Partitions that are defined as having turned 
“on” contain a template molecule that amplified, whereas partitions that are ”off” either lack 
a template molecule or have not yet begun amplification. The sum of the partitions passing 
the threshold out of the total number of partitions with solution was used to determine a 
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precise bulk concentration of template in the sample using the Poisson equation, as has 
been documented elsewhere.32,33 We plotted the calculated concentration as it changed over 
time in Figure 6.2e (solid lines). 
When the aim is to determine a precise concentration, we need to determine the best time at 
which to stop the assay. Deciding the best time to end the assay is complicated because each 
reaction initiates stochastically,16,21 causing the calculated concentration to asymptotically 
approach the true concentration (Figure 6.2e). It would be ideal for the calculated 
concentration to rapidly rise to the true bulk concentration and plateau near the true 
concentration; however, the reaction should be stopped before the rise in non-specific 
amplification (observed in our example starting at 60 min; red curves, Figure 6.2e–f). We 
tested whether there is heterogeneity in amplification rate (i.e. whether partitions with slow 
amplification rates take longer to reach the fluorescence intensity threshold than partitions 
with fast amplification rates) and found that initiation time was stochastic, but the reaction 
rates for true and false positives were consistent (Figure 6.2g). Hence, two molecules could 
have the same TTP, yet initiate at different moments, resulting in variable amplification rates. 
Combining information about the concentration of template (Figure 6.2e) and the time it 
takes for partitions to turn “on” (Figure 6.2f) can be used to inform the choice of an optimal 
assay length for endpoint measurements, for situations where real-time quantification is not 
feasible. For example, in Figure 6.2, the optimal assay length for an endpoint readout would 
be ~45 min. This approach allows one to balance stochastic initiation of amplification, 
overcome enzymatic heterogeneity, and reduce the incidence of false positives caused by 
non-specific amplification. 
However, in cases where real-time measurements are desirable, thresholding by rate may be 
used to separate specific and non-specific amplification. For example, to correct for the 
observed increase in non-specific amplification (after 45 min), we implemented a threshold 
(Figure 6.2d) on the maximum rate per partition, thus eliminating some of the non-specific 
amplification in both the presence and absence of template (compare solid and dashed lines 
in Figure 6.2e). For example, the measured value at 60 min is 280 copies per μL (solid line), 
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and the corrected value is 258 copies per μL (dashed line). In the no-template control, at 
60 min, the measured value is 16 copies per μL (solid line), whereas the corrected value is 3 
copies per μL (dashed line). The correction is more pronounced at 80 min where non-specific 
amplification is greater. At 80 min, the measured value in the presence of template is 325 
copies per μL and the corrected value 266 copies per μL, indicating that almost 20% of the 
signal could arise from non-specific amplification. In the absence of template, the 
uncorrected value at 80 min is 187 copies per μL, however if rate is accounted for, then the 
value can be corrected to 16 copies per μL, thus eliminating the majority of the false 
positives. 
Finally, we note that although we calculated template concentration, the value is precise but 
could be inaccurate if not all target molecules loaded into the chip undergo amplification (in 
other words, if efficiency of amplification is not 100%). Thus, we next sought to measure the 
absolute likelihood of detecting a molecule as a function of reaction condition. 
 
Evaluation of the effect of temperature on dLAMP with two different enzymes to analyze the 
interplay of amplification efficiency, background, and speed of amplification 
After establishing a protocol for generating real-time, digital measurements, we evaluated 
the absolute amplification efficiency of LAMP as a function of temperature for two different 
enzymes. We selected two commercial polymerases that worked well for us previously. Both 
enzymes are in silico homologues on the Bacillus stearothermophilus DNA Polymerase I 
and Large Fragment. NEB describes Bst 3.0 as an improvement of Bst 2.0 by adding reverse 
transcriptase activity, increased amplification speed, and increased thermostability. We 
sought to understand the differences in performance between these two enzymes at the single 
template level. For this experiment, we used the previously described RTAI.30 The field of 
view for this instrument is larger than a microscope, allowing up to six samples to be 
observed concurrently. Hence, both the positive and negative controls could be collected in 
triplicate simultaneously. We expect some differences in measurements made on different 
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instruments as a result of differing camera sensitivities and differences in the heating 
mechanism. Indeed, when we ran a single-concentration amplification reaction under 
identical conditions and compared measurements from the microscope and the RTAI, we 
found that there was significant difference (P = 0.03) in amplification efficiency between the 
two instruments (Figure 6.6), with the RTAI generating higher amplification efficiency. 
Hence, we performed all enzyme-performance comparisons on a single instrument. 
 
Amplification efficiency  
First, we sought to establish the amplification efficiency of dLAMP, i.e. the fraction of 
template copies loaded that are detected (Figure 6.3a-b). We calculated the bulk 
concentration of template molecules from the digital measurement and plotted the observed 
template concentration as a fraction of template molecules loaded. To calculate the 
amplification efficiency, we determined template concentration using ddPCR and assumed 
all template molecules amplified. Using the real-time component of our measurements, we 
plotted the percent of copies detected over time compared with ddPCR. 
We next asked how temperature impacts amplification efficiency. In general, we observed 
greater amplification efficiency at longer amplification times, which aligned with our 
previous observation (Figure 6.2d–e). Second, when observing at a fixed time, increasing 
temperature increased amplification efficiency to an optimum (green box in Figure 6.3a-b) 
before activity decreased. 
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Figure 6.3: Evaluation of reaction conditions (enzymes and temperature) using 
real-time digital LAMP. 
(a,b) Amplification efficiency (percent template copies detected out of copies loaded) 
of Bst 2.0 (a) and Bst 3.0 (b) as a function of temperature. Green boxes indicate the 
optimal temperature range for the greatest probability of template detection. (c,d) 
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Nonspecific amplification in template-free buffer samples using Bst 2.0 (c) and Bst 
3.0 (d) for conditions matching (a) and (b). (e,f) Distribution of time to fluorescence 
threshold using Bst 2.0 (e) and Bst 3.0 (f). (g) The fractional cumulative distribution 
function (CDF) compares the enzymes at their optimal temperatures (68 °C). (h) 
Fractional CDF plots of Bst 3.0 rate at three temperatures. Error bars are SD. For all 
data sets, N = 3 chips (technical replicates). CDF plots are the sum of three technical 
replicates. 
 
Several observations can be made by comparing the results from Bst 2.0 and Bst 3.0 (Figure 
6.3a-b). Although Bst 2.0 and Bst 3.0 have an identical reported optimal incubation 
temperature in bulk (65°C), we observed they had different optimal temperature ranges for 
amplification efficiency (Bst 2.0 at 66–68 °C; Bst 3.0 at 68–70 °C). We detected lower 
amplification efficiency at higher temperatures with Bst 2.0 compared with Bst 3.0. Bst 2.0 
failed to amplify at 72 °C, whereas Bst 3.0 continued amplifying until 76 oC. At short 
amplification times, (such as 10 min), Bst 3.0 had greater amplification efficiency than Bst 
2.0 (42.8% vs 20.8%, respectively). In contrast, at longer amplification times, such as 30 or 
45 min, efficiency for the enzymes was similar (77.6% vs 71.5% at 45 min, respectively), 
though Bst 2.0 had slightly greater amplification efficiency than Bst 3.0.  
We hypothesize that increased temperature improved amplification efficiency (presumably 
by increasing the breathing of dsDNA and facilitating primer annealing) until, at higher 
temperatures, a combination of enzyme denaturation or failure of the primers to anneal 
occurred. Our primers had melting temperatures ranging from 56–61 °C, when excluding the 
secondary FIP and BIP anealing regions, as calculated using OligoCalc.35 We found that 
chip-to-chip variability was extremely low. Relative error for Bst 2.0 at optimal temperature 
(68 °C) and 45 min of amplification was ~2% (Figure 6.2a), whereas the predicted Poisson 
noise for a single chip is 0.7%. Achieving such high precision using bulk measurements 
would require hundreds of experiments. The low variability among these measurements 
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indicates that we were correctly determining whether a partition contained solution and 
whether it amplified. 
 
Non-specific background amplification 
Next, we quantified the amount of non-specific amplification (Figure 6.3c-d) as a function 
of time and temperature. We plotted the number of wells that turned “on” in the absence of 
template relative to the total number of wells filled with LAMP solution. As previously 
stated, these non-specific amplification reactions included buffer in place of template and 
represent a best-case scenario. We concluded that at least for these idealized conditions, non-
specific amplification in dLAMP was extremely low. For example, a fraction of 0.001 could 
correspond to 20 partitions turning on from among a total of 20,000 possible partitions. For 
both enzymes, we found the maximum fraction of non-specific amplification per total 
partitions was 0.0012 for times 20 min or less. The highest fraction of non-specific 
amplification observed was 0.017 at 45 min, corresponding to fewer than 350 non-specific 
partitions of the 20,000 total (Figure 6.3c-d). Furthermore, we observed higher temperatures 
resulted in lower non-specific amplification (Figure 6.3c-d). Finally, at extremely long 
amplification times (e.g. 60 min amplification, data not shown) Bst 2.0 had lower background 
than Bst 3.0. 
 
Variation in speed and amplification efficiency 
Third, we quantified the variation in speed and amplification efficiency across partitions in 
the time to reach fluorescence intensity threshold (Figure 6.3e-f). We first plotted the percent 
copies detected as a function of time for each temperature. As described previously, these 
curves represent the distribution in the time to threshold across all partitions and thus 
illustrate the interplay of (i) detecting a molecule (area under the curve from zero to a given 
time corresponding to the values plotted in Figure 6.3a-b), (ii) the speed of the reaction (the 
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time at which the peak reaches a maxima), and (iii) several parameters of peak width 
summarized in Table 6-1. We hypothesize peak width is related to both the enzyme 
amplification rate, overall amplification efficiency, and the time at which the reaction 
initiates. Next, we plotted the peak time to threshold (Figure 6.5). Images were collected in 
30-sec intervals and we report the average of three trials. In some cases, the difference in 
time to threshold was less than the imaging time interval. For each time point, if fewer than 
15 partitions (0.075% of total partitions) were “on,” that time point was not included in the 
calculation of the mode. For these measurements, at the start of the reaction, the heat block 
was at 25 °C, and the time to threshold included the time for the heat block to come to reaction 
temperature (~70 sec). Hence, there will be minor differences (seconds) in the time for each 
reaction to reach the fixed temperature. We do not see evidence that this difference manifests 
in the mode time to positive (TTP) measurements.  
In reactions with Bst 2.0, below 68 °C, mode TTP was narrowly clustered around 9.5 min. 
At 70 °C, mode TTP increased, and the reaction failed to amplify beyond 72 °C. In reactions 
with Bst 3.0, the mode TTP decreased from 8.2 ± 0.3 (mode ± S.D.) min at 64 °C to 6.6 ± 
0.3 min at 70 °C, then increased with increasing temperature until amplification failed for all 
partitions at temperatures ≥76 °C. In the negative controls for both enzymes (Figure 6.5), 
amplification either failed or started after 75 min.  
Several observations can be made by comparing the results from Figure 6.3e-f. We found 
that the optimal temperature for time to threshold corresponded with the optimal temperature 
for amplification efficiency (Figure 6.3a-b), and that the optimal temperatures also had the 
smallest tailing factors, Full Width at Half Maximum (FWHM) and asymmetric factor (i.e. 
narrowest peak widths) (Figure 6.3e-f; Table 6-1). At optimal efficiency, Bst 3.0 was 
approximately 2 min faster in mode TTP, had much narrower FWHM, smaller tailing factor, 
and lower asymmetry than Bst 2.0. Finally, as efficiency decreases, measurements of peak 
shape and width increase. To the best of our knowledge, this is the first published 
quantification that explicitly tests and quantifies the time dependence of LAMP efficiency 
using these enzymes. Real-time digital enables us to identify the time point at which the 
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observed concentration most closely approximates the true concentration thus optimizing 
the assay duration. 
 
Rates of amplification (specific and non-specific) 
Fourth, we compared the rates of specific and non-specific amplification between Bst 2.0 and 
Bst 3.0. The data shown represent the combined rates of three separate trials. We found that 
non-specific amplification rates were similar for the two enzymes (Figure 6.3g, dashed 
lines), whereas in the presence of template, amplification rates were faster for Bst 2.0 than 
Bst 3.0 (Figure 6.3g, solid lines), despite lower efficiency at short times. Differences in 
camera sensitivity between the microscope (used for real-time images in Figure 6.2) and the 
RTAI (used for Figure 6.3) result in different apparent amplification rates.  
We also examined the relationship between temperature, efficiency, and maximum rate. In 
the case of Bst 3.0, maximum reaction amplification rate does not correspond with optimal 
efficiency (Figure 6.3h). 64 °C had the fastest amplification rates, but suboptimal efficiency 
(57.3% at 45 min). Optimal amplification efficiency occurs at 68 °C (71.5% at 45 min), but 
slightly slower amplification rate than 64 °C. At 74 °C, we observed both poor efficiency 
(32.7% at 45 min) and slowest reaction rate. We attribute this to a combination of decreased 
enzymatic velocity and decreased primer annealing. Additionally, we note that different 
thresholds for amplification rate would be needed for each temperature. This is expected 
given changes in enzymatic velocity. 
 
Application of the pipeline to a phenotypic antibiotic susceptibility test (AST) using clinical 
samples  
We next asked whether we could apply the output of this digital real-time pipeline to perform 
a rapid phenotypic AST. Specifically, we aimed to categorically sort clinical samples as 
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phenotypically “susceptible” or “resistant” to an antibiotic in agreement with the gold-
standard reference method. This study was constructed as a demonstration of the capability 
of the microfluidic chips and the value gained from using this digital real-time pipeline to 
optimize reaction conditions — it was not an assessment of the digital AST (dAST) 
methodology established previously.17,18 We selected the optimal dLAMP conditions for Bst 
3.0 based on the measurements of mode TTP and amplification efficiency established in the 
previous experiments (Figure 6.3b) — 70 °C and a reaction time of 10 min. We used 
archived clinical urine samples from patients diagnosed with urinary tract infections (UTI) 
containing E. coli. These samples had been categorized as phenotypically susceptible or 
resistant to the antibiotics ciprofloxacin or nitrofurantoin using the gold-standard (broth 
microdilution) method.18 We tested exactly 17 samples and observed 100% categorical 
agreement with the gold-standard method (0 major errors; 0 minor errors). We conclude that 
the pipeline presented in this paper performs well and could be used, among other 
applications, to optimize reaction conditions for speed and sensitivity and apply those 
conditions to a determination of phenotypic antibiotic susceptibility in clinical samples. 
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Figure 6.4: Phenotypic antibiotic susceptibility tests of 17 clinical urine samples 
from patients infected with a urinary tract infection containing E. coli. 
Susceptibility to the antibiotics nitrofurantoin and ciprofloxacin were tested using 
dLAMP conditions optimized using digital real-time experiments (Figure 6.3). Urine 
samples were exposed to media without antibiotic (control) or media with an 
antibiotic (treated) for 15 min and then concentrations of nucleic acids were 
quantified to calculate a control:treated (C:T) ratio. Samples were categorized by 
dLAMP as susceptible (above the susceptibility threshold) or resistant (below the 
threshold). All samples were categorized in agreement with the clinical gold-standard 
method. 
 
Conclusions 
We have presented a pipeline to generate real-time, digital isothermal amplification 
measurements using only commercial and open-source components. We used this pipeline 
to examine how small changes in reaction conditions influence the interplay of LAMP 
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efficiency, speed, and background by performing 124 real-time dLAMP experiments. As 
one practical application of this approach, we determined the optimal reaction conditions for 
a phenotypic test of antibiotic susceptibility using 17 clinical urine samples from patients 
diagnosed with urinary tract infections. In all cases, the results of the optimized dLAMP 
assays were in agreement with the clinical gold-standard AST.  
These experiments validate that real-time digital measurements enable tests of enzymatic 
performance in dLAMP. Generally, we found that each enzyme had a unique optimal 
temperature for amplification efficiency (probability of detecting a target molecule) and for 
eliminating non-specific amplification. This “optimal” temperature produced the fastest 
mode TTP and the narrowest, most symmetrical distribution curves; interestingly, the 
optimal temperature did not necessarily yield the fastest amplification rate. Together, these 
data suggest that amplification efficiency is an interplay of enzymatic rate, diffusive 
transport, and DNA breathing. When reactions are performed away from optimal 
temperature, the distribution curves broaden and decrease in total area, resulting in reduced 
overall amplification efficiency and slower mode TTP; whereas amplification rate decreases 
with increasing temperature. With regard to the specific enzymes in this study, although 
efficiency was similar at long amplification times (> 20 min), Bst 3.0 had a faster mode TTP 
than Bst 2.0 by approximately 2 min, and more narrow and symmetrical distribution curves. 
However, Bst 2.0 had faster amplification rates than Bst 3.0, so reactions with Bst 2.0 took 
longer to initiate, but proceeded more rapidly. For both polymerases, non-specific 
amplification in buffer was extremely low. 
In the future, this pipeline can be used to understand the fundamental pieces of LAMP. The 
field of diagnostics would benefit from a thorough mechanistic study of LAMP asking which 
components determine amplification fate, and how components, such as primers and heating 
rate (Figure 6.6), impact reaction and enzymatic speed. This pipeline makes such a 
mechanistic study possible. For example, in this study we corrected the observed 
concentration by separating true positives from background amplification using rate and 
fluorescence, but we did not explore the origins of non-specific amplicons—which deserves 
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its own study and development of more precise tools for studies of non-specific 
amplification. Finally, this pipeline can be extended to optimize other isothermal 
amplification chemistries that could be suited to other types of diagnostic assays.  
Ultimately, this pipeline will make digital real-time measurements more accessible to 
researchers, even those who lack microfluidic expertise or specialized equipment. The 
commercially available chips and reagents used here could be coupled with many 
combinations of standard laboratory or field equipment, such as a hot plate and a fluorescent 
stereoscope, or a chemical heater and a cell phone camera. While we believe the general 
trends found in this manuscript will extend to other primer sets, we hope this pipeline will 
enable others to study other primer sets and conditions of interest to them. 
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Supporting Information 
Summary of MATLAB script functions 
In order to quantify the reactions on chips using the Poisson distribution, we needed to know 
the number of partitions that contained solution and the number of partitions that were empty. 
(It would be naïve to assume that all 20,000 partitions were loaded with solution; visual 
inspection shows that was rare.) We counted the total number of partitions with solution 
using the image of the autofluorescence of SYTO 9 dye before heating at time 0 (Figure 
6.2a). SYTO 9 had uniform autofluorescence independent of template presence, making it 
easy to count all partitions loaded with solution.  
To track the mean fluorescence intensity of each partition over time, we solved two 
challenges. First, when the microfluidic chip was heated (especially during the first 2 min), 
the chip moved. As the chip heated, it lost the initial autofluorescence from SYTO 9. 
Consequently, it was not possible to track this movement with the fluorescence of a single 
fluorophore. We solved this challenge by creating a mask (using image segmentation) that 
outlined each detectable partition at the chip’s final position using a frame at the end of 
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amplification. An advantage to using only the detectable partitions that met a minimum 
fluorescence intensity (out of a total of 20,000 partitions per chip) reduced overall 
computation time because only a fraction of the total partitions were tracked in real-time.  
A second challenge when tracking mean fluorescence intensity of each partition over time 
using only the detectable partitions is that partitions can appear to be different sizes because 
of differences in fluorescence intensity (dark partitions can appear artificially smaller and 
bright partitions can appear artificially larger). To counteract the effect of each partition 
having a different average intensity, we performed multi-level thresholding with tight 
restrictions for the area and major axis filters. We set a minimum fluorescence intensity 
(threshold) for each pixel at a given time and used this information to segment (define the 
perimeter) each individual partition. This threshold was combined with selection criteria for 
the area and major axis. The area filter defined the smallest and largest partitions while the 
major axis filter ensured that detected regions were circular. We repeated this for different 
threshold values and merged the resulting partitions. This technique restricted partitions to a 
specific size and shape while enabling detection over many intensity values.  
Finally, we used the information from quantifying the number of partitions containing 
solution and tracking mean fluorescence of each partition over time to calculate the 
concentration of template in the bulk solution. To smooth the traces and reduce the noise, we 
first applied a Gaussian-weighted moving average filter with window length 10 frames to 
each intensity curve. To ensure all partitions start at zero intensity, we determined the 
baseline intensity by calculating the average partition intensity for selected frames after 
heating but prior to detectable amplification (between 2.5 min and 5 min). The baseline 
intensity was subtracted from all frames. Finally, we manually defined a threshold to 
determine whether a partition would be counted as a “positive” or “negative.” Using the 
adjusted traces, threshold, and the total number of partitions, we determined the fraction of 
partitions that were “on” for any given time. Using the fraction of partitions that were “off,” 
we calculated via the Poisson distribution the concentration of template detected in the bulk 
solution for any given time point. From this measurement of concentration, we can calculate 
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the amplification efficiency by dividing the measured concentration by the known (true) 
concentration.  
The MATLAB script described here has been deposited in the open-access online repository 
GitHub and may be accessed using the following direct link: 
https://github.com/IsmagilovLab/Digital_NAAT_Analyzer  
 
Acquiring real-time data using microscopy 
Images were acquired in 30-sec intervals on a Leica DMI-6000B (Leica, Buffalo Grove, IL, 
USA) with a 1.25x 0.04NA HCX PL FLUOTAR Objective (506215) and 0.55x coupler 
(Leica C-mount 11541544) using a 1-sec exposure through the L5 (GFP) Nomarski prism 
and a Hamamatsu ORCA-ER CCD camera (Hamamatsu Photonics K.K., Hamamatsu City, 
Shizuoka, Japan; Ref. C4742-80-12AG). Heating was performed using an integrated circuit 
(IC) board prototype for temperature control developed by Green Domain Design (San 
Diego, CA, USA). The IC board was connected to a DC power supply (Model 3670; Electro 
Industries, Monticello, MN, USA), a Nichrome wire (12 ohm) attached to a 5 x 25 x 25 mm 
aluminum block. A thermistor was mounted within the block to measure the temperature of 
the heating block. When the temperature of the heating block was lower than the set-point 
temperature, the IC board supplied current to the Nichrome wire resistive heater. With this 
setup, heating was achieved to 70.0 ± 2 °C within 2 min. Images obtained on the microscope 
were processed with our MATLAB script (Supporting Information, S-I) using the 
following parameters: Area Bound [5 40] pixels, Major Axis [2 9] pixels, Threshold [250] 
Relative Fluorescence Units (RFU), Baseline Smoothing Frames [6 11], Masking Image 
Frame [175]. 
 
Acquiring data using a custom large-format real-time amplification instrument (RTAI) 
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Images were acquired in 30-sec intervals on a custom-built, public-domain real-time 
amplification instrument (RTAI), described previously,30 using the FAM channel with a 15-
sec exposure at f/5.6. Heating was achieved using the built-in PCT-200 thermocycler, which 
heats to 70.0 ± 0.3 °C within 70 sec. The temperature of the thermocycler block was held at 
25 °C to start all reactions, with the exception of an experiment where the block was 
preheated to the optimal temperature (Figure 6.2, Figure 6.6b). We equipped the 
thermocycler with an aluminum block with two sloped planes (each set at 11°—an angle 
defined by the microfluidic chip manufacturer’s requirements) to segregate bubbles formed 
during the reaction to a specifically designed bubble trap. It was advantageous to use this 
instrument to analyze up to six chips in parallel in a single field of view and under a uniform 
temperature. By running multiple chips on a real-time instrument we achieved “multiplexed” 
assays (wherein multiple measurements are made simultaneously). Images obtained on the 
RTAI were processed through our MATLAB script (Supporting Information, S-I) using 
the following parameters: Area Bound [4 12] pixels, Major Axis [2 5] pixels, Threshold [100] 
RFU, Baseline Smoothing frames [6 11], Masking Image Frame [175]. 
 
Limitations of chips used 
A limitation of chips that discretize by capillary action is that solution can spread among the 
partitions. For example, during dLAMP quantification of extractions for three of the clinical 
samples, we observed spreading of one positive partition to its adjacent partitions. We 
attribute this spreading to liquid bridges forming among adjacent wells, resulting in transfer 
of the amplicon among compartments. These bridges could arise from defects in surface 
coatings of commercial chips or from an excess of surface active molecules present in some 
clinical samples. To test whether spreading was due to surface active impurities in the 
samples, samples were diluted in Tris-EDTA (TE) buffer and in the subsequent test, 
spreading was eliminated for one sample. For the remaining samples, dilution reduced the 
spreading enough that quantification at 10 min was not hindered, although some spreading 
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was observed at later times. Quantification of the C:T ratio remained consistent (and the 
susceptibility call the same) because we use a ratiometric calculation. 
 
Calculation of peak width metrics 
The average distribution curve (averaged over three trials) was calculated for each 
temperature and all values normalized to the peak prominence. Time resolution was 
estimated to the nearest 15 sec interval. Calculations were based on: John V. Hinshaw. “How 
Do Your Peaks Measure Up?” Oct 01, 2013, LCGC Europe, Volume 26, Issue 10, pg 575–
582.  
Full Width at Half Maximum was calculated at the time difference between the leading at 
tailing edges at 50% peak prominence.  
Asymmetric factor was calculated by dividing the time between the peak prominence and 
the tailing edge (“b0.1“) by the time between the peak prominence and the leading edge at 
10% peak height (“f0.1“). 
Equation 6-1 
 
Tailing factor was calculated as the total peak width at 5% of the prominence (or the distance 
from the leading edge to the time of peak prominence (“f0.05”) plus the distance from the 
time of peak prominence to the tailing edge (“b0.05”)) divided by twice the distance from 
the leading edge to the time of peak prominence.  
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Equation 6-2 
 
Table 6-1: Tabular quantification of the time to threshold distribution curves. 
 
 
Time to mode positive 
 
Figure 6.5: Bar graphs of the time location of the peak of the distribution curve 
(time to mode positive) using Bst 2.0 (a) and Bst 3.0 (b). 
We required 15 or greater partitions turn on at a given time (0.075% of total 
partitions), to include the time point for the mode. Data are summarized in Table 6-1. 
 
Hardware and pre-heating condition 
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We asked if multiple instrumentation formats could be used to collect the data and if 
hardware format impacted the amplification efficiency. We used the optimal conditions for 
Bst 3.0. First, we compared the performance of the large-format real-time amplification 
instrument (RTAI) to a wide-field microscope fitted with a heat block—a set-up that would 
be accessible to most laboratories. We found that the heater ramp rate was slower on the 
microscope than the RTAI (120 sec versus 70 sec) resulting in 9.0 ±1.0 min time to mode 
positive (Figure 6.6a).  
Next, we looked at the effect of pre-heating using the RTAI. We compared the optimal 
conditions using Bst 3.0 and starting from 25 °C (green curve) with the same instrument and 
heating block already at the optimal reaction temperature of 70 °C (orange curve). When the 
block is preheated, we observed the mode time to threshold reduced from 6.7 ±0.3 min to 6.0 
±0.0 min (Figure 6.6a).  
Next, we asked if differences in hardware configuration and the heating rates between the 
instruments would also correspond to differences in probability of detection. We observed 
significant variation in amplification efficiency (RTAI vs RTAI with preheating P = 0.002; 
RTAI vs microscope with heater P = 0.031, RTAI with preheating vs microscope with heater 
P < 0.001) and concluded that heating rate may impact probability of amplification (Figure 
6.6b). Hence, all comparisons made in this study were instrument specific. Though it remains 
to be tested, we suspect more precise hardware, with improved heating control, could 
improve device performance. 
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Figure 6.6: Effect of hardware and heating on (a) the distribution in time to 
fluorescence threshold and (b) quantification of amplification efficiency (mean 
percentage copies detected ± S.D.) at 40 min. 
 
Optimization of Bst 2.0 buffer composition 
Following the protocol described previously,18 buffer conditions for Bst 2.0 were optimized 
in bulk at 713 copies/μL (e.g. ~4,280 or 0 copies per 6 μL reaction). Optimal buffer 
composition was selected based on fastest bulk time to positive. 
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Figure 6.7: Magnesium optimization for Bst 2.0. 
A value of 0.25 indicates that no amplification was observed. Amplification was 
performed at 67.5° C. N=1 for all TTP values. 
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7 .  C h a p t e r  7  
REAL-TIME KINETICS AND HIGH-RESOLUTION MELT CURVES 
IN SINGLE-MOLECULE DIGITAL LAMP TO DIFFERENTIATE 
AND STUDY SPECIFIC AND NONSPECIFIC AMPLIFICATION 
 
J.C. Rolando, E. Jue, J. Barlow, and R.F. Ismagilov. 2020. Nucleic Acids Research. 48(1):42. 
doi:10.1093/nar/gkaa099 
 
Abstract 
Isothermal amplification assays, such as loop-mediated isothermal amplification (LAMP), 
show great utility for the development of rapid diagnostics for infectious diseases because 
they have high sensitivity, pathogen-specificity, and potential for implementation at the point 
of care. However, elimination of nonspecific amplification remains a key challenge for the 
optimization of LAMP assays. Here, using chlamydia DNA as a clinically relevant target 
and high throughput sequencing as an analytical tool, we investigate a potential mechanism 
of nonspecific amplification. We then develop a real-time digital LAMP (dLAMP) with 
high-resolution melting temperature (HRM) analysis and use this single-molecule approach 
to analyze approximately 1.2 million amplification events. We show that single-molecule 
HRM provides insight into specific and nonspecific amplification in LAMP that are difficult 
to deduce from bulk measurements. We use real-time dLAMP with HRM to evaluate 
differences between polymerase enzymes, the impact of assay parameters (e.g., time, rate, or 
florescence intensity), and the effect background human DNA. By differentiating true and 
false positives, HRM enables determination of the optimal assay and analysis parameters that 
leads to the lowest limit of detection (LOD) in a digital isothermal amplification assay. 
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Introduction 
Isothermal methods, such as loop-mediated isothermal amplification (LAMP), are attractive 
for nucleic acid amplification tests (NAATs) in point-of-care and limited-resource settings 
(1,2). LAMP in particular shows promise as a NAAT with fewer hardware requirements 
compared with PCR (3). Despite advancements, the ability to optimize LAMP NAATs for a 
specific target sequence and primer set (specific to a target organism) remains constrained 
by a limited understanding of how amplification is affected by myriad factors, including 
polymerase choice, primer design, temperature, time, and ion concentrations. In particular, 
addressing nonspecific amplification remains a core problem as it constrains an assay’s limit 
of detection (LOD). In reactions containing template target molecules, both specific and 
nonspecific amplification reactions may occur. Unlike PCR, LAMP lacks a temperature-
gating mechanism, so nonspecific reactions consume reagents and compete with specific 
amplification impacting its kinetics. The presence of nonspecific amplicons therefore 
adversely impacts both the assay’s analytical sensitivity (the fewest template molecules that 
can be detected) and its analytical specificity (ability to detect the target template in the 
presence of competing reactions). Classifying reactions as either specific or nonspecific 
amplification would therefore be invaluable both during assay optimization and assay 
deployment in clinical diagnostics. 
Substantial research is focused on using isothermal amplification chemistries for diagnosis 
of infectious disease. For example, chlamydia (caused by the pathogen Chlamydia 
trachomatis, CT) is the most common sexually transmitted infection worldwide, with more 
than 110 million cases reported annually (4). Diagnosis of CT infections is challenged by a 
lack of standard symptoms (many infections are asymptomatic) (5) and the presence of 
mixed flora (particularly in the female reproductive tract) (6). Thus, rapid NAATs with high 
sensitivity and specificity are critically needed, especially NAATs that can deal with the high 
levels of host or background DNA likely to be present in clinical samples such as urine 
samples and swabs (7,8). 
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Optimizing LAMP for CT and other infectious pathogens requires addressing and 
reducing nonspecific amplification or a method for separating nonspecific reactions from 
specific amplification. Reactions run in bulk (i.e., in a tube) in the absence of template can 
be informative to provide information on performance of nonspecific amplification. Another 
method to identify nonspecific amplification includes mathematical modeling in conjunction 
with electrophoresis to distinguish between nonspecific and specific banding patterns(9). 
However, in the presence of template, although specific and nonspecific reactions occur 
simultaneously, they cannot be monitored simultaneously. Thus, bulk reactions have three 
important limitations with regard to assay optimization: (i) differences in the kinetics of 
specific and nonspecific reactions cannot be separated; (ii) rare but significant events, such 
as early but infrequent nonspecific amplification, cannot be easily characterized; and (iii) 
testing the full design space requires many hundreds of replicates to obtain statistically 
significant data. To improve an assay’s analytical specificity and sensitivity, one strategy is 
to eliminate the detection of nonspecific amplification. In bulk LAMP experiments, 
nonspecific amplification can be excluded from detection by using probes, beacons, FRET, 
or reporter-quencher schemes that show only specific amplification of the target (10-19). 
Although these methods improve the assay, they do not capture nonspecific reactions and 
thus cannot give insights into the origin of nonspecific amplification or the conditions that 
led to nonspecific amplicons. Moreover, probes and beacons do not eliminate nonspecific 
amplification; nonspecific amplification still competes for reagents and can limit the extent 
of the signal generated by specific amplification events (20). Hence, it is highly desirable to 
distinguish specific from nonspecific amplification. 
In this study, we combined sequencing and digital single-molecule LAMP (dLAMP) with 
high-resolution melting temperature (HRM) to probe the fundamental mechanics of 
amplification reactions. We used dLAMP to extract real-time kinetic information to identify 
the digital threshold data-processing parameters that minimize nonspecific amplification 
events and elucidate how an interfering molecule impacts amplification. Digital single-
molecule methods separating individual amplification events into discrete compartments, 
eliminating interference among individual amplification events (21,22). Furthermore, digital 
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experiments consist of thousands of reactions that run in parallel and thus provide 
valuable statistical information (21-23). We used real-time imaging to monitor the kinetics 
of 20,000 dLAMP reactions per experiment and observe ~ 1.2 x 106 reactions in total. We 
hypothesized that high-resolution melting analysis (HRM) could be a tool for separating 
specific from nonspecific amplification events and for identifying the optimal digital 
threshold data-processing parameters to distinguish specific and nonspecific amplification 
events (even when an assay is deployed without HRM). To test this hypothesis, we used a 
dLAMP assay with CT DNA as the target (combined with sequencing to identify the 
products of bulk reactions) to analyze both specific and nonspecific amplification under 
conditions that include clinically relevant concentrations of background human DNA. 
 
Materials and Methods 
LAMP reagents 
IsoAmp I (#B0537S), IsoAmp II (#B0374S), MgSO4 (#B1003S), deoxynucleotide solution 
(#N0447S), Bovine Serum Albumen (BSA, #B9000S0), Bst 2.0 (8,000 U/mL, #M0537S), 
and Bst 3.0 (8,000 U/mL, #M0374S) were purchased from New England Biolabs (Ipswich, 
MA, USA). Ambion RNase Cocktail (#AM2286), Ambion nuclease-free water (#AM9932), 
Invitrogen SYTO 9 (S34854), and Invitrogen ROX Reference Dye (#12223012) were 
purchased from Thermo Fisher Scientific (Waltham, MA, USA). We found it important to 
use SYTO 9 dilutions within one week of preparation. 
Primers sequences were targeted against the Chlamydia trachomatis 23S ribosomal gene 
using Primer Explorer V5 (Eiken Chemical, Tokyo, Japan) and checked in SnapGene (GSL 
Biotech, Chicago, IL, USA) to ensure the sequences were in a mutation-free region from the 
available Genebank sequences of CT. Primers were purchased from Integrated DNA 
Technologies (San Diego, CA, USA) and suspended in nuclease-free water. For all 
experiments, the final concentrations of primers were 1.6 µM FIP/BIP, 0.2 µM FOP/BOP, 
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and 0.4 µM LoopF/LoopB. Primer sequences are listed in Supplementary Materials and 
Methods. 
LAMP experiments using Bst 2.0 were amplified at 68 °C in nuclease-free water, with final 
concentrations of: 1x IsoAmp I Buffer, 7mM total MgSO4 (5 mM additional), 1.4 mM each 
dNTP, 1.25 uM ROX Reference Dye, 1 mg/mL BSA, 320 U/mL Bst 2.0, 1x Ambion RNase 
Cocktail, and 2 uM SYTO 9. 
LAMP experiments using Bst 3.0 were amplified at 69 °C in nuclease-free water, with final 
concentrations of: 1x IsoAmp II Buffer, 8mM total MgSO4 (6 mM additional), 1.4 mM each 
dNTP, 1.25 uM ROX Reference Dye, 1 mg/mL BSA, 320 U/mL Bst 2.0, 1x Ambion RNase 
Cocktail, and 2 uM SYTO 9. 
For both enzymes, after 90 min of amplification, reactions were ramped to 95°C at maximum 
output and held for 30 sec to inactivate the enzymes. Chips were cooling to 55°C and the 
melt performed at a ramp rate of 1 °C per image from 55–90 °C, and a ramp rate of 0.5 °C 
per image from 90–95 °C. 
 
Extraction of spiked Chlamydia trachomatis (CT) from a relevant clinical matrix 
A frozen stock of live CT (D-UW3, Z054, Zeptometrix, Buffalo, NY, USA) was re-
suspended in pre-warmed (37 °C) SPG buffer (219 mM sucrose, 3.7 mM KH2PO4, 8.5 mM 
NA2HPO4, and 4.9 mM L-glutamate) to 1E8 IFU/mL. It was then diluted 10-fold into a 
freshly donated urine sample to 1x107 IFU/mL. Urine from a healthy human donor (>18 
years of age) was acquired and used in accordance with approved Caltech Institutional 
Review Board (IRB) protocol 15-0566. Written informed consent was obtained from all 
participants, donations were never tied to personal identifiers, and all research was performed 
in accordance with relevant institutional biosafety regulations. A 250 µL aliquot from this 
CT-spiked urine sample was then extracted following the ZR Viral DNA/RNA Kit protocol 
(#D7020, Zymo Research, Irvine, CA, USA). Briefly, 250 µL of CT-spiked urine was mixed 
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with 250 µL DNA/RNA shield and 1000 µL DNA/RNA Viral Buffer. 1500 µL (750 µL 
x 2) was added to the column and centrifuged at 16,000 xg for 1 min. Then, 500 µL Viral 
Wash buffer was added to the column and centrifuged at 16,000 xg for 2 min. Lastly, 60 µL 
DNAse/RNAse-free water was added directly to the column and centrifuged at 16,000 xg for 
30 s. The eluent was treated by adding 2.5 µL Ambion RNAse Cocktail (#AM2286, Thermo 
Fisher Scientific) to 47.5 µL template. Stocks were prepared in 0.5x TE buffer and dilutions 
quantified using the QX200 droplet digital PCR system (Bio-Rad Laboratories, Hercules, 
CA, USA), outer primers at 500 nM each, and 1x EvaGreen Supermix (Bio-Rad). 
 
Fabrication of thermoelectric unit and mount 
A Thermoelectric Module (VT-127-1.4-1.5-72), Thermister (MP-3022), Controller (TC-
720), and 12V Power Supply (PS-12-8.4; TE Tech, Traverse City, MI, USA) were wired 
according to the manufacturer’s instructions. 
While the Peltier can be used out of the box, we manufactured a heat plate and sink to 
improve the efficiency in the cooling mode. Instructions for fabrication can be found in the 
Supplementary Materials and Methods, “Fabrication of thermoelectric unit mount.” The 
ability of the embedded thermocouple to accurately assess temperature of the aluminum 
block was verified with an independent K-type mini-thermcouple read through a General 
IRT659K [IR] Thermometer.  
 
Shearing of genomic DNA 
Human genomic DNA from buffy coat leukocytes (Roche (via Sigma Aldrich), Reference 
11691112001) was fragmented using a Covaris Focused Ultrasonicator M220 (Woburn, 
MA, USA) equipped with 130 µL microTUBE AFA Fiber Snap-Cap at 50W peak power, 
5% duty factor, 200 cycles per burst, for 80 sec. Fragment concentration was determined 
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using a Qbit 3 Fluorimiter (Thermo Fisher, Ref # Q33216) with dsDNA HS assay kit 
(ThermoFisher, Ref #Q32851), and mean fragment size determined as 365 bp using an 
Agilent 4200 TapeStation (#G2991AA, Agilent, Santa Clara, CA, USA) and High 
Sensitivity D5000 ScreenTape (#5067-5592) with ladder (#5190-7747), and D100 
ScreenTape (#5067-5584) with High Sensitivity D1000 Reagents (#5067-5585). Dilutions 
were prepared with a final concentration of 0.5x TE buffer. 
 
Microfluidic chips 
Microfluidic chips for dLAMP (#A26316; Applied Biosystems, Foster City, CA, USA) were 
loaded as we have described previously (23) at a concentration where ~40% of partitions 
would fluoresce (corresponding to the Poisson maximum single template per partition 
loading of 660 cp/µL). We estimated the volume of each partition to be 750 pL. To achieve 
this concentration of template molecules, we diluted template stocks from storage in 0.5x TE 
to ~0.03x TE for all experiments. Genomic DNA (gDNA) stocks, also stored in 0.5x TE, 
were diluted to a final concentration of 0.077x. Thus, the total final concentration of TE for 
all experiments of was approximately 0.1081x TE buffer. 
 
Microscopy data collection 
Data were collected in 30-sec intervals using a DMI-6000B microscope (Leica, Buffalo 
Grove, IL, USA) equipped with a 1.25x 0.04NA HCX PL FLUOTAR Objective and 0.55x 
coupler (Leica C-mount 11541544). The response from SYTO 9 was recorded using a 1.5-
sec exposure through an L5 (GFP) Nomarski prism, while the ROX Reference Dye was 
collected using a 1-sec exposure through a Texas Red prism. Images were collected using a 
Hamamatsu ORCA-ER CCD camera (Hamamatsu Photonics K.K., Hamamatsu City, Japan) 
at 100 gain. Temperature was recoded using the built-in features of the TC-720 Controller in 
approximately one second intervals and correlated to the images via image metadata. 
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In these experiments, we chose to use a microscope, instead of the custom real-time 
amplification instrument we used previously (23,24), because the microscope has superior 
optical properties (greater pixels per partition and lower exposure time requirements) to 
access higher temporal resolution and enhanced kinetic measurements. 
 
MATLAB script processing 
The MATLAB script processes a .txt file with temperature-time data generated from the TE 
Tech Controller and a TIF stack containing 2-channel images of the LAMP and melt curve 
from the LEICA microscope. Partitions are identified using a custom iterative thresholding 
algorithm, and labels are propagated throughout the TIF stack using a custom labeling 
algorithm. Average well intensity is tracked over time to generate LAMP curves and plotted 
against temperature to generate the melt curves. Complete details of the script are in the 
Supplementary Materials and Methods, “MATLAB script.” 
Bulk LAMP reactions were conducted in 10 µL volumes within a well plate on a CFX96 
Real-time Thermocycler (Bio-Rad) at buffer conditions and temperatures matching the 
dLAMP reactions. 
Enzymatic digestions of bulk LAMP products were conducted using CAC8I (Ref #R0579S), 
Hpy166II (Ref #R0616S), ACCI (Ref #R0161S), AciI (Ref #SR0551S), MseI (Ref 
#R0525S), and HpyCH4III (Ref #R0618S) purchased from New England Biolabs and were 
conducted in 50 µl reaction volumes containing 1 µL enzyme, 1 µg DNA, in 1 x Cut Smart 
Buffer, and incubated for 1 h at 37 °C. Samples were inactivated for 1 h at 80 °C and diluted 
to 1 ng/µL (~1:300) to run on an Agilent 4200 TapeStation using High Sensitivity D5000 
ScreenTape (#5067-5592) with ladder (#5190-7747), and D100 ScreenTape (#5067-5584) 
with High Sensitivity D1000 Reagents (#5067-5585). 
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Library preparation and sequencing 
300-500 ng of amplified DNA products were fragmented to the average size of 200 bp with 
Qsonica Q800R sonicator (power: 20%; pulse: 15 sec on/15 sec off; sonication time: 12 min), 
and libraries were constructed using NEBNext Ultra™ II DNA Library Prep Kit (NEB, 
#E7645) following manufacturer’s instructions. Briefly, fragmented DNA was end-repaired, 
dA tailed, and ligated to NEBNext hairpin adaptors (NEB, #E7335). After ligation, adapters 
were converted to the ”Y” shape by treating with USER enzyme and DNA fragments were 
size selected using Agencourt AMPure XP beads (Beckman Coulter, Ref #A63880) to 
generate fragment sizes between 250 and 350 bp. Adaptor-ligated DNA was PCR amplified 
with 5 cycles followed by AMPure XP bead clean up. Libraries were quantified with Qubit 
dsDNA HS Kit (ThermoFisher Scientific, #Q32854), and the size distribution was confirmed 
with High Sensitivity DNA Kit for Bioanalyzer (Agilent Technologies, #5067). Libraries 
were sequenced on Illumina HiSeq2500 in single-read mode with the read length of 50 nt to 
the sequencing depth of 10 million reads per sample, following manufacturer's instructions. 
Base calls were performed with RTA 1.18.64 followed by conversion to FASTQ with 
bcl2fastq 1.8.4. 
 
Sequencing analysis 
Raw FASTQ files were first analyzed with FastQC v0.11.8. Overrepresented sequences were 
compared with input primer sequences to find reads consisting of potential products from the 
LAMP reactions. To verify that all adjoining products were accounted for, the FASTQ files 
were aligned to the predicted products using Bowtie2 v2.3.4.3 with global very-sensitive 
settings. Unaligned reads were checked for any remaining possible amplification products. 
All regions consisting of sequences from multiple primers were tallied by counting the reads 
with a substring of n=11 from the end of each primer. One adjoining region between primers 
contained a random insertion of nucleotides and was analyzed by first extracting all reads 
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containing the primer before and after the random nucleotides. The length and sequence 
distribution of random inserts was then analyzed from the extracted reads. 
 
Results and Discussion 
Bulk LAMP studies reveal nonspecific products with high melting temperature (Tm) 
We first wished to test whether melting temperature (Tm) could be used to separate specific 
and nonspecific amplification in a LAMP assay run in bulk. To start, we selected a 
concentration near the LOD where we might observe both specific and nonspecific 
amplification. We used extracted CT genomic DNA in the presence of two commercially 
available polymerases, Bst 2.0 and Bst 3.0, with CT 23S as the amplification target. At target 
molecule concentrations of 10 copies per µL (cp/µL), amplification using Bst 2.0 polymerase 
began between 10-11 min (Figure 7.1A) and had uniform Tm (Figure 7.1B). Amplification 
using Bst 3.0 polymerase (Figure 7.1C), also yielded amplification from 10-11 min; 
however, we also observed a nonspecific amplification at 15 min, defined as having a 
different Tm than the specific amplification events (Figure 7.1D). This indicated Bst 3.0 
could be a useful model for studying nonspecific amplification. We observed that early 
amplifying products corresponded to specific amplification events, and the later products 
corresponded to nonspecific amplification, supporting our prediction that we could use Tm 
as a proxy for sequence identity, as is common with PCR, and has been used previously in 
LAMP (25-29). 
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Figure 7.1: Amplification and melting temperature (Tm) curves of Chlamydia 
trachomatis in a bulk reaction show nonspecific amplification products with 
high Tm. 
Plots of fluorescence as a function of time during a LAMP reaction (A,C,E,G,I,K) 
and the derivative plot of fluorescence as a function of temperature for the 
corresponding melting curves (B,D,F,H,I,J). Reactions using Bst 2.0 at 10 copies per 
microliter (cp/µL) (A,B), and using Bst 3.0 at 10 cp/µL (C,D), 3.16 cp/µL (E,F), 1 
cp/µL (G,H), 0.316 cp/µL (I,J), and without template (K,L). Reactions of specific 
amplification are different shades of blue; nonspecific amplification is different 
shades of red. The number of false-positive reactions is reported within each panel 
as N/Nreaction False. NTotal for all conditions = 159 reactions. 
 
Using Bst 3.0 at low concentrations of target is a useful system to study nonspecific 
amplification. To investigate the role of the concentration of the target on the incidence of 
nonspecific amplification, we performed half-log dilutions of template from 10 to 0.316 
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cp/µL. At 3.16 cp/µL (Figure 7.1E-F), only specific amplification occurred (24 replicate 
wells/plate). However, once template concentrations reached 1 cp/µL (Figure 7.1G-H), 
nonspecific amplification occurred with greater frequency than specific amplification (18 of 
the 24 replicates generated false positives). Similarly, for 0.316 cp/µL (Figure 7.1I-J) 15 of 
the 24 replicates generated false positives. We next ran the same assay in the absence of 
template (no-template control, NTC) (Figure 7.1K-L). Even though we did not expect 
amplification, we observed all reactions amplified. 44 of 45 replicates amplified at a Tm of 
91 °C, consistent with the Tm of nonspecific amplification in the presence of template. 
Although it is possible for a reaction to generate multiple different nonspecific amplification 
products, even ones with Tm matching to the specific products, the single amplicon observed 
at 88 °C in the NTC was a contaminant that appeared to have the same sequence as the 
specific products (Figure 7.2A [well F8]). In general, when the specific target was present, 
it amplified sooner and outcompeted the nonspecific amplification, thereby reducing the 
number of observations of nonspecific amplification. To determine if the nonspecific 
amplification was inherent to the polymerase or a consequence of buffer selection, we 
conducted additional studies using both Bst polymerases (Supplementary Figure 7.11 and 
Table 7-1).  
To better understand nonspecific amplification in LAMP, we investigated the sequence 
identity of the nonspecific products with high Tm using sequencing and gel analysis and 
compared them with the specific products. The Tm of specific amplification differed between 
the two polymerases tested. Specific amplification for Bst 2.0 had a Tm of 85.5 °C, whereas 
specific amplification using Bst 3.0 had a Tm of 88 °C, and demonstrated nonspecific 
amplification at Tm of 91 °C. The nonspecific amplification had identical Tm to 
amplification in absence of template (Figure 7.1K,L). Despite the specific amplification 
products of Bst 2.0 and Bst 3.0 producing similar gel banding patterns (Figure 7.3) and the 
same sequencing results (see Figure 7.2B), they had different Tm (Figure 7.1B,D 
respectively). We determined the difference in Tm was due to differences in buffer 
conditions (Supplementary Figure 7.11 and Table 7-1).  
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Figure 7.2: Quantification of junctions using next-generation sequencing of 
select Chlamydia trachomatis amplification products from bulk reactions. 
Nonspecific amplification from the no-template control using Bst 3.0 (A), including 
amplification of a specific target contamination (well F8) corresponding to Figure 
7.1K,L. Amplification in the presence of 10 cp/µL template (B), using Bst 2.0 (wells 
A1-A3) corresponding to Figure 7.1A,B, and Bst 3.0 (wells C1-C3) corresponding 
to Figure 7.1C,D. Nonspecific amplification in the presence of 10 cp/µL template 
and Bst 3.0 (well C7) corresponding to Figure 7.1C,D. For a complete list of 
abbreviations used in this figure, see Supplementary Table 7-2. 
 
In all bulk reactions, we observed nonspecific products with high Tm. This was surprising 
because in PCR, primer dimers have low Tm; moreover, in previous demonstrations of 
LAMP, Tm was lower for nonspecific compared with specific products (27). Thus, we 
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investigated the sequence identity of the nonspecific product with high Tm. We ran the 
LAMP products on a gel and observed that the characteristic pattern of the specific 
amplification products differed substantially from the banding pattern seen in the high-Tm 
nonspecific products (Figure 7.3). Interestingly, the high-Tm nonspecific product had a 
ladder pattern resembling that of specific LAMP products. 
To determine the identity of the high-Tm nonspecific products, we performed next 
generation sequencing (NGS). We observed that the nonspecific products lacked the 
corresponding target sequence and identified the product as a mixture of full-length FIP, BIP, 
and their complements, as well as fragments of BIP (Figure 7.2A). 
To confirm the sequence identity of the amplicon, we targeted the FIP and BIP regions using 
several restriction endonucleases. Digestion of the specific and nonspecific products resulted 
in different banding patterns than the undigested samples, and was consistent with the 
presence of both FIP and BIP endonuclease recognition sites within the sequence 
(Supplementary Figure 7.12). Specific amplification products were 47% GC; nonspecific 
amplification products were 53% GC. 
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Figure 7.3: Composite image of select Chlamydia trachomatis amplification 
products from a bulk reaction. 
Products were collected using D5000 tape on Agilent TapeStation. Amplification in 
the presence of 10 cp/µL template using Bst 2.0 (lanes A1-A3) corresponding to 
Figure 7.1A,B, and Bst 3.0 (lanes C1-C3, C7) corresponding to Figure 7.1C,D. 
Nonspecific amplification in the no-template control (NTC; lanes E2-H1) 
corresponds to Figure 7.1K,L. Contrast was determined using the automatic “scale 
to sample” feature in the Agilent TapeStation analysis software. 
 
 
A proposed mechanism for formation of nonspecific product 
We hypothesize a mechanism for the formation of the nonspecific product with high Tm 
originating as a consequence of interactions of the Bst polymerase and LAMP inner primers. 
Other potential mechanisms include LIMA (30) and UIMA (31), but are inconsistent with 
our sequencing results, which observe nearly equal reads of the forward and reverse strand 
as measured by counting the complementary sequences between each junction. Our proposed 
mechanism requires properties that have been observed with Bst enzymes: a strand-
displacing polymerase lacking 3’-5’ exonuclease activity—common to polymerases from 
thermophilic bacteria (32,33), template switching ability to allow synthesis across a 
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discontinuous template (33), terminal transferase activity, or the ability to perform non-
templated synthesis (32,34,35). Briefly, the nonspecific product likely arises from extension 
of a low probability homo-dimerization of the Backward Inner Primer (BIP), followed by 
elongation across a discontinuous junction (“template switching”) to form a double-stranded 
product incorporating Forward Inner Primer (FIP). Through breathing of the molecule, the 
3’ of one strand may form a second hairpin and amplify. Some of these amplification events 
incorporate several random nucleotides via terminal nucleotidyl transferase activity resulting 
in a pool of hairpins with 3’ randomers. Sequences with complementary randomers are 
selected in vitro to amplify. The double-stranded product of this amplification can, through 
intramolecular hydrogen bonding, form two dumbbell-like structures and amplify in a 
fashion similar to the standard LAMP mechanism, but primed by BIP. Repetitive cycles of 
self-priming and hairpin priming by BIP result in numerous sequences with complementarity 
and the possibility of multiple replication loci within a single molecule. This process can give 
rise to very long amplicons, and even a branched, mesh-like network from the multimeric 
sequences annealing to their neighbors or in a self-complementary fashion. A simplified 
version of this mechanism, annotated with sequencing data, can be found in Supplementary 
Figure 7.13. 
In more detail, a potential mechanism of formation of nonspecific products is as follows: 
Initially, a double-stranded amplicon is generated by homo-dimerization of BIP, and 3’ 
extension of the homodimer to produce a partial reverse complement of BIP (prcBIP) 
(Figure 7.4-1). Bst polymerase is highly prone to mismatched extension (36), and the two 
base pairs of CG provide a sufficient anchoring in the 3’ to start elongation. Multiple Primer 
Analyzer (ThermoFisher) does not identify the BIP homodimer, unless maximum sensitivity 
is used. Alternatively, BIP-prcBIP product may arise from a single stranded BIP-hairpin, as 
has been observed by others (37), although UNAfold (IDT) does not predict the formation 
of the hairpin for this primer. These structures may not need to be abundant at equilibrium, 
but as long as they are extended by the polymerase, the product will be stabilized and will 
accumulate. 
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Upon accumulation of the BIP-prcBIP construct, the reverse complement of FIP (rcFIP) 
is incorporated by template switching (Figure 7.4-2). The 3’ of FIP is within spatial 
proximity of the homo-BIP sequence due to microhomology of to 5’ end of the double-
stranded sequence coupled with rapid breathing of two base pairs of TA. This allows 
temporary insertion and hybridization of FIP with the double-stranded BIP-prcBIP sequence 
(Figure 7.4-3). When the polymerase is also in proximity of this reaction, FIP slips out of 
the junction, and the polymerase elongates across the 3’ discontinuous junction (33,35) 
templated by FIP (Figure 7.4-4). We confirmed the interaction of FIP and BIP produced the 
high-Tm nonspecific amplification, and that elimination of 3’ microhomology could 
significantly reduce high-Tm nonspecific amplification (Supplementary Figure 7.14-16, 
Table 7-3, Table 7-4). After elongation, the FIP which has served as template, is poised to 
prime in the opposite direction (Figure 7.4-5). This either displaces the initial BIP mispairing 
(BIP*) or opens the hairpin, resulting in a double-stranded BIP-prcBIP-FIP product (Figure 
7.4-6). This three-part junction is observed as a complete product in NGS data. Breathing of 
double-stranded BIP-prcBIP-FIP is prone to formation of an intramolecular self-priming 
hairpin of rcBIP-pBIP (Figure 7.4-7). Elongation of the 3’ hairpin results in a double-
stranded FIP-pBIP-rcBIP-rcFIP hairpin (Figure 7.4-8) and displacement of a BIP-prcBIP-
rcFIP hairpin (Figure 7.4-9), which may be primed by FIP to restart this cycle (Figure 7.4-
10). With each amplification, and re-prime by FIP, a single product is generated. This process 
of hairpin accumulation would cause the linear “rinsing” baseline observed by other 
researchers (37). 
Within this pool of linear amplifying products, the Bst enzyme will randomly incorporate 
additional nucleotides at the 3’ end of FIP-pBIP-rcBIP-rcFIP via terminal transferase activity 
(Figure 7.4-11). Our sequencing methods are unable to observe a FIP-randomer hairpin 
because adapter ligation requires double-stranded products. This pool of hairpins with 
random sequences will accumulate until LAMP selects for sequences that amplify by sharing 
complementary 3’ “toe holds” (Figure 7.4-12). Much like in vitro evolution, those sequences 
with the highest probability of amplification are selected (32). The lack of a thermal gating 
mechanism in LAMP and lack of 3’–5’ exonuclease activity makes the amplification reaction 
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especially prone to in vitro evolution of self-amplifying products. When considered in 
this light, it is unsurprising that nonspecific amplification could arise from mechanisms 
similar to the specific products. Within a given bulk reaction, variation in randomer sequence 
length and identity was low. However, between different samples, randomer sequences of 
multiple lengths and identities were observed. These two results further suggest that in bulk 
reactions amplification occurs from one or a few sequences (Supplementary Table 7-5, 
Table 7-6, Table 7-7). 
Elongation from the randomer overhang results in a double-stranded products, leading to 
dumbbell structures, and LAMP-like amplification. First, elongation of hairpins with 
complementary randomer toe holds produces a dimer of FIP-BIP-prcBIP-rcFIP coupled 
through the randomer (Figure 7.4-13). Breathing of the molecule can result in formation of 
intramolecular hairpins, and eventual disassociation into two separate self-priming, dumbbell 
shaped hairpins (Figure 7.4-15 and -16). The products of elongation from self-priming 
amplification doubles the amount of dsDNA present and forms sequences with internal 
hairpins capable of priming by BIP (Figure 7.4-17). Elongation from BIP priming creates a 
new double-stranded product and reveals a self-priming 3’ hairpin of the original strand 
(Figure 7.4-18), which upon elongation, displaces the sequence primed by BIP (Figure 7.4-
19) while transforming the trimer of FIP-BIP-prcBIP-rcFIP to a pentamer (more than tripling 
the amount of ds products from structures 15 and 16). The pentamer still contains an rcBIP 
hairpin, and may amplify in a functionally similar method as previously (Figure 7.4-17). The 
displaced product Figure 7.4-19 is similar to Figure 7.4-16 but missing 5’-FIP. However, 
much as with Figure 7.4-16, this products is self-priming and produces a structure with an 
internal rcBIP hairpin (Figure 7.4-20). A second priming of the hairpin by BIP of the rcBIP-
pBIP hairpin and subsequent elongation, creates a new double-stranded product and reveals 
a self-priming 3’ hairpin of the original strand (Figure 7.4-21). As previously, upon 
elongation, the sequence primed by BIP is displaced (Figure 7.4-22). Simultaneously, the 
self-priming event turns the FIP-BIP-prcBIP trimer to a pentamer, which may continue to be 
amplified by BIP. The released sequence (Figure 7.4-22) is again self-priming, and its 
product is equivalent to Figure 7.4-20 to restarts the cycle. Further, amplified hairpins may, 
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in addition to BIP priming of the hairpin, duplicate through self-priming by breathing 
and formation of a 3’ rcBIP-pBIP hairpin (Figure 7.4-23). 
The products of these reactions are capable of forming a branched, mesh-like network 
resulting in the observed high temperature melting. Products may experience random internal 
priming by through hairpin formation (e.g. Figure 7.4-13,-17,-20), or 3’ self-priming 
(Figure 7.4-23). Consequently, multiple replication loci may exist within a single strand, and 
products may have internal stem loop structures (Figure 7.4-24). Furthermore, in addition to 
intramolecular bonding, the highly repetitive nature of these products allows for melting of 
fragment, which reanneals to self in a different conformation, or a neighboring strand. 
Though the initial steps of generating a double-stranded hairpin will be unique to our 
particular primer set, once a seed is generated, the processes of template switching and 
terminal transferase activity should be a general phenomenon associated with nonspecific 
amplification of thermophilic polymerase resulting in exponential amplification. As 
evidenced, when the mechanism of seed formation is disrupted through elimination of the 
microhomology, amplicons with high Tm still occur, albeit with lower frequency and 
delayed occurrence (Supplementary Figure 7.14-16, Table 7-3, Table 7-4). Template 
switching and non-template synthesis are 100x slower than template extension (33). 
However, once the self-amplifying products are selected, the reaction follows standard 
exponential LAMP enrichment. Thus, accumulation of a sufficient pool of randomers may 
take time, but still result in a delayed bulk exponential amplification event. Furthermore, 
should a hairpin with attached randomer form, it is possible that the rising baseline, attributed 
to hairpin formation (37), may also be in vitro selection of the products, leading to and 
resulting in spontaneous exponential amplification. 
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Figure 7.4: Illustration of a mechanism for formation of nonspecific 
amplification products in LAMP reactions. 
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Putative structures and intermediates are labeled with numbers. Forward sequences 
are illustrated as a straight line, and the reverse compliment as a wavy line of 
matching color. Abbreviations used in this figure: BIP, Backward Inner Primer; 
rcBIP, Reverse compliment of BIP; FIP, Forward Inner Primer; rc FIP, Reverse 
Compliment of FIP; prcFIP, Partial Reverse Compliment of FIP. 
 
 
Melting temperature differentiates specific and nonspecific reactions in dLAMP 
To study specific and nonspecific amplification events at the digital single-molecule level, 
we developed a new approach that enabled HRM analysis (obtaining “melt curves”) to be 
performed on each partition. We used a commercially available microfluidic chip with 
20,000 partitions and a previously published open-source dLAMP method accessible to most 
standard laboratories (23) with the following improvements: incorporation of an off-the-shelf 
thermoelectric unit to both heat and cool the chips, and an enhanced MATLAB script to 
allow for multicolor tracking. We used the temperature-independent fluorophore ROX to 
track each partition’s location and the dsDNA intercalating fluorophore SYTO 9 to follow 
amplification and hybridization status. This two-channel approach is required to follow a 
partition through both amplification and the entirety of the HRM when fluorescence from 
SYTO 9 is lost. 
As an illustration of the capabilities of our approach, we first used real-time dLAMP to study 
the kinetic parameters of individual reactions, and we used Tm to classify reaction outcome 
(Figure 7.5). Using real-time dLAMP, we followed individual partitions as they amplified 
as a function of time (Figure 7.5A) and then by temperature as they went through HRM 
(Figure 7.5B). Real-time imaging of individual partitions enables us to reconstruct the 
standard amplification curves of intensity for each partition as a function of time (Figure 
7.5C), and plotting the fluorescence intensity as a function of temperature yields an HRM 
trace (Figure 7.5D); the negative derivative plot (Figure 7.5E) of this melt trace is the 
standard melt curve. Analogous to bulk measurements, the standard melt curve is used to 
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classify reactions as specific or nonspecific. We used these classifications to identify 
important patterns in the kinetics of each type of amplification (Figure 7.5F-H). 
We next used real-time dLAMP with HRM to determine whether differences in time to 
positive (TTP) were due to a difference in amplification initiation or in rate. We expect this 
information would be valuable for elucidating whether the molecules that lead to bulk 
amplification are the ones that are first to initiate or the ones that initiate with the fastest rates. 
We found that TTP can be heterogeneous while Tm is constant (28.6±8.9 min with 87.5±0.2 
°C), indicating that the same product may initiate at different times (Figure 7.5F). This is 
consistent with our knowledge of the stochastic initiation of LAMP (23,38,39). Further, we 
observed some variability in the maximum rate despite similar Tm (23.7±6.8 RFU/30 sec, 
with 87.5±0.2 °C Tm), which indicates the same product may amplify at different velocities. 
(Figure 7.5G). In general, we observed that maximum rate often corresponds to the point 
when the reaction first began to amplify. Finally, by plotting rate as a function of TTP 
(Figure 7.5H), we observed little fluctuation in rate across a range of different TTPs 
(23.7±6.8 RFU/30 sec with 28.6±8.9 min), indicating that the differences in TTP are mostly 
delays in the initiation of amplification rather than differences in the rate of amplification. 
The use of real-time data revealed heterogeneity in the timing of amplification initiation and 
the amplification rate, but homogeneity in Tm, indicating stochasticity in initiation of 
amplification. In some cases, outlier data points for rate occurred. To determine whether 
removing these outliers impacted the distribution of enzymatic rates, we performed a non-
parametric test (Supplementary Figure 7.17) and found no significant differences in 
enzymatic rates when these outliers were excluded. 
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Figure 7.5: Specific amplification in digital single-molecule experiments using 
Bst 2.0. (A) Fluorescence micrographs of individual partitions are traced over 
time. 
For simplicity, we illustrate a subset of 250 of 20,000 possible partitions at three time 
points (0, 20, and 45 min). Of the 250 partitions in this micrograph, 30 partitions 
amplified. Partitions A and B are visible at 20 min; partition C becomes visible at 45 
min. (B) Fluorescence micrographs of individual partitions are traced across 
temperatures during an HRM experiment. As the double-stranded DNA in each 
partition de-hybridizes, the intercalating dye is released and fluorescence decreases. 
(C) Plotting the fluorescence intensity as function of time generates the standard 
amplification traces of individual partitions generated during a 90-min LAMP 
 
 
229 
experiment. Orange curves correspond to partitions A–C from panel A. (D) Traces 
of fluorescence intensity as a function of temperature for individual partitions during 
melting experiments. By quantifying real-time intensity of individual partitions as 
temperature increases, melting traces are obtained. Temperature resolution is 1 °C 
from 55–90 °C, and 0.5 °C from 90–95 °C. (E) The derivative plot of panel d 
generates the standard melting curve. The temperature at which the derivative 
maximum occurs corresponds to the “melting point” of the LAMP products in the 
individual partition. (F) The time each partition reached a fluorescence intensity of 
250 RFU (TTP) as a function of temperature. (G) Maximum rate as a function of Tm 
for each partition. (H) TTP as a function of maximum rate for each partition. 
 
 
We next asked whether we could observe in dLAMP the same pattern of high-Tm 
nonspecific amplification and low-Tm specific amplification that we observed in bulk. We 
performed dLAMP using three chips containing template, and three chips lacking template 
(NTC), and observed ~55,000 partitions for each condition. Although 60,000 partitions are 
possible, not all partitions filled nor can all partitions be tracked for the full duration of an 
experiment. For the melt curve, fluorescence readings were taken at 1 °C increments from 
55-90 °C; and at 0.5 °C increments from 90–95 °C to give higher resolution. Due to slight 
differences in the timing between the heating element and the image collection, some chips 
were observed at slightly different temperatures (<0.5 °C). 
Our approach enabled us to differentiate specific and nonspecific amplification events using 
HRM. When using the polymerase Bst 2.0 and template (Figure 7.6A, blue points), we 
observed a large band of amplification in the temperature range 88.5–90.3 °C, in agreement 
with the Tm observed when performing the reaction in bulk (Figure 7.1). In contrast, the 
NTC (Figure 7.6A, red points) had very few amplification events in that temperature range 
(68 out of 51,279 partitions). Hence, we defined events that occurred in the Tm range 88.5–
90.3°C as true positives (specific amplification events), and we defined those that occurred 
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outside this range (in both the NTC and in the presence of template) as false positives 
(nonspecific amplification events). When using the polymerase Bst 3.0, we observed a large 
band of amplification from 91.25–92.75 °C in the presence of template (Figure 7.6B, blue 
points) that did not correspond with amplification in the NTC (Figure 7.6B, red points), so 
we defined these as specific amplification events. As with bulk measurements, we 
determined the difference in Tm between specific amplification events between Bst 2.0 and 
Bst 3.0 was due to the difference in buffer composition (Supplementary Figure 7.11, Table 
7-1). 
During these experiments, we observed two common patterns. First, the Tm for specific 
amplification events was 3–5 °C lower in digital compared with bulk measurements. We 
attribute this difference to temperature calibration; the thermocycler is calibrated to the liquid 
temperature, whereas the thermoelectric element measures the temperature of the heating 
element. Second, false positives in the NTC had predominantly high Tm, which we attribute 
to the nonspecific product we identified in the bulk reactions. We also observed differences 
in total amplification events between the two polymerases. Assays with Bst 3.0 resulted in 
substantially more nonspecific amplification than those with Bst 2.0 and confirmed this was 
not an issue with buffer selection (Supplementary Figure 7.11, Table 7-1). After 90 min, 
Bst 3.0 yielded 15,200 nonspecific events (out of 54,337 observed paritions) in the NTC, 
whereas Bst 2.0 yielded only 74 nonspecific events (out of 51,279) in the NTC. Occasionally, 
outliers occurred in the NTC and would be misidentified as positives by fluorescence and 
Tm. For Bst 3.0 this occurred in 29 partitions; for Bst 2.0, it occurred in only 3 out of ~55,000 
partitions. 
Next, we tested whether TTP is different for specific and nonspecific amplification. Because 
LAMP follows a “winner-takes-all” format, frequent and early nonspecific amplification 
events may dominate bulk amplification. In general, for both Bst 2.0 and Bst 3.0, specific 
amplification had earlier TTP than nonspecific amplification, although there was some 
overlap, mostly >90.5 °C (Figure 7.6A-B). We were able to distinguish the clustering of 
high-Tm nonspecific products separately from specific amplification using a threshold of 
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88.5–90.3 °C (Figure 7.6C and Supplementary Figure 7.18A). We illustrate each 
partition with only partial opacity so that when false positives in the NTC (red) overlap with 
false positives in the template-containing sample (blue), the overlap of multiple colors 
appears purple (Figure 7.6D). Color intensity indicates the abundance of paritions at a given 
TTP and temperature. To further illustrate how this approach can be used to differentiate 
specific and nonspecific amplification, we next selected a region where both specific and 
nonspecific products were observed. For Bst 3.0, we were able to distinguish the clustering 
of high-Tm nonspecific products separately from specific amplification using the threshold 
of 91.25–92.75 °C (Figure 7.6E), and we observed better separation of specific and 
nonspecific amplification than with Bst 2.0 (Figure 7.6F and Supplementary Figure 
7.18B). Both enzymes had highly variable TTP, which we have observed previously (23), 
and attribute to stochastic initiation of LAMP. Bst 2.0 had both earlier specific amplification 
and later nonspecific amplification than Bst 3.0. Bst 2.0 reactions containing template 
generally started at 10 min, whereas nonspecific amplification began at ~40 min. In contrast, 
Bst 3.0 reactions containing template began at 11.5 min, and nonspecific amplification began 
at ~20 min. 
Next we asked whether there is a difference between the maximum rates of specific and 
nonspecific amplification. Previously, we demonstrated that rate could be used to correct for 
some nonspecific amplification using E. coli 23S primers (23), so we wished to test whether 
we could use maximum rate as a way to differentiate specific and nonspecific amplification. 
Generally, specific and nonspecific amplification reactions did not have the same maximum 
rate. For Bst 2.0, nonspecific amplification tended to have a slower max rate than specific 
amplification, although there was some overlap (Figure 7.6G). At high Tm, the clustering 
of nonspecific amplification in both the presence of template and in the NTC were observed 
at >90.5 °C and below approximatley 50 RFU/30 sec (Figure 7.6H). For Bst 3.0, although 
there was substantial overlap, we again observed that nonspecific amplification tended to 
have slower maximum rate than specific amplification (Figure 7.6I). Examining the high-
Tm amplification events, nonspecific amplification collects above 92.75 °C and has 
maximum rate extending out to 75 RFU/30 sec (Figure 7.6J). For both enzymes, overlap 
 
 
232 
between specific and nonspecific amplification was similar, and specific amplification 
tended to be faster. However, the maximum rate of specific amplification between the two 
enzymes differed; Bst 2.0 had a maxium rate of 150 RFU/30 sec, whereas Bst 3.0 did not 
exceed 100 RFU/30 sec. Bst 2.0 performing faster than Bst 3.0 is consistent with our previous 
observations using an E. Coli 23S primer set (23). Additionally, the maximum rate of 
nonspecific amplification in Bst 2.0 tended to be lower than nonspecific amplification in Bst 
3.0 (50 and 75 RFU/30 sec, respectively). Consequently, the extent of overlap of specific and 
nonspecific amplificaiton was greater for Bst 3.0 than Bst 2.0. 
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Figure 7.6: Properties of specific and nonspecific amplification using real-time 
kinetics and Tm. 
Blue indicates amplification events in the presence of template, red indicates 
amplification in the absence of template (NTC). Among these amplification events, 
true positives were identified using Tm (88.5–90.3 °C for Bst 2.0 and 91.25–92.75 
°C using Bst 3.0). Color intensity indicates the abundance of paritions at a given TTP 
and temperature (partitions in panels A,C,D,G,H,K,M using Bst 2.0 are rendered at 
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20% opacity in the NTC and in the presence of template; panels B,E,F,I,J,L,N using 
Bst 3.0 are rendered at 5% opacity in the NTC and 20% in the presence of template. 
(A) Tm of individual amplification events as a function of TTP using Bst 2.0. (B) Tm 
of individual amplification events as a function of TTP using Bst 3.0. (C) Individual 
partitions with Tm between 88 and 95°C as a function of TTP using Bst 2.0. (D) 
Individual partitions with Tm between 88 and 95°C and TTP between 60 and 70 min 
using Bst 2.0. Dashed line at 90.3 °C indicates the upper threshold separating specific 
and nonspecific amplification.  (E) Individual partitions with Tm between 91 and 
95°C as a function of TTP using Bst 3.0. (F) Individual partitions with Tm between 
91 and 95°C and TTP between 35 and 45 min using Bst 3.0. Dashed line at 92.75 °C 
indicates the upper threshold separating specific and nonspecific amplification. (G) 
Tm of individual amplification events as a function of maximum rate using Bst 2.0. 
(H) Tm of individual amplification events between 88 and 95°C as a function of 
maximum rate using Bst 2.0. (I) Tm of individual amplification events as a function 
of maximum rate using Bst 3.0. (J) Tm of individual amplification events between 
88 and 95°C as a function of maximum rate using Bst 3.0. (K) The final intensity of 
individual amplification events as a function of maximum rate using Bst 2.0. (L) The 
final intensity of individual amplification events as a function of maximum rate using 
Bst 3.0. (K-L) Partitions with a final intensity less than 250 RFU (dotted line) were 
excluded from analyses. (M) The maximum rate of individual amplification events 
as a function of TTP using Bst 2 and (N) using Bst 3.0. (O) Plot of maximum rate 
from false-positive amplifications in NTC (red), false positives amplifications in the 
presence of template (blue) and true-positive amplifications by Tm (black) as a 
function of TTP using Bst 2.0 and (P) using Bst 3.0. (Q) 3D plot comparing maximum 
rate, Tm, TTP, and final intensity of individual partitions using Bst 2.0 and (R) using 
Bst 3.0. 
 
We observed an unexpected relationship between the final intensity of each partition and the 
maximum rate of that partition. After 90 min of amplification, a partition should theoretically 
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reach a fluorescence maximum whereby all reagents are consumed, amplification 
plateaus, and thus the final intensity would be independent of the maximum rate of 
amplification. However, surprisingly, we observed a general scaling between the maximum 
rate and the final intensity of the partition. For Bst 2.0, all amplification in the NTC has final 
intensity less than 1017 RFU and maximum rate less than 53.4 RFU/30 sec. In the presence 
of template, 79.7% of nonspecific amplification and 52.3% of specific amplification had final 
intensity and maximum rate less than these thresholds. For Bst 3.0, 87.7% of amplification 
in the NTC has final intensity less than 1017 RFU and maximum rate less than 53.4 RFU/30 
sec. In the presence of template, 89.0% of nonspecific amplification but only 45.6% of 
specific amplification fell within these thresholds using Bst 3.0. Thus, false positives were 
generally dimmer and had slower maximum rates than most true‐positive events. When 
examining the brightest partitions, Bst 2.0 (Figure 7.6K) and Bst 3.0 (Figure 7.6L) exhibit 
a similar maximal final intensity near 3000 RFU. These maxima are also surprising, 
considering our 12-bit camera is capable of imaging up to 4096 RFU (the detector was not 
at saturation). We suspect that this maxima corresponds to consumption of one of the 
reagents; while scaling between maximum rate and final intensity occurs when stochastically 
initiated reactions have not completely amplified, resulting in partitions dimmer than the 
maxima and proportional to their rate of amplification. 
During these dLAMP experiments, we also observed a relationship between maximum rate 
and TTP. In bulk reactions, the first and fastest amplification event determines the reaction 
outcome by consuming all of the reagents. Thus, we hypothesized that reaction conditions 
that promote fast and early amplification in the NTC would lead to a high false-positive rate 
in bulk and thus misidentification of amplification. In both Bst 2.0 (Figure 7.6M) and Bst 
3.0 (Figure 7.6N) we observed a general trend of fast amplification events occurring earlier, 
and slow events occurring later. In Bst 2.0, we observed greater heterogeneity in TTP and 
rate than in Bst 3.0. Furthermore, nonspecific amplicons in the NTC tended to produce slower 
and later amplification events. Occasional outliers occurred at both fast and early times. 
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Next, to explicitly test whether fast and early events correspond to specific amplification, 
we analyzed the relationship between a partition’s TTP, its maximum rate, and Tm. In the 
first 12 min of amplification, we observed six nonspecific amplification events in Bst 2.0 
(four in the presence of template; two in the NTC; Figure 7.6O), and we observed 13 
nonspecific events in Bst 3.0 (10 in the presence of template; three in the NTC; Figure 7.6P). 
For both polymerases, we were able to distinguish the rare, fast, and early nonspecific 
amplicons from true positives. For Bst 2.0, these nonspecific amplifications were slower than 
the fastest true positives, and occurred at similar times. In contrast, for Bst 3.0, the earliest 
amplification events were false positives and tended to have similar rates to the true positives. 
We hypothesize that in bulk reactions, the fast and early nonspecific amplification events (as 
seen in Bst 3.0 Figure 7.6P) lead to nonspecific measurements, whereas nonspecific 
amplification that coincides with specific amplification, but proceeds at a slower rate (as seen 
in Bst 2.0 Figure 7.6O), would still produce specific amplification in bulk. This hypothesis 
is corroborated by sequencing of bulk LAMP reactions (Figure 7.2). Though individual bulk 
reactions may be assigned a homogeneous label as “true positive” or “false positive” by Tm, 
sequencing identifies multiple products within each reaction, and the Tm is determined by 
the dominant product. For example, we observed a “false positive” by Tm (Figure 7.1C-D), 
despite the presence of template. The sequencing of this product, contained nonspecific 
product sequences, similar to those observed in the NTC, at high prevalence, as well as the 
specific target sequences in low abundance (Figure 7.2 [well C7]). Similarly, though “true 
positive” is assigned to other bulk reactions in the presence of template, the nonspecific 
products are still observed at low abundance (Figure 7.2 [well F8]). Further, a greater 
number of nonspecific partitions in digital using Bst 3.0 as compared to Bst 2.0, is correlated 
with a greater number of nonspecific reads despite the presence of template in the sequencing 
data (Comparing Figure 7.6A-B and Figure 7.2B group A vs C). We hypothesize that the 
combination of real-time parameters (such as rate and TTP), combined with the ability of 
digital assays to yield probabilities and to assign reaction identity through HRM, may 
ultimately help researchers optimize bulk reaction conditions. 
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A complex interplay exists among TTP, max rate, final intensity, and Tm 
To better visualize how TTP, max rate, final intensity, and Tm data are interrelated, we next 
plotted these data in a four-dimensional (4D) space (Figure 7.6Q-R, Supplementary 
Videos S1 and S2 available online). We observed that among all partitions, regarless of if 
the product was specific or nonspecific amplificiation, fluorescence was brighter when 
amplification occurred earlier and faster. This was true for both polymerases. Additionally, 
we observed two types of nonspecific amplification. The first type of nonspecific was the 
traditional “primer-dimer” cloud, which is characterized by a low Tm, low final fluorescence 
intensity, a slow max rate, and a generally late TTP. The second type of nonspecific cloud 
matches only in its high Tm, and spans a wide range of rates, TTP, and final intensities. The 
high-Tm nonspecific amplification occurs with greater frequency than the low-Tm 
nonspecific amplification. The major differences between the polymerases can also be 
resolved with this visualization. The number of nonspecific amplification events is much 
fewer for Bst 2.0 than for Bst 3.0. Further, these nonspecific events in Bst 2.0 never achieve 
same fluorescene intensity or maximum rate as with Bst 3.0. We include the 4D 
representation as part of our MATLAB code, and as videos in the SI. 
 
Classification of true or false positives enables optimal analysis parameter selection 
We next asked whether using a combination of digital real-time parameters, in conjunction 
with Tm, could be used to improve the performance (LOD) of a dLAMP assay. For any given 
assay, there is a large combination of possible parameters (e.g. amplification rate, TTP, 
fluorescence intensity) that are used to determine when a digital partition is ”on” or ”off.” 
Use of these parameters and selection of thresholds will influence assay performance 
(analytical specificity and sensitivity). Assay performance is affected by amplification time 
and the combination of choices of parameters used to process the data impacting LOD, the 
probability of detecting a molecule (efficiency), and the clinical sensitivity and specificity. 
Having established that there is a direct relationship between Tm, sequence identity, and 
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structure, we determined that Tm allows us to explicitly differentiate specific and 
nonspecific amplification in dLAMP, and thus, differentiate true from false positives. 
We foresee two separate situations of dLAMP analysis using HRM. The first is where HRM 
is not incorporated in the final assay, but is used during assay development. Second is the 
ideal situation for quantitative performance, where HRM is incorporated into the final LAMP 
assay. We expect the first group of LAMP assays to exist because collecting Tm data adds 
additional time to an assay and requires more advanced hardware to run. This may be unideal 
in situations requiring more rapid diagnostics or limited-resource and field settings where the 
hardware may be impractical. Nonetheless, running HRM is still useful during LAMP assay 
development to select the optimal combination of parameters for end-point or real-time 
LAMP without using Tm. Hence, Tm allows one to identify the correct combination of assay 
parameters, and how to analyze the data for best LOD. 
LOD is a key parameter when optimizing clinical assays because pathogen load is low in 
many infections (e.g. in blood infections or asymptomatic sexually transmitted infections). 
We thus illustrated the optimization of parameters using improved LOD as the selection 
criteria. The combination of real-time dLAMP with HRM can uniquely define LOD because 
of the combination of digital and Tm. Unlike bulk assays, which require a concentration 
titration curve (and are thus dependent on integrated signal intensity and enzymatic turnover), 
digital assays only require that an event (target molecule) is or is not observed, and can be 
counted relative to the partition volume (40,41). The minimum LOD for any digital assay 
corresponds to one target or amplification event per partition volume. Hence, we can define 
LOD from a single concentration point by Eq. 1:  
Equation 7-1 
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where CTrue
 is the concentration of target molecules loaded by ddPCR counts in copies 
per microliter, NTrue is the number of true positive (specific) amplification events observed 
on a chip, NFalse is the number of nonspecific amplification events observed on a chip, and 
NCI is the number of expected molecules for a given confidence interval. In this equation, the 
NTrue and NFalse are chip-specific, and take into account the total volume of the chip, the 
number of partitions, and the volume of partitions. Furthermore, in Eq. 1, amplification 
efficiency is implicitly taken into account via the NTrue parameter (in other words, for a less 
efficient amplification process, a given CTrue on a given chip would lead to a lower value of 
NTrue). Finally, for simplicity, Eq. 1 makes the assumption that the measurements are 
performed at sufficiently low concentrations (as is typical for LOD experiments) that only a 
very small fraction of occupied partitions contain more than one molecule, and therefore, 
there is a linear relationship between CTrue and NTrue. 
The concentration loaded, CTrue, generates N total counts of both true- and false-positive 
events. We can divide this concentration by the minimal number of counts needed to identify 
a specific amplification event and define this as the LOD. The minimum number of counts 
needed to guarantee a specific amplification event is observed is determined by NTrue, NFalse, 
and NCI. NTrue and NFalse are determined empirically, whereas NCI is calculated from the 
desired expected number of molecules that will yield at least one detection event for a given 
confidence interval (NCI) from the Poisson equation. If we require a 95% CI to observe a true 
positive across an entire chip, the minimum number of counted events is 3 (i.e. 5% of the 
time, the Poisson expected loading of 3 target molecules will still measure zero events). For 
a 98% CI, NCI would be 4 counts. Hence, all true-positive counts in excess of NCI are counts 
observed above the LOD. Uncertainty in the LOD is given by Supplementary Equations S1-
S2.  
Counting only true positives does not account for interference from false positives. In order 
to meet our minimum counts for detection, our equation must remove false counts (NFalse.) 
The generally accepted procedure for LOD calculations with a 99.7% CI is to assign NTrue 
only when the counts exceed the background plus three standard deviations of the 
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background (𝑁𝐹𝑎𝑙𝑠𝑒 + 3 × √𝑁𝐹𝑎𝑙𝑠𝑒). We approximate the variance in the background 
using the counting error as three times the square root of the number of false-positive events 
counted and subtract those counts from the true-positive counts to yield the equation. 
Using this calculation of LOD to optimize an assay has three limitations. First, Eq. 1 fails to 
produce a number with physical meaning when the number of true-positive events (NTrue) is 
less than the number of false-positive events plus three times the standard deviation in false 
amplification (𝑁𝐹𝑎𝑙𝑠𝑒 + 3 × √𝑁𝐹𝑎𝑙𝑠𝑒). In this case, it is not possible to conclusively observe 
a true positive, and the LOD becomes irrelevant. Second, Eq. 1 gives an absolute LOD. The 
numerator (concentration of template molecules loaded on the chip, as determined by PCR) 
is corrected for the probability of observing a molecule amplify (efficiency) by the true-
positive counts. NFalse
 accounts for the nonspecific amplification, and NCI accounts for the 
Poisson probability associated with loading a target molecule. Third, this equation is specific 
to digital assays. 
We first sought to demonstrate the selection of optimal parameters for situations where HRM 
is not incorporated into the final assay. Using this process, one can pick any threshold and 
use Tm to determine the optimal trade-off between true and false positives. All initial 
experiments testing the utility of LOD, juxtaposed against receiver operating characteristic 
(ROC) curves, to identify optimal parameters were done using Bst 3.0. We began by 
determining the optimal thresholds for max rate, fluorescence intensity, and amplification 
time. We demonstrate optimization of all three parameters, using Tm as the arbiter, to 
illustrate the utility of our method. 
We tested the use of ROC curves (commonly used to indicate clinical sensitivity and 
specificity) to compare the performance in response to a given parameter. ROC curves 
provide a visual representation of the ability to distinguish between a true-positive and false-
positive event, as a function of a given threshold, but can be difficult to use for optimal 
selection of LOD. ROC curves show the fractions of true and false positives, where the true-
positive fraction is the number of true positives at a given threshold out of the total number 
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of true positives observed by Tm; and the false-positive fraction is the number of false 
positives counted at the given threshold, divided by the total number of false positives 
observed by Tm. A perfect classifying test will yield the largest true-positive fraction and 
smallest false-positive fraction. 
When plotting the ROC curve for maximum rate (Figure 7.19A), we observed that rate 
initially performs very well for eliminating false positives (the false-positive fraction is very 
small for very high rates). However, as the digital threshold (analogous to ROC “cut-point”) 
for rate decreases, a greater number of both false and true-positive values are counted. Closer 
examination of this range of thresholds (Figure 7.19B) emphasizes the Youden Index at 34.6 
true-positive fraction and 4.6 false-positive fraction as a possible choice for optimum 
threshold, although the assay performance in terms of LOD is unclear. The choice for optimal 
final-intensity threshold is even less clear with the ROC curve (Figure 7.19C), as the ROC 
curves do not give clear indication of the optimal LOD (the ROC curve is a gentle concave 
slope). Even relatively high fluorescence thresholds do not give indications of the optimal 
cut-point (Figure 7.19D). 
Filtering using LOD revealed a clear optimum. We plot the total number of events for both 
true and false positives and LOD as a function of maximum rate (Figure 7.7A). The LOD 
curve revealed a clear minima, corresponding to the optimal cut-point using rate. Selecting 
the threshold of 49.8 RFU/30 seconds generated an LOD of 2.11±0.92 cp/µL. Similarly, 
plotting LOD against final intensity resulted in a clear minima, despite the histogram 
appearing as a continuum and the cut-point being thus ambiguous (Figure 7.7B). Using final 
intensity, an LOD of 2.14±0.89 cp/µL can be achieved at 1393 RFU. 
The ROC curve for TTP presented a narrow range of thresholds, with ~50% true-positive 
fraction and 2% false-positive fraction, although the precise optimal threshold was not 
obvious (Figure 7.19E). To refine this threshold, we plotted the LOD and the cumulative 
counts as a function of time in both linear (Figure 7.7C) and logarithmic scales (Figure 
7.7D). 
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Figure 7.7: Classification of amplification reactions using HRM to determine 
optimal performance of dLAMP assays. 
(A) Histogram of the false positives identified by Tm within the presence of template 
(red), true positives by Tm (blue), and false positives in the NTC (green), binned by 
max rate of the partition and a LOD curve plotted as a function of max rate using Bst 
3.0. B) Histogram of the false positives identified by Tm within the presence of 
template (red), true positives by Tm (blue), and false positives in the NTC (green), 
binned by final intensity of the partition and an LOD curve plotted as a function of 
final intensity using Bst 3.0. C) LOD Curves using Bst 3.0 as a function of time 
without using Tm in the final assay (blue) and using Tm in the final device (black). 
Plots of cumulative counts of true positives (red dashed), false positives (blue 
dashed), and incorrectly identified partitions (black dashed). D) Logarithmic plot of 
LOD curves using Bst 3.0 as a function of time without using Tm in the final assay 
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(blue) and using Tm in the final device (black). Plots of cumulative counts of true 
positives (red dashed), false positives (blue dashed), and incorrectly identified 
partitions (black dashed). E) LOD plotted as a function of fluorescence intensity, 
when the assay is measured at the optimal TTP of 34 min. F) Logarithmic plot of 
LOD curves, using Bst 2.0, as a function of time without using Tm in the final assay 
(blue) and using Tm in the final device (black). The blue and black plots overlay. 
Plots of cumulative counts of true positives (blue dashed), false positives (red 
dashed), and incorrectly identified partitions (black dashed). G) Plot of LOD curves 
as a function of time comparing Bst 2.0 (solid blue with Tm, dotted blue without Tm) 
and Bst 3.0 (solid red with Tm, dotted red without Tm). Curves for Bst 2.0 overlap. 
 
Assays employing HRM only during the development of the assay can improve the LOD of 
the final assays by selecting (making an informed choice of the optimum threshold). The 
LOD decreases (blue curve) as the true positives begin to amplify (blue dashed) and increase, 
as the false positives amplify (red dashed). The minima for this system occurs at 34 min and 
0.93±16 cp/µL, striking a balance between allowing many true positives to amplify, and only 
a small amount of false positives to occur (53.6% true-positive fraction and 1.5% false-
positive fraction) and is clearly defined using the linear scale (Figure 7.7C). Plotting of LOD 
on the logarithmic scale (Figure 7.7D) emphasizes improperly selecting a threshold can 
result in several orders of magnitude loss in assay performance (for example, stopping the 
assay too early or allowing the assay to run for too long). Although dLAMP is robust to 
perturbations, selecting the appropriate duration for amplification is important. 
In contrast, assays using HRM as part of the final readout can distinguish false positives from 
the true positives and improve LOD further by excluding nonspecific amplification from the 
analysis. In some instances, a NTC may incorrectly identify partitions as true positives by 
Tm (black dashed). We incorporate these events as nonspecific amplification in case HRM 
is used in the final readout. If nonspecific amplification is eliminated, the assay LOD (Figure 
7.7C,F, black solid) continues to improve with time, and is only dependent on the stochastic 
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probability that a true positive will initiate and amplify. In this scenario, there is no 
penalty allowing the assay to amplify for extended periods of time. 
In this scenario the LOD equation simplifies to  
Equation 7-2 
 
 
Additionally, there is no limitation on the number of parameters that can be used to identify 
the optimal LOD. Using multiple parameters to filter the data may be useful for individuals 
not employing HRM in the final assay or in assays only employing end-point measurement 
(e.g. an assay without real-time measurements will be unable to generate data on rate, but 
still benefit from selecting optimal assay time and fluorescence threshold). As a 
demonstration, we filtered first by optimal TTP, then for the optima of a second parameter. 
In this case, we selected the optimal TTP of 34 min, and scanned for optimal fluorescence 
threshold. We plotted LOD as a function of fluorescence threshold and determined that the 
optimal fluorescence threshold at 34 min would be 248 RFU and correspond to an LOD of 
0.97±0.16 cp/µL (Figure 7.7E). 
Do filter parameters exhibit the same LOD minima when using Bst 2.0 as they did for Bst 
3.0? Bst 2.0 had much lower nonspecific background than Bst 3.0, and could behave similarly 
or may behave differently. 
First, does the ROC curve for TTP display a clear optimum? Similar to the TTP ROC for Bst 
3.0 (Figure 7.19E), the TTP ROC for Bst 2.0 has a concave slope making choice of the 
optimum a matter of computation (Figure 7.19F). We can visually estimate the balance of 
true and false-positive fraction in the range of 50% true and 10% false. Similar curves for 
max rate and final intensity could be generated but are not shown here. 
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Second, is there an advantage to using HRM in the final assay with Bst 2.0? To answer 
this question, we plot LOD and the cumulative counts of true and false positives as a function 
of time for Bst 2.0 (Figure 7.7F). Similarly to Bst 3.0, we observe LOD improve rapidly as 
true-positive events are counted. However, unlike Bst 3.0, the nonspecific amplification 
events are few, and their presence does not have an impact on LOD. Thus, when using Bst 
2.0, the curves representing LOD with or without HRM in the final assay overlay and indicate 
using HRM in the final assay has no additional benefit. Furthermore, the continuously 
decreasing LOD with time for either case indicates that use of ROC curves to determine an 
optimum can be misleading. While the ROC implies that an optimum exists, the false-
positive incidence is rare enough that a TTP optimum selected by LOD does not exist. Hence, 
assay developers may select assay time based on requirements other than LOD. 
We next assessed whether we could use HRM to compare the performance of the two 
polymerases, to see which one would give the best LOD and which combination of hardware 
components would give the optimum assay performance. (Figure 7.7G) For both 
polymerases, we observed a similar, rapid decrease in LOD in the initial moments as true-
positive events are detected. However, we also noticed several differences. Bst 2.0 has a 
lower LOD than Bst 3.0 at any amplification time. We attribute this difference to the higher 
incidence of false positives when using Bst 3.0 compared with Bst 2.0. An additional 
consequence of the low false-positive incidence using Bst 2.0, regardless of the use of HRM 
in the assay, is the LOD continues to improve with time as additional true positives are 
counted. In contrast, Bst 3.0 benefits greatly from use of HRM in the final assay. If HRM is 
not included in the assay (Figure 7.7G, red dashed), a clear optimum for LOD occurs at 34 
min and 0.93±0.16 cp/µL. However, if HRM is employed in the assay, the LOD more closely 
resembles the LOD curve for Bst 2.0 and improves with increased detection of true-positive 
events. 
We made several overarching conclusions regarding improving the LOD of dLAMP using a 
combination of digital real-time parameters and Tm. First, filter parameters can be used 
singly or in combination to improve the performance (LOD) of dLAMP. In certain assays, 
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one parameter may perform better than another for this selection. For this primer set, 
LOD for Bst 3.0 was lower (better) when using TTP (0.93±0.16 cp/µL) than max rate 
(2.11±0.92 cp/µL) or final intensity (2.14±0.89 cp/µL). Second, incorporation of HRM into 
the final assay readout will benefit some assays more than others. We observed incorporation 
of HRM as a part of the final assay improved the perofmance of Bst 3.0 greater than the 
perofmance of Bst 2.0, and was vital for long assay times. 
 
Classification demonstrates host genomic DNA alters specific and nonspecific amplification 
in dLAMP 
Assays with high clinical sensitivity and specificity are critically needed. Clinical samples of 
CT, originating from urine and swabs, pose an intrinsic challenge because they contain 
variable levels of host DNA and DNA from other flora. The analysis of these clinical samples 
needs not only to be sensitive (good LOD), but also to be able to function in the presence of 
nonspecific, potentially amplifiable genomic secondary structures and other possible 
environmental contaminants, while remaining consistent between samples. 
We sought to investigate the impact of host human genomic DNA (hgDNA) on nonspecific 
background amplification. We hypothesized that nonspecific structures (like hairpins and 
regulatory elements), may amplify in the presence of LAMP and contribute to nonspecific 
background amplification. We titrated sheared buffy coat gDNA (i.e. leukocytes) 
concentrations from zero to 2.5x103 cells per µL, a concentration 2.5x greater than that 
expected to cause interference (8), and observed the impact on specific and nonspecific 
amplification of CT (Figure 7.8). We measured the concentration of hgDNA in Human 
Haploid Genome Equivalents (HHGE) or half the total amount of hgDNA in a diploid cell. 
For each concentration of host DNA and enzyme, we ran at least three chips in the presence 
of CT template and three in the absence of template across multiple days and sample lots. In 
total, we observed 1,196,038 different reaction partitions. At the highest concentration of 
hgDNA, there was 3,030,000 times more hgDNA than bacterial DNA by mass. 
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We first asked how background DNA impacted TTP qualitatively. We observed for both 
Bst 2.0 and Bst 3.0 enzymes, specific and nonspecific amplification were qualitative similar 
independent of background DNA concentration below 5000 HHGE per µL. As with previous 
measurements, Bst 2.0 rarely produced low-Tm nonspecific events; whereas Bst 3.0 
produced both high- and low-Tm nonspecific events. Further, there were more nonspecific 
amplification events for Bst 3.0 than Bst 2.0 at both high and low Tm. 
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Figure 7.8: Impacts of host (human) genomic DNA in human haploid genome 
equivalents (HHGE) on specific and nonspecific amplification. 
Plots of Tm as a function TTP using Bst 2.0 at (A) 0 HHGE per µL; (B) 0.01 HHGE 
per µL, C) 1 HHGE per µL, D) 100 HHGE per µL, and E) 5000 HHGE per µL; and 
using Bst 3.0 at (F) 0 HHGE per µL, (G) 0.01 HHGE per µL, H) 1 HHGE per µL, I) 
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100 HHGE per µL J) 5000 HHGE per µL in the presence of template (blue) and NTC 
(red). N = 3 for all conditions, except Bst 3.0 at 0 and 100 HHGE per µL in the 
presence of template, where N = 6. 
 
We next asked how background hgDNA impacts specific and nonspecific amplification 
quantitatively. We categorized amplification events as specific and nonspecific based on Tm 
as previously. First, we asked: Is there a relationship between fraction of template molecules 
amplified in dLAMP and amplification time? We then determined the total number of 
template copies loaded into a chip relative to the copies measured by ddPCR. If amplification 
initiation is stochastic, as observed in Figure 7.5F and Figure 7.6A-B, does longer assay 
time increase ”efficiency” and thereby improve LOD when using Tm (as seen in Figure 
7.7C,F)? We observe that for Bst 2.0, a large number of partitions amplify at in the first 11.5 
min, followed by a second phase after 20 min where additional partitions amplify with lower 
frequency (Figure 7.9A). The mode TTP for concentrations less than 5000 HHGE per µL 
was ~11.6±0.2 min (Table 7-8, Figure 7.20A, Figure 7.21C). After the mode TTP, the 
frequency of observing specific amplification in the absence of HHGE decreases from a 
maximum frequency of 1.2±0.1% copies detected per 30 sec to a lower average frequency 
of 0.23±0.04 % copies per 30 sec from 20 to 90 min (Figure 7.9A). For Bst 3.0 (Figure 
7.20A), we observe a similar trend temporally, though mode TTP was at least 2 min slower 
and had greater variability than Bst 2.0 (Table 7-8, Figure 7.20B, Figure 7.21D). Further, 
Bst 3.0 consistently amplified fewer target molecules than Bst 2.0 at all time points. This 
highlights the stochastic nature of amplification using LAMP and the importance in choice 
of enzyme on sensitivity. In theory, assays employing Tm could be run until all partitions 
amplify as either a false or true positive. Allow all partitions to amplify would give the 
highest possible number of target copies amplified and lowest possible LOD when using Tm 
in the final assay. 
Second, we asked, what is the impact of hgDNA on efficiency as a function of time? For 
both Bst 2.0 and 3.0 (Figure 7.19A, Figure 7.20A), when comparing within a given enzyme, 
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we observed that the fraction of copies detected, and the moment the majority of reactions 
initiate, were indistinguishable for concentrations less than 5000 HHGE per µL. At 5000 
HHGE per µL, a decrease in the fraction of copies detected and a delay in amplification 
initiation was observed (see also Figure 7.21C,D). Bst 2.0 had a mode TTP of delay of 4.7 
min to 16.3±2.7 min, whereas in Bst 3.0, the mode TTP was 17.2±2.1 min at 5000 HHGE 
per µL (Table 7-8, Figure 7.21). Thus, high concentrations of hgDNA may suppress specific 
amplification. 
Third, we asked, what is the impact of hgDNA and time on nonspecific amplification? For 
Bst 2.0, we observed consistent nonspecific amplification products with high and low Tm, 
regardless of concentration of hgDNA. Single digital partition counts were observed at low-
Tm nonspecific amplification in both the presence of template and the NTC and independent 
of hgDNA concentration (Figure 7.19B-C). The fraction of partitions generating a false-
positive amplification at low Tm was less than 3.3x10-4 through 45 min (i.e. 7 or fewer events 
in 20,000 partitions per chip). Similarly, partition counts of high-Tm nonspecific 
amplification are <10 per chip until 45 min. After 90 min, high-Tm nonspecific amplification 
is more prevalent than low-Tm nonspecific amplification, and the reactions finish with fewer 
than nonspecific 260 counts in 20,000 partitions corresponding to a false-positive fraction of 
1.3 x 10-2. One exception is the nonspecific high-Tm amplification in the absence template 
and HHGE. This condition appears to have lower nonspecific background than other 
conditions. We collected each replicate on separate days and were able to observe the 
experimental variability between the presence and absence fo template, which might be 
otherwise lost when examining the NTC alone. This experiment emphasizes the advantage 
of determining nonspecific amplificaiton using Tm from the same experiment as specific 
amplification is counted. At low background rates, such as when using Bst 2.0, inherent 
variability exists in the false-positive fraction and can impact LOD. Meauring nonspecific 
amplificaiton from within an experiment eliminates the assumption that the false-positive 
rate remains identical to the NTC or between experimental runs. 
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For Bst 3.0, nonspecific amplification was variable, but tended to be fewer for higher 
concentrations of hgDNA. At any given time, high-Tm nonspecific amplification was on 
average ~30 fold more likely to occur than a low-Tm nonspecific product. At 45 min, low-
Tm nonspecific amplification had false-positive fraction less than 3.1x10-3 (62 or fewer 
events per chip), amplification events with high Tm had a false-positive fraction less than 
1.9x10-2 (386 or fewer events per chip). At the completion of the experiment, high-Tm 
nonspecific amplification events account for as much as 35% of the total partitions per chip; 
a value exceeding the total observed true-positive events. In these scenarios, utilization of 
Tm to identify true and false amplification will be critical to successful quantification of 
target analytes. 
For this CT primer set, both Bst 2.0 and Bst 3.0 similarly demonstrate that the presence of 
high concentrations of hgDNA may suppress the likelihood of nonspecific amplification 
occurring. In general, for this primer set and target, we find that Bst 2.0 performs significantly 
better than Bst 3.0 as a consequence of having higher probability of detecting a target 
molecule and low likelihood of generating a nonspecific amplification event. 
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Figure 7.9: Quantification of the impact of hgDNA on specific and nonspecific 
amplification using Bst 2.0 a as a function of time. 
(A) Plot of the % copies detected (specific amplification) as a function of time. (B-
C) The fraction of partitions with nonspecific amplification with Tm less than the 
specific amplification in the NTC (B) and in the presence of template (C) as a 
function of time. (D-E) The fraction of partitions with nonspecific amplification with 
Tm greater than the specific amplification in the NTC (D) and in the presence of 
template (E) as a function of time. Panel (A) is available in tabular form as 
Supplementary Table 7-9. 
 
Fourth, we asked, is maximum rate impacted by the concentration of hgDNA? We 
hypothesize that background hgDNA may compete for the binding site of the polymerase 
with the target DNA or generate competing amplification events and thus, decrease the 
maximum observed velocity in a given partition. This phenomena would be challenging to 
untangle in bulk. We find that maximum rates are similar for a given enzyme, until 5000 
HHGE per µL for Bst 2.0 (Figure 7.21A), and above 100 HHGE per µL for Bst 3.0 (Figure 
7.21B). Thus demonstrating that high concentrations of HHGE may slow the rate of 
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amplification. Furthermore, in general, and echoing the conclusions of Figure 7.6G,I, 
we observe that Bst 2.0 has faster maximum rate than Bst 3.0, regardless of the hgDNA 
concentration. 
Fifth, we asked, how is LOD impacted by the concentration of hgDNA? For Bst 2.0 (Figure 
7.21E), the LOD at a given time was similar for concentrations less than 5000 HHGE per 
µL. Meanwhile, the LOD in the presence of 5000 HHGE per µL was slightly worse as 
evidenced by the detection of fewer target molecules (e.g. 0.7 vs 0.5 cp/µL at 45 min). As 
previously, incorporation of HRM into the final assay does not impact the LOD when using 
Bst 2.0. When using Bst 3.0 (Figure 7.21F) and HRM to remove nonspecific amplification, 
LOD tracks with the number of true-positive events. Thus, LOD becomes worse when 
efficiency is lower (i.e., at 5000 HHGE per µL). Similarly, when HRM is not incorporated 
in the assay, higher concentrations of HHGE tend to result in a worse LOD. However, at 
long amplification times, high concentrations of HHGE suppress nonspecific amplification 
more than specific amplification, resulting in LOD enhancement relative to low 
concentrations of HHGE. 
Cumulatively, these data show high background DNA may reduce the probability of 
detecting a specific molecule (analytical sensitivity), suppress the false-positive fraction 
(analytical specificity), reduce the velocity of amplification, and delay the start of 
amplification at clinically relevant concentrations of hgDNA. Thus, we conclude background 
hgDNA impacts dLAMP for this primer set. Generally, investigators should examine their 
own primer sets in the presence of high concentrations of hgDNA and take caution when 
examining clinical samples with high leukocyte concentrations (as reported by urinanalysis). 
For example, CT infection is not inherently associated with high concentrations of 
leukocytes, and many infections are asymptomatic. Ultimately, these experiments 
underscore the value of quantifying nonspecific amplificaiton variability, using HRM, from 
within the same experiment as a target is quantified. Because nonspecific amplificaiton is 
measured within a given sample, one no longer needs to assume it remains identical to the 
NTC or between experimental runs. 
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Figure 7.10: Quantification of the impact of hgDNA on specific and nonspecific 
amplification using Bst 3.0 as a function of time. 
(A) The percentage copies detected (specific amplification) as a function of time. (B-
C) The fraction of partitions with nonspecific amplification with Tm less than the 
specific amplification in the NTC (B) and in the presence of template (C) as a 
function of time. (D-E) The fraction of partitions with nonspecific amplification with 
Tm greater than the specific amplification in the NTC (D) and in the presence of 
template (E) as a function of time. Panel (A) is available in tabular form as 
Supplementary Table 7-10. 
 
Conclusions 
We predict that the combination of HRM and real-time dLAMP will be invaluable for 
answering many questions across a wide variety of applications, and thus our approach was 
designed to be accessible to most standard labs. We employed commercial chips for 
digitization, a commercial thermoelectric unit for heating and cooling, a commercial 
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microscope for optical analyses, and we made our data-processing script freely available. 
Our intention was to design an accessible system with readily available components to enable 
others to access the advantages of digital microfluidics to study and optimize primer sets, 
enzymes, and reaction conditions of interest to them. We predict these capabilities will be 
particularly valuable for people working with variable sample matrixes, high background 
DNA, poorly performing primer sets, or poorly performing enzymes. 
We derived four major lessons from this study. First, LAMP can produce nonspecific 
amplicons with high Tm. The formation of these nonspecific amplicons occurs from the 
interaction of multiple primers and the use of a polymerase with template switching ability, 
terminal transferase activity, and lacking 3′–5′ exonuclease activity. Interaction of primers 
may lead not only lead to rising background fluorescence (37), but to spontaneous 
exponential amplification as well. Primer design and enzyme selection therefore should be 
judicious to avoid formation of hairpins within primers, as well as microhomology at the 3’ 
with any other primer, in order to prevent nonspecific amplification. 
Second, HRM in LAMP is a useful method for differentiating specific and nonspecific 
amplification events. Digital experiments measure the fate and rate of each template, in 
contrast, bulk experiments are biased towards early amplification events. The combination 
of dLAMP and HRM allows observation of many amplification events and assignment of 
the nature of that amplification as true or false. Further, dLAMP with HRM quantifies 
nonspecific amplification experimentally in the presence of specific amplification, 
eliminating the assumption that incidence of false positives in the presence of template 
remains identical to the NTC or between experimental runs. 
Third, by differentiating specific and nonspecific amplification, HRM is helpful in 
determining the combination processing and assay parameters that will lead to the best LOD 
in a digital assay. When HRM is incorporated into a dLAMP assay, true and false-positive 
amplification events can easily be separated. LOD is improved by elimination of nonspecific 
background and thus becomes dependent on the number of molecules that amplify (i.e. 
amplification efficiency or fraction of copies detected), without dependence on the incidence 
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of false positives. In contrast, if HRM were employed in a bulk reaction, the LOD would 
still be limited by the competition between specific and nonspecific amplification (which 
amplifies first) and would require a high number of trials to achieve sufficient statistical 
power. Importantly, even when HRM will not be used in the final assay, it can still be 
incorporated during the assay-development stage to improve the assay’s LOD by 
determining the optimal choice of parameters based on rate, TTP, final intensity, or any 
combination of these parameters. Furthermore, our mathematical description of LOD is 
generalizable to other amplification methods that are measured in digital and can separate 
specific and nonspecific amplification. 
Fourth, high levels of nonspecific host gDNA suppress analytical sensitivity and specificity, 
reduce amplification velocity, and delay the start of amplification. However, low-to-
moderate levels of nonspecific host gDNA do not impact the analytical specificity or 
sensitivity of dLAMP. We ran our assays through clinically relevant concentrations of 
background DNA and did not observe interference until the upper range of concentrations 
expected to cause interference to demonstrate the clinical utility of real-time dLAMP with 
HRM. 
Real-time dLAMP with HRM will enable the mechanistic optimization of primers and 
myriad assay conditions (such as buffer, Mg2+, and reaction temperature). Because real-time 
dLAMP with HRM reveals the incidence of nonspecific amplification products with high 
and low Tm as a function of time, dLAMP with HRM can be used to investigate approaches 
that will eliminate different nonspecific products. For example, fast or early nonspecific 
events in digital may indicate primers or conditions that will be especially vulnerable to 
failure in a bulk reaction. Thus, real-time dLAMP with HRM could be used to design primers 
that will suppress nonspecific amplification in bulk, by generating only nonspecific 
amplicons that occur at slow rates and late TTP. 
Future efforts should investigate the combination of real-time dLAMP (and other digital 
isothermal amplification technologies) and HRM as a way to increase multiplexing of 
dLAMP when using a single reporter. In PCR, HRM has been used to differentiate among 
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multiple amplification products by measuring differences in Tm (42-46), with 
applications that include among others multiplexed pathogen identification and antibiotic 
susceptibility testing. Finally, studies with clinical samples should be performed using the 
dLAMP with HRM method to understand the carryover effects from relevant matrices. 
 
Data Availability 
The complete sequencing data generated during this study are available in the National 
Center for Biotechnology Information Sequence Read Archive repository with the 
BioProject ID: PRJNA574638. 
The MATLAB script described here has been deposited in the open-access online repository 
GitHub and may be accessed using the following direct link:  
https://github.com/IsmagilovLab/Digital_NAAT_2Ch_MeltCurve_Analyzer 
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Primer Sequences 
Primers had the following sequences: 
 BIP: AAG CAC GCG GAC GAT TGG AAA AAA GCG GAT TTG CCT AAC CG 
 BOP: CGA ACA TTC CCC TTG ATC GC 
 FIP: GCT GCT CCA TCG TCT ACG CAG TTT TGC TCG TCT TCC CTG GGT T 
 FIPShort: GCT GCT CCA TCG TCT ACG CAG TTT TGC TCG TCT TCC CTG GG 
 FOP: CCA AGG TTT CCA GGG TCA A 
 LoopB: CCG TAG AGC GAT GAG AAC G 
 LoopF: GCC TCA ACT TAG GGG CCG 
 
Fabrication of thermoelectric unit mount 
Starting from 1/4" thick aluminum stock; a block was squared and milled to 58x61 mm and 
slightly less than ¼” thick. Both the side in contact with the microfluidic chips and with the 
thermoelectric unit were finished with a single pass of a ½” fly bit to generate a mirror finish. 
Four holes for screws holes were counter bored to ensure the heads remained below the 
surface of the block and mounted to a 1.1 °C/W Half Brick DC Converter Heat Sink 
(AAVID, via Newark Electronics, 241214B92200G) using four #6-32, 5/8” long screws. A 
7/16” hole was clearance drilled into the side of the aluminum to ¾” depth and a thermistor 
(TE Tech, MP-3002) was inserted and mounted using Thermal Compound (Arctic Alumina 
Silver Ceramic Polysynthetic). The thermoelectic unit was mounted between the aluminum 
block and heat sink using Thermal Compound and the screws finger tightened. Desired 
torque was calculated to be 0.89-7.175 ft*lbs per screw (total pressure 70-170 psi). 
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Once mounted, a QuantStudio chip was place on top of the block (to mimic total load on 
the instrument) and the PID tuned following instructions from the TC-720 Controller manual. 
With I&D set at zero; P was found to oscillate at 1.35 at 70 °C (the expected dLAMP 
temperature). The oscillation period was 6 seconds. Thus, the Proportional BW was set at 
1.7*1.35 = 2.3. The Integral gain was calculated as I = 1.2/T in min = 1.2/0.1 = 12. The 
derivative gain was calculated as 0.075xT=0.075*0.1= 0.0075 min. With these settings, the 
observed temperature overshoot from room temperature to 70 °C at maximum output was 
0.05 °C, whereas at 95 °C the observed overshoot was 1 °C. 
The ability of the embedded thermocouple to accurately assess temperature of the aluminum 
block was verified with an independent K-type mini-thermcouple read through a General 
IRT659K [IR] Thermometer. 
 
MATLAB script 
The MATLAB script works as follows: First, the TIF stack containing 2-channel images of 
the LAMP amplification and melt curve along with a .txt file containing temperature over 
time data are loaded into memory. We used the first image of the ROX channel to define all 
of the partitions. A custom iterative thresholding algorithm was applied to detect partitions 
despite lighting non-uniformities, imaging artifacts, or possible debris. The size of a well was 
pre-defined using the areaBound parameter. For our study, we defined partitions as having 
areas between 20 to 45 pixels. The algorithm scans through increasing threshold sensitivities, 
applies the partition size filter, and combines the results into a final mask. This is repeated 
for each image in the stack. 
In order to track the partition intensities over time, it is important to track the same partition. 
This is challenging because partition move due to thermal expansion during the LAMP 
heating and melt curve, partitions touching the edge of the image may appear or disappear 
from the field of view, and bubbles during the melt curve can distort image. To account for 
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this, we applied the built-in MATLAB labeling function to the first image of the stack to 
assign a unique number to each partition. We assume that a partition will not translate a 
distance greater than its radius from frame to frame. Using this, we find the centroid of each 
labeled partition in the first frame and overlay this with the second frame. If a labeled centroid 
overlaps a partition, the entire partition is assigned the label. If not, the partition was not 
found and was discarded from the analysis. This method is repeated for the centroids of the 
second frame onto partition of the third frame and so on. On average, more than 18,000 of 
the 20,000 partitions were attained for analysis, which is plenty for statistical confidence. 
To analyze partitions, the intensity of each partition is averaged for each frame and plotting 
against time for the LAMP curve. The data is smoothed using a Gaussian blur, using the 
gaussWinSize parameter, with window size of 5 frames. The background baseline is 
subtracted from the LAMP curve. It is calculated by averaging the intensities from the six 
frames after the temperature of the experiment reached the optimal LAMP temperature. Time 
to positive (TTP) was calculated as the frame at which the intensity crossed a threshold of 
250 RFU, defined using the “threshold” parameter. The derivative of the LAMP curve was 
calculated and the maximum slope was determined for each curve. 
Partitions of interest for melt curve analysis were identified by exceeding a minimum 
intensity or slope (rate) threshold. Once selected, the average partition intensities during 
HRM were determined and smoothed similarly as for the LAMP curves. Using the 
temperature and time data from the .txt file, the melt intensities were replotted with 
temperature as the x-axis. The negative derivative of the melt curve was used to calculate the 
peak melt temperature for each partition. We have reported other processing parameters 
previously (22). 
The following processing parameters were used: 
 mask_thresh = .08:.002:.16; 
 areaBound = [20 45] Pixels; 
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 threshold = 250 RFU; 
 gaussWinSize = 5 Frames; 
 maxSlope = 200 RFU/Frame; 
 maxSlopeThreshold = 30 RFU/Frame; 
 time between Frames (“time_spacing”) = 30 sec; 
 LAMP Start (“LAMP_start”) = Frame 1; 
 LAMP End (“LAMP_end”) = Frame 185; 
 melt Curve Start (“MC_start”) = Frame 194; 
 melt Curve End (“MC_end”) = Frame 241; 
 
Propagation of LOD uncertainty 
The digital loading of molecules onto a chip is a Poisson process. However, because the 
number of counting events is large, we can assume the counting events are approximately 
normally distributed, parameterized by a mean and standard deviation, σ. When measured 
quantities are normally distributed, then the error in any derived quantities can be found with 
the following expression (46): 
  
Equation 7-3 
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In our specific scenario, the variance of the derived quantity LOD (Equation 1) can be 
expressed as: 
  
Equation 7-4 
 
 
Impact of buffer conditions on specific and nonspecific amplification and Tm 
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Figure 7.11: Amplification and melting temperature (Tm) curves of Chlamydia 
trachomatis in bulk reactions indicate enzyme sensitivity to varying buffer 
conditions. 
(A-B) Amplification curves in the presence of template (A) and Tm curves (B). (C-
D) Nonspecific amplification curves in the no-template control (NTC) (C) and the 
associated Tm curves (D).   
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Table 7-1: Summary table of LAMP time to positive (TTP) and product melting 
temperature (Tm) of Chlamydia trachomatis amplicons under a range of buffer 
conditions. 
 
 
We next wished to determine if the behavior associated with nonspecific amplification was 
inherent to the polymerase or the buffer for both Bst polymerases. Buffer composition may 
influence nonspecific amplification more than the selection of polymerase. We conducted 
bulk reactions in the presence and absence of template using the standard buffer 
compositions (Materials and Methods) and the same reactions with each polymerase in the 
opposite buffer. When we used Bst 2.0 polymerase with the Bst 3.0 buffer, amplification 
failed to occur in both the presence and absence of template. When we used Bst 3.0 
polymerase with Bst 2.0 buffer, we observed (i) an 8.6 min delay in TTP (from 16.33±0.30 
min to 24.95±0.41 min) in the presence of template (ii) earlier nonspecific amplification in 
the absence of template, and (iii) greater variation in TTP (from 37.84±1.59 min to 
30.75±7.62 min).  From these data, we concluded that the difference in nonspecific 
amplification between conditions was an issue inherent to polymerase selection.  
 
We next tested if the differences in Tm of the target amplicons were due to buffer 
components. We observed similar sequencing results for these products, but differing Tm. 
We conducted bulk reactions in the presence of template using the standard buffer 
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composition (Materials and Methods) and the same reactions with each polymerase in 
the opposite buffer. When all buffer components were switched between the polymerases, 
Bst 2.0 failed to amplify, whereas Bst 3.0 resulted in amplicons with Tm similar to Bst 2.0 in 
standard conditions (85.08±0.19 °C). We concluded the Bst polymerase produced similar 
specific products and differences in Tm were due to differences in buffer conditions.   
 
Table 7-2: List of abbreviations used in Figure 7.2, Figure 7.4. 
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Figure 7.12: Composite images of restriction digestion of Chlamydia trachomatis 
(CT) bulk amplification products. 
Digestion of specific amplification products using a D1000 DNA ScreenTape (A) 
and a D5000 DNA ScreenTape (B). Digestion of nonspecific amplification products 
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using a D1000 DNA ScreenTape (C) and a D5000 DNA ScreenTape (D). AccI and 
Hpy16II target restriction site in FIP, MseI in the specific products targets a region 
within the CT sequences, and in the presence of nonspecific amplification products 
targets the interface (synthesis across a discontinuous junction) of FIP and BIP. AciI 
and HpyCh4III target restriction endonuclease sites within BIP. 
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Figure 7.13: Illustration of a simplified mechanism for nonspecific amplification 
products in LAMP reactions. 
Structures and intermediates are labeled with numbers. Percentage abundance 
reported from Figure 7.2, Sample E2. 
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Bulk and dLAMP reactions with modified primer sets 
 
Figure 7.14: Amplification and melting temperature (Tm) curves of Chlamydia 
trachomatis (CT) in a bulk reaction using multiple primer sets show reduced 
nonspecific amplification upon elimination of primer microhomology.   
Plots of average fluorescence as a function of time during the LAMP reaction in the 
NTC (A) and the corresponding derivative plot of fluorescence as a function of 
temperature (B). N per condition = 12. 
 
Table 7-3: Time to mean positive and Tm in bulk reactions using multiple 
primer sets. 
N per condition = 12. 
 
 
We analyzed multiple primer sets (Table S3) to determine if the nonspecific amplification 
species produced in the NTC were indeed produced from a combination of primers, as 
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described by the sequencing data in Figure 7.2 and the mechanism proposed in Figure 
7.4. We also wished to test whether nonspecific amplification could occur by single primers, 
as is known to occur. We conducted bulk reactions in the absence of template using Bst 3.0 
and the standard primer mixture, FIP and BIP in combination, and the Inner Primers alone 
and compared the TTP and Tm of these mixtures. The standard primer mixture (consisting 
of Inner, Outer, and Loop primers) had nonspecific amplification at 18.3±0.7 min with 
uniform Tm of 91.0±0.0 °C. When the Outer and Loop primers were removed, leaving only 
FIP and BIP, the mixture amplified with similar TTP and Tm (18.1±1.1 min and 91.0±0.1 
°C, respectively) as the standard mixture. In contrast, using BIP alone failed to amplify within 
45 min, and FIP alone amplified much later (42.3±1.8 min) and with different Tm (91.7±0.8) 
than FIP and BIP together or the standard primer mixture. We thus concluded that both FIP 
and BIP were required to generate the nonspecific products we observed.   
The mechanism proposed in Figure 7.4 requires an interaction between BIP and FIP via 
microhomology of the 3’ of FIP. To confirm the suspected interaction between FIP and BIP, 
we removed two bases from the 3’ end of the FIP primer (hereafter FIPShort). In bulk reactions 
using FIPShort and BIP with Bst 3.0 in the absence of template, we did not observe nonspecific 
amplification within 45 min. Consequently, we concluded, some of the nonspecific 
amplification was due to an interaction of the 3’ of FIP with BIP. 
We next ran the modified primer set in digital LAMP using Bst 3.0 to improve our 
understanding of what occurs at the single-molecule level when primer microhomology is 
eliminated. We ran three chips in the presence of template and three chips in the absence of 
template, using the standard primer set (Figure 7.14A), and compared the results to the same 
experiments run with a primer set with FIPShort (Figure 7.14B). We observed a significant 
increase in the percentage of copies detected when using FIPShort (Figure 7.14C) using a two-
tailed paired t-test (P = 0.002), without a difference in TTP (Table 7-3). The use of FIPShort 
did not significantly impact nonspecific amplification products with low Tm in any pairwise 
ANOVA comparison (Figure 7.14D,E). However, we observed a 10-100 fold decrease in 
nonspecific products with high Tm (Figure 7.14F, G). In the absence of template, 
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nonspecific amplification was reduced (Figure 7.14E); whereas in the presence of 
template, the number of nonspecific amplification products with high Tm was significantly 
lower at all time points (Figure 7.14G).  
 
 
Figure 7.15: Digital, single-molecule plots of specific and nonspecific 
amplification for multiple primer sets of Chlamydia trachomatis show 
significantly reduced nonspecific amplification with high melting temperature 
(Tm) upon elimination of primer microhomology. 
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(A-B) Individual amplification events using Bst 3.0 and a primer mixture where FIP 
is replaced with FIPShort (A) and the standard primer mixture (B). Blue indicates 
amplification events in the presence of template; red indicates amplification in the 
absence of template (NTC). A box is placed around events that occur within 45 min, 
corresponding to the bulk amplification time. Partitions are rendered at 50% opacity. 
(C) Plot of the percentage of copies detected (specific amplification) as a function of 
time. (D-E) The fraction of partitions with nonspecific amplification with Tm less 
than the specific amplification as a function of time in the absence of template (D) 
and in the presence of template (E). (F-G) The fraction of partitions with nonspecific 
amplification with Tm greater than the specific amplification in the NTC as a 
function of time (F) and in the presence of template (G). Within panels D-G, pairwise 
P-values by t-test are written above each time point. 
 
Table 7-4: Digital, single-molecule comparison of specific and nonspecific 
amplification for multiple primer sets of Chlamydia trachomatis using Bst 3.0. 
 
 
The decrease in nonspecific products with high Tm, upon elimination of the microhomology 
between FIP and BIP, is consistent with the formation of a nonspecific product predicted by 
the proposed mechanism in Figure 7.4. However, the continued existence of nonspecific 
products indicates it is possible to form a variety of nonspecific products. Our results indicate 
that nonspecific products with high-Tm occur even with further primer optimization.  The 
formation of products with high Tm is consistent with our proposed mechanism of branched, 
mesh-like network. Further investigation should determine if this problem is ubiquitous, even 
in optimized systems.  Additionally, the delay in nonspecific amplification in digital could 
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explain why we did not observe these products in bulk (and thus cannot sequence them).   
 
We believe the mechanism described in Figure 7.4 is potentially applicable to other primer 
sets. Amplification observed by FIP alone may follow a similar amplification scheme to 
Figure 7.4 via homo-dimerization (Figure 7.16A), non-templated synthesis, hairpin 
dimerization (Figure 7.16B), and eventually dumbbell-like amplification (Figure 7.16D,E). 
We observe products consistent with these structures in some of the sequencing data (e.g. 
Figure 7.2, Well E1, which contains elevated rcFIP_pFIP and rcpFIP_FIP). 
 
 
Figure 7.16: Illustration of a mechanism for amplification of FIP alone. 
After 3’ extension of a FIP homodimer (A), random nucleotides may be incorporated 
(orange) resulting in self-complimentary hairpins (B). The extension of these hairpins 
products produce (C): top strand, FIP-prcFIP-rand-pFIP-rcFIP. Upon melting, two 
self-amplifying dumbbell structures can be produced (D), and undergo further 
LAMP-like amplification primed by FIP (E). 
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Table 7-5: Table group of NGS of Randomer inserts within Bulk Sample E1. 
 
 
Table 7-6: Table group of NGS of Randomer inserts within Bulk Sample E2. 
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Table 7-7: Table group of NGS of Randomer inserts within Bulk Sample F1. 
 
 
Does removing outliers impact the distribution of maximum rates? 
Occasionally, we observed outlier data points in maximum rate. We asked what caused one 
point (green circle, max rate 56 RFU, Figure 7.12A) to separate from the majority of the 
data (17 to 30 RFU/30 sec), if these points were common, and if these points were likely to 
misrepresent the max rate data. We determined the individual trace corresponding to the 
outlier amplification event (green trace, Figure 7.12B) and observed that the maximum rate 
for this partition was at 52.5 min, corresponding to a fluctuation in the plateau phase of 
amplification (dotted line). 
We hypothesized that the maximum rate should occur at the observed initial moment of 
exponential amplification, often slightly before the fluorescence TTP threshold (250 RFU) 
is reached. To test this hypothesis, we determined the frame (2 per minute) where the 
amplification trace reached the TTP. From this frame, we subtracted the frame where 
maximum rate was calculated and plot it against maximum rate (Figure 7.12C). Values 
greater than zero represent partitions where the frame the maximum rate occurs before the 
fame of TTP, while negative values occur when fame the max rate occurs is after the frame 
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of TTP. We draw a vertical line separating partitions that occur more than 15 min after 
the TTP (left), from all other partitions. 
For the case of Bst 2.0, we observed that the mode max rate occurred before the fluorescence 
TTP by 1 frame (30 sec). Of the 9099 partitions exceeding the 250 RFU threshold, 821 
(9.02%) were more than 15 min after the TTP. We expect these partitions to have max rate 
within the noise of the plateau phase. 
A similar trend was observed for Bst 3.0 (Figure 7.12D). With Bst 3.0, the mode max rate 
occurred 2 frames before the fluorescence TTP (1 min). This value is later than Bst 2.0 and 
is consistent with a slower max rate for Bst 3.0 than for Bst 2.0. Of the 24,466 partitions 
reaching the 250 RFU threshold, 1113 (4.55%) were more than 15 min after TTP. 
To determine whether removing the partitions with max rate more than 15 min after the TTP 
impacted the distribution of enzymatic rates, we plotted the fractional cumulative distribution 
function (CDF) of max rate for all partitions (blue), and the same fractional CDF removing 
those points more than 15 min after the fluorescence intensity based TTP (red) for Bst 2.0 
(Figure 7.12E) and Bst 3.0 (Figure 7.12F). Performing a non-parametric based 
Kolmogorov–Smirnov test to compare the exclusion of partitions with late max rate indicated 
non-significance between the two CDFs (Bst 2.0 P=0.3255, and Bst 3.0 P = 0.1236). Thus, 
we concluded removing late max rate data from the distributions did not impact the CDFs, 
and therefore does not significantly impact the integrity of our data reporting. 
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Figure 7.17: Removing outlier data in max rate does not significantly impact 
summary data. 
Plot of observed melting temperature (Tm) as a function of maximum rate, with a 
possible outlier point highlighted in green (A). Fluorescence traces of individual 
partition amplification events, with the possible outlier partition’s trace highlighted 
in green (B). The maximum rate for the green trace occurred at 52.5 min (dotted line), 
corresponding to a fluctuation in the plateau phase of amplification. Plot of maximum 
rate as a function of the difference between the TTP and max rate frames using Bst 
2.0 (C) and Bst 3.0 (D). Partitions lower than the dashed vertical line represent 
partitions whose max rate occurred more than 15 min after the TTP frame. Fractional 
Cumulative Distribution Plots of maximum rate for Bst 2.0 (E) and Bst 3.0 (f), where 
the CDF includes all possible partitions (blue), and the same fractional CDF 
removing those points more than 15 min after the Fluorescence Intensity based TTP 
(red). 
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Figure 7.18: Histogram plots of Tm after 90 min of digital LAMP targeting CT 
in the presence of template (blue) and NTC (red) can be used to distinguish 
specific from nonspecific amplification. 
Tm of amplification using Bst 2.0 (A) and Bst 3.0 (B). Dashed lines indicates the 
upper and lower bounds used for separating specific and nonspecific amplification. 
Bst 2.0: 88.5-90.3°C, Bst 3.0: 91.25-92.75 °C. Bin width in both graphs 0.5 °C, with 
the (+) template left of the tick and NTC right of the tick. NTC is illustrated with red 
bars, and the presence of template with blue bars. 
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Figure 7.19: Receiver operating characteristic (ROC) curves using HRM to 
determine optimal performance of dLAMP assays. 
(A) ROC curve using Bst 3.0, plotting the fraction of true positives detected versus 
the fraction of false positives detected using a threshold on max rate. (B) ROC curve 
using Bst 3.0, plotting the fraction of true positives detected less than 40% versus the 
fraction of false positives detected less than 20% using a threshold on maximum rate. 
Arrow indicates corresponding LOD. (C) ROC curve using Bst 3.0, plotting the 
fraction of true positives detected versus the fraction of false positives detected using 
a threshold on final intensity of the partition. (D) ROC curve using Bst 3.0, plotting 
the fraction of true positives detected less than 10% versus the fraction of false 
positives detected less than 10% using a threshold on final intensity of the partition. 
Arrows indicate final-intensity thresholds of >2000 RFU and >1300 RFU. (E) ROC 
curve using Bst 3.0, plotting the fraction of true positives detected versus the fraction 
of false positives detected using a threshold on TTP. Arrow indicates LOD. (F) ROC 
curve using Bst 2.0, plotting the fractions of true versus false positives detected using 
a threshold on TTP. 
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Summary Data of Mode TTP 
Table 7-8: Time to mode positive in minutes. 
N=3 chips per set. Human Haploid Genome Equivalents (HHGE) are per microliter. 
 
 
 
Figure 7.20: Time to mode positive for Bst 2.0 (A) and Bst 3.0 (B) under variable 
concentrations of host human genomic DNA (hgDNA). 
Human Haploid Genome Equivalents (HHGE) are per microliter. 
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Figure 7.21: Evaluation of the impact of gDNA on assay performance. 
Fractional cumulative distribution function (CDF) of maximum rates of 
amplification using Bst 2.0. (A) and Bst 3.0 (B) CDFs are plotted as the sum of 
replicates. Distribution plot of time to fluorescence threshold for Bst 2.0 (C) and Bst 
3.0 (D) using arithmetic mean. LOD as a function of time using Bst 2.0. (E) and Bst 
3.0 (F). 
 
Table 7-9: Tabular form of % copies detected from Figure 7.9 using Bst 2.0. 
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Table 7-10: Tabular form of % copies detected from Figure 7.10 using Bst 3.0. 
 
 
Caption for 4D videos 
Videos plot the TTP, max rate, final intensity, and Tm data of both specific and nonspecific 
amplification reactions using either Bst 2.0 (Video 1) and using Bst 3.0 (Video 2). Time to 
positive (TTP), max rate, and melting temperature (Tm) are plotted on the axes; final 
intensity is indicated by the color of each data point (scale provided in Figure 7.6Q-R).  
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8 .  C h a p t e r  8  
ADDITIONAL TOOLS FOR SAMPLE-TO-ANSWER POINT-OF-
CARE NUCLEIC ACID AMPLIFICATION TESTING 
 
Introduction 
The development of a fully-integrated sample-to-answer point-of-care NAAT which meets 
all of the ASSURED criteria remains a critical challenge for the diagnostics field. NAAT is 
inherently complex, and to realize a fully-integrated sample-to-answer point-of-care 
diagnostic requires many components which can perform multiple steps: sample transfer, 
nucleic acid extraction, nucleic acid amplification, readout, and analysis. Each component 
must fulfill the ASSURED criteria individually (e.g. Affordable, User-friendly, Rapid, 
Robust, Equipment-free, Deliverable). These characteristics must further be retained when 
these components are combined, and the fully-integrated test must additionally be Sensitive 
and Specific. A system which integrates of all of these components while meeting 
performance requirements has yet to be realized.  
In this chapter, I develop a fully-integrated sample-to-answer point-of-care NAAT kit.1 The 
test kit is composed of the following components: (1) meter-mix device presented in Chapter 
4, (2) sample preparation module, (3) amplification module, (4) cell-phone readout, (5) 
automated MATLAB image processing, and (6) an automated base station. I will elaborate 
on the design of each component (with the exception of the meter-mix device) followed by 
an evaluation of integrated device performance.   
 
Sample preparation module 
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EJ designed the simultaneous pre-pressurization pumping lid approach and contributed 
to sealing surface improvements. Created the 6x pressure sensor capable of measuring all 
chambers simulataneously using an adaptation of David Selck’s previously developed 
LabView script. 
Daan Witters, Stefano Begolo, and Feng Shen all contributed to the design of the sample 
preparation module. 
 
Design 
The sample preparation module takes lysed sample (mixed with Zymo buffers DNA/RNA 
shield and DNA/RNA lysis buffer) as input. Both DNA and RNA are purified on a silica 
column using NA extraction buffers and eluted with either water or Tris-EDTA (TE) buffer. 
There are three innovations which improve the performance of the sample preparation 
module over existing centrifugation protocols. First, the sample preparation module uses an 
additional two-phase wash buffer as presented in Chapter 2, which improves extraction 
purity. Secondly, the sample preparation module uses positive pressure to push liquids 
through the column rather than a centrifugation. This allows the sample preparation module 
to be smaller, more portable, and 3D-printed. Lastly, the sample preparation module uses 
SlipValve technology, which reduces user interactions resulting in a quick 4-min extraction.  
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Figure 8.1: Sample preparation module design 
(left) Solidworks exploded view showing pumping lid to generate and hold positive 
pressure, chamber layer to hold (1) lysed sample, (2) Zymo viral wash buffer, (3) 1-
undecanol two-phase wash, (4) air push, (5) elution, and (6) negative control, rotating 
layer which houses the SlipColumn, and a waste layer to capture flow-through waste. 
(right) Schematic showing the steps to use the sample preparation module. The user 
adds the lysed sample (step A), pushes down the pumping lid (step B), and presses 
start (steps C-E).  
 
Pressurization and SlipValving 
The positive pressurize mechanism works by pushing the pumping lid onto the chamber 
layer. In this moment, all 6 chambers are simulataneous pre-pressurized and the pumping lid 
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locks into place due to the snap-fit feature. Because the chambers are well-sealed, the 
pressure in each chamber is maintained over the course of the 4 min extraction. When the 
user presses start, the motor of the base station activates the rotating layer, bringing the 
SlipValve (containing the silica column) below each chamber sequentially. Once the 
SlipValve transits below the first chamber where the lysed sample is stored, the lysed sample 
pushes through the silica column thereby binding DNA and RNA to the column. The motor 
pauses to allow all of the lysed sample to pump through to the waste layer, and then the motor 
automatically rotates again to the next position to pump through wash buffer. This repeat 
until the elution step, and the elution containing purified DNA and RNA routes automatically 
to the amplification module. 
 
Holding Pressure Validation 
To ensure that pressure is held in each chamber, I developed a pressure sensor capable of 
measuring the pressure in all six chambers in real-time. The pressure sensor software was 
developed in LabView (adaptation of program originally programmed by Dr. David Selck), 
and the pressure sensors were physically wired on a solderable prototyping board. After 
placing the pumping lid, we observed that the pressure held constant for at least 30 min. 
When the base station operates the rotating layer according to the pre-programmed rotation 
schedule, a pressure drop is observed at the appropriate time (Figure 8.2). 
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Figure 8.2: Sample preparation module holding pressure validation  
Four repeated experiments showing the initial pre-pressurization of six chambers by 
placing the pumping lid onto the sample preparation module. The motor 
automatically moves the rotating layer and SlipValve below each chamber at the pre-
programmed time.  
 
Parallel-filled amplification module 
EJ designed the parallel-filling to dead-end hydrophobic membrane strategy. EJ contributed 
to material selection and assembly practices 
DW (Daan Witters) contributed to material selection and assembly practices 
 
Design 
Here we present the design for an easy-to-fabricate 5-plex uL volume SlipChip for running 
NAAT reactions. There are 2 inlets, one for the test which accesses 3 of the 5 wells and one 
for the control which accesses the remaining 2 wells. The bottom plate have 5 wells where 
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lyophilized reagents (LAMP) are pre-stored. The top plate has channels from the inlets 
to each well and from each well to a separate outlet. The outlet has a hydrophobic membrane 
to allow air to escape but blocks the flow of fluid. This strategy allows parallel filling 
whereby a single input fluid fills many wells at once, each containing its own set of 
lyophilized reactants. After well filling, the device is slipped rotationally to isolate each well. 
With this design, we expect no cross-contamination of rehydrated amplification reagents 
between different wells. Features on the outer edge of the device constrain slipping to 
rotation. 
 
Figure 8.3: Parallel filling of amplification modules. 
(A-B) Solidworks 3D models of parallel filling amplification modules in (A) 
unslipped and (B) slipped positions. (C) Parallel filling of the amplification module 
integrated with multi-chamber sample preparation module and filled with green 
(representing eluent) and blue (representing negative control) dyes. The multi-
chamber pumping lid from the sample preparation module provides the filling 
pressure. (D) LAMP reagents lyophilized in the wells of the bottom plate. 
 
Fabrication and assembly 
The geometry of the amplification module was designed in CAD software and fabricated 
using a combination of laser cutting (Epilog Zing 24) and multi-material 3D printing. There 
are 4 primary components: (i) top plate, (ii) bottom plate, (iii) inner and outer pins, and (iv) 
inner and outer clamps. A layer of 3M 300 LSE was laminated on the top and bottom side of 
 
 
295 
the bottom plate. The top (2.1 mm) and bottom plates (1.5mm) were laser cut from cast 
acrylic (McMaster), using vector cutting to generate the outline, wells, and outlets and using 
engraving for the channels. A laser-cut donut of 0.175mm PMMA (Goodfellow Cambridge 
Limited) was attached to the bottom 300LSE on the bottom plate. A thin coat of Krytox GPL 
205 was applied by smearing Krytox between two glass slides and stamping the top 300LSE 
of the bottom plate with Krytox. The appropriate LAMP mix (see below) was added to each 
respective well and bottom plates were lyophilized overnight. The bottom side of the top 
plate (without 300LSE) was smeared with a thin layer of Krytox GPL 205. A layer of pre-
cut 300LSE that matches the top plate pattern was attached to the top plate. 3 mm discs 
polypropylene hydrophobic membranes (Sterlitech, 0.22 micro) were applied to the top 
300LSE of the top plate to cover the well outlets.  
For lyophilization, the 2.5% mannitol was added to the LAMP reaction, glycerol-free Bst 2.0 
and AMV RT were used, and the addition of water was minimized. The AdVantage Pro EL 
lyophilizer shelves were set to precool at -50C with frost seal. Bottom plates were placed 
onto a tray and inserted into the lyophilizer. The lyophilizer performed thermal treatment by 
holding -50 °C with 75 min ramp and 60 min hold. Drying had 4 steps: -45 °C with 0 min 
ramp, 840 min hold at 100 mTorr, -20 °C with 60 min ramp, 5 min hold at 100 mTorr, 0 °C 
with 60 min ramp, 5 min hold at 100 mTorr, and 25 °C with 120 min ramp, 60 min hold at 
100 mTorr. Product was held at 25 C and 100 mTorr until removed from the lyophilizer. 
Following lyophilization, bottom plates were removed from the lyophilizer under dry 
nitrogen and placed into a dry nitrogen glove bag. Bottom and top plates were sandwiched 
together, and mostly assembled except the final clamping step using the 3D printed inner and 
outer pin and clamp sets. Nearly assembled amplification modules were stored with desiccant 
and vacuum sealed (Weston Pro-2300) under dry nitrogen in mylar bags (4 mil).   
 
Validation 
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To validate the stability of the lyophilized reagents in the amplification module, purified 
nucleic acids from Neisseria Gonorrhoeae at 500 CFU/mL and nuclease-free water were 
used to rehydrate the lyophilized reagents on the amplification module. Real-time imaging 
was used to monitor the RT LAMP reaction in the amplification module. As shown in Figure 
8.4, the wells containing purified nucleic acids (“positive wells”) displayed increased 
fluorescence, with a TTP of 13.6 min, compared with 11.6 min when using standard liquid 
LAMP reagents in an ECO plate. The observed 2 min delay is presumably due to the delay 
in heating of reagents in our amplification module (~90 sec) compared with the standard 
ECO-machine (Illumina) heating elements.  
 
 
Figure 8.4: (A) Amplification data and (B) fluorescence image showing real-time 
imaging of an amplification module that contained lyophilized reagents for the 
detection of NG. 
The positive wells of the amplification module were loaded with purified nucleic 
acids from NG, whereas the negative wells were loaded with nuclease-free water. 
The time-to-positive for the positive wells was 13.6 min, whereas there was no 
significant increase in fluorescence intensity in the negative wells.  
 
 
 
297 
Cell-phone readout and automated analysis  
EJ designed and printed the cell-phone dongle and programmed the MATLAB code. 
 
A cell-phone dongle was designed, 3D printed, and painted black to block out ambient light. 
The sample preparation and amplification module assembly directly connects to the cell-
phone dongle to allow fluorescent readout of the wells. The cell-phone dongle is powered by 
connecting to the base station. A blue LED passes through a blue filter and shines onto each 
well. A cell-phone with a yellow filter on the camera is placed onto the dongle and a photo 
was taken. Following image capture, the photo is automatically uploaded to the cloud for 
automated image analysis and email delivery of results.  
 
Figure 8.5: Automated cell-phone image processing.  
(Left) un-processed cell-phone image, (middle) MATLAB processed image, and 
(right) automated email delivery of results. 
 
 
Automated base station 
AS (Andrey Shur) designed the basic circuit and Arduino code for rotation and heating 
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EJ further modified the circuit, Arduino code, integrated the base station with other 
components, and validated the device. 
 
We have successfully built a prototype base station controlled with an $8.50 Arduino Mini 
Pro operating on 6 AA rechargeable battery pack which performs combined heating and 
rotations (Figure 8.6A). Power may alternatively be provided by an AC adapter which has 
greater voltage and amperage capabilities. Heating is performed with a proportional control 
algorithm, thermistor, and thin-film heater attached to an aluminum disk for even heat 
distribution. The heater reaches 68°C within 95s and is capable of maintaining temperature 
within a range of 1°C for at least 40 min. Rotation is controlled by the Arduino and a $5 
Polulu DRV8880 Motor Driver connected to a bipolar-modified 28BYJ-48 stepper motor 
with a 3D-printed gear train (gear ratio of 11.3). Using a TRH605 Futek Torque Sensor, we 
measured base station output torque at 1.1 N-m and the torque required to turn the 
SlipColumn at 0.7 N-m. The base station rotation is responsible for controlling the position 
of the slip valve of the sample preparation module and for automated slipping of the 
amplification module (by rotating in the opposite direction). The motor draws little power, 
and its full sequence (6 rotations and slipping) can be run at least 40 times without recharging. 
The base station could instead be designed to operate using an AC power supply, which has 
fewer power restrictions. 
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Figure 8.6: Automated base station components. 
(A) Angled-view and top-down view of the gear rotation mechanism. (B) 3 panels 
showing automated slip step using rotation. (C) A photo of the Arduino board. (D) 
Heating profile measured by Arduino and a thermistor connected to the heater. (E) A 
measure of battery voltage over time. Under no-load, the voltage is high (8.5 V) and 
while heating the voltage drops (7.5). Voltage switching is rapid giving the 
appearance of two curves.  
 
 
Integrated device performance 
We tested three sample-to-answer experiments using the NAAT kit and either Chlamydia 
Trachomatis (CT), Neisseria Gonorrhoeae (NG), or both pathogens spiked into normal 
human donated urine samples at 5000 CFU or IFU/mL. We found that the kit accurately 
detected the CT samples, but sometimes the kit failed to detect the NG samples (Figure 8.7). 
Follow-up experiments also confirmed this result. After analyzing the number of NA copies 
we would expect to find in the final LAMP reaction (stock concentration times input volume 
times extraction efficiency times reaction volume divided by elution volume), we calculated 
that there would be up to 340,000 NG RNA copies. For a lyophilized LAMP reaction, we 
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measured a limit-of-detection around 4000 copies. Therefore, our assay kit sometimes 
failed to detect NG even though we expect 85x more copies than the limit-of-detection. 
 
Figure 8.7: Integrated NAAT kit performance 
(left) Accurate detection of CT at 5000 IFU/mL in a urine sample on the integrated 
NAAT kit platform. (middle) Accurate detection of NG at 5000 CFU/mL. (right) 
Accurate detection of CT at 5000 IFU/mL but inaccurate detection of NG at 5000 
CFU/mL. 
 
 
Conclusions 
In this chapter, we demonstrated a fully-integrated sample-to-answer device capable of 
processing 250 µL of urine sample. The NAAT kit is portable with a total weight of less than 
1 kilogram and can be held in the palm of a hand. The NAAT kit is rapid with a total assay 
time of 26 min. Lastly, the NAAT is easy-to-use with 1 min of hands-on time at the start of 
the assay and 30s hands-on time at the end. With this NAAT kit, we have nearly met our 
requirements for fulfilling the desired ASSURED criteria.  
However, we observed that our assay sensitivity was lacking. In some (but not all) cases, we 
were unable to detect Neisseria Gonorrhoeae at a concentration that we expected to be 85x 
higher than our limit-of-detection. We suspect this is due to the greater carry-over of 
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extraction buffers when using a pressure-based approach as compared to centrifugation. 
In Chapter 2, I demonstrated how extraction buffer carry-over can be mitigated by the 
addition of the two-phase wash. The next step of this project is to more carefully examine 
extraction buffer carry-over using the sample preparation module by applying similar 
experimental techniques from Chapter 2 (carefully controlled experiments which will 
determine the extent of carry-over). I anticipate that once buffer carry-over is characterized 
and understood, it will be possible to further reduce buffer carry-over by adjusting pressures, 
modifying the two-phase wash conditions, and/or changing device geometry. I am hopeful 
that these changes could improve the sensitivity of the NAAT kit, thereby meeting all of the 
ASSURED criteria for a sample-to-answer POC molecular test. 
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